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Introduction: Immunologically mediated-adverse drug reactions threaten the 
viability of drugs and the health of patients (1, 2). The mechanistic basis for abacavir 
hypersensitivity is understood and preventable through HLA-B*57:01 screening. The 
immunopathogenesis of most immunologically mediated-adverse drug reaction 
remain unsolved, representing an opportunity to improve drug safety. 
Methods: Using a repository of clinically phenotyped and HLA typed human 
Donors and Controls, this work aimed to shed light on the immunopathogenesis of 
nevirapine and carbamazepine severe cutaneous adverse reactions. Cellular and 
molecular, techniques were employed including ex-vivo/in-vitro immunophenotyping, 
detection, stimulation and expansion of drug-specific responses, and characterisation 
of the specific T-cell receptor using droplet digital PCR. Virtual and Bioinformatics 
approaches were used to define potential interactions between nevirapine and  
class-I HLA 
Results and discussion: In carbamazepine associated Steven-Johnson’s 
Syndrome / toxic epidermal necrolysis, increased expression of granulysin was seen 
ex-vivo in CD8+ T cells exposed to carbamazepine. To explore the hypothesis that 
this is related to a cross-reactive memory cytotoxic T-cell response, we examined 
responses to human simplex virus 1 / 2 responses in HLA-B*15:02   carbamazepine 
associated Steven-Johnson’s Syndrome / toxic epidermal necrolysis patients and 
identified a shared epitope. Common T-cell receptor clonotypes were identified using 
droplet digital PCR in HLA-B*15:02   carbamazepine associated Steven-Johnson’s 
Syndrome / toxic epidermal necrolysis patients.  
Nevirapine severe cutaneous adverse reactions are associated with multiple class-I 
HLA alleles across differing ethnicities. The hypothesis that this relates to shared 
peptide-binding specificities between these alleles was confirmed using 
bioinformatics, statistical, and virtual approaches. This showed the strongest 
association across European, Asian and African-American ethnicities to be with two 
HLA class C alleles HLA-C*04:01 and C*05:01 defined by a unique F-binding pocket.  
Conclusion: Continuing work should build on the results presented and the unique 
techniques used, to further understand the underlying immunopathogenesis and the 
mechanistic basis for these adverse reactions, leading to the development of 
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1.1 Adverse Drug Reactions 
Adverse drug reactions (ADR) represent a major cause of iatrogenic and preventable 
disease and death (1, 2). A meta-analysis covering 39 different studies from 1966 to 
1996 estimates that 2.2 million serious ADR occur every year in the US alone, with 
over 100 thousand (4.5%) resulting in death (3-6). ADR are a common cause of 
mortality in the developed world (2). ADR place high demands on hospitals, healthcare 
facilities, and auxiliary healthcare services. The enormous burden and cost of ADR are 
incompletely captured and underestimated (1, 5, 7). 
Even with the stringency and oversight governing drug patents, development, and 
licensing an estimated 1500 patients are likely to be exposed to a newly developed 
drug during pre-clinical, pre-marketing testing phases (8-10). Only those ADR which 
show a frequency of 1 in 500 or greater are identified during the pre-marketing phases 
of drug development (8-10). The burden of ADR are likely to increase over time due to 
new medication development, the discovery of new uses for already marketed 
medications, and an ageing population in many developed countries. There are no 
effective strategies to determine the propensity for a drug to cause severe 
immunologically mediated-adverse drug reactions (IM-ADR) during development  
(1, 3). 
The different ADR classifications have been covered in the literature including the 
paper by Rive et al. 2013 entitled Testing for Drug Hypersensitivity Syndromes 
(Appendix 9, Journal Publications 9.4.1) (2). This paper reviewed IM-ADR or 
hypersensitivity reactions (HSR), in particular, the well-known immediate 
immunoglobulin (Ig) E and IgE-like HSR and the T-cell mediated, delayed IM-ADR. 
Here we focus on the latter, looking at the severe cutaneous adverse drug reactions 
(SCARs) that are mediated through adaptive, T cell-mediated immune responses  
(2, 11). 
1.2 Adaptive, Cell-Mediated Immune Response 
Delayed IM-ADR are driven through adaptive, cell-mediated immune responses. 
Adaptive, cell-mediated immunity involves T-cell activation through the T-cell receptor 
(TCR) recognition of antigenic molecules, presented by the major histocompatiblity 
complex (MHC) or human leukocyte antigen (HLA) cell-surface molecules. 
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1.2.1 Human Leukocyte Antigen 
The antigen-presenting cell-surface HLA proteins are encoded by HLA genes in the 
MHC chromosomal region, a 3.6 megabase pair section of deoxyribonucleic acid 
(DNA) on the short arm of chromosome number 6 in humans (6q21.3). HLA class-I 
proteins are encoded by three major loci: HLA-A, HLA-B, and HLA-C and three minor 
loci: HLA-E, HLA-F, and HLA-G while the HLA class-II proteins are encoded by three 
major loci: HLA-DR, HLA-DP, and HLA-DQ and two minor loci; HLA-DM and HLA-DO 
(Figure 1.1) (2, 12). The HLA class-III region includes both immune and non-immune 
associated genes like the tumour necrosis factor gene and heat shock proteins' genes 
(Figure 1.1) (13, 14). 
HLA class-I and class-II genes are highly variable, with polymorphic changes resulting 
in amino acid changes within the HLA peptide-binding cleft/groove of the specific HLA 
protein it encodes, influencing the peptide-binding capabilities of each HLA allotype 
and therefore altering the repertoire of peptides that each HLA allotype can present 
(15, 16). 
 
Figure 1.1: Human chromosome 6, the location of Major histocompatiblity complex (MHC 6p21.1-21.3) 
and the Human leukocyte antigen (HLA) class-I, class-II, and class-III genes. Adapted from Urayama 
KY et al. 2013 (13) 
1.2.2 Antigen Processing and Presentation 
1.2.2.1 HLA class-I endogenous antigen processing 
HLA class-I molecules are expressed by all nucleated cells and are composed of a 
conserved Beta 2-Microglobulin (β2M) and a polymorphic alpha (α) chain, made of 
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three domains, α1 to α3 (Figure 1.2a) (17, 18). The peptide-binding cleft consists of 
two antiparallel α-helices, formed by the α1 and α2 domains of the α chain and eight 
antiparallel beta (β) sheets, which provides a binding cleft with specific peptide-binding 
cleft pockets, identified as pockets A to F, at its base (Figure 1.2c) (17-19). The 
chemical characteristics and size of each binding cleft pocket define the repertoire of 
peptides that can be accommodated by the different HLA allotypes. 
As highlighted in Figure 1.3a antigenic peptide presentation by HLA class-I  
cell-surface protein to the TCR of T cells co-expressing the cluster of differentiation 
(CD) 8 molecule, requires the endogenous processing of foreign or abnormal antigens 
present in the cytoplasm (18, 20-22). HLA class-I bind and express antigenic peptides 
8-9 amino acids in length, however, longer antigenic peptides of ten or more amino 
acids can be accommodated by HLA class-I (17, 18). 
1.2.2.2 HLA Class-II exogenous antigen processing 
HLA class-II molecules differ from HLA class-I molecules in that, under normal 
circumstances, HLA class-II are only expressed by specialised professional antigen-
presenting cells (APCs), including dendritic cells (DC), macrophages,  
B cells, and certain activated epithelial cells. HLA class-II molecules are consists of 
two α chain and two β chain domains (Figure 1.2b) (17, 18). The peptide-binding 
groove is made by the interaction between the α1 and β1 domains which provides a 
binding groove with specific peptide-binding groove pockets, P1 to P9 (Figure 1.2d) 
(17-19). The binding groove pockets accommodate the amino acids residues of a 
bound peptide. 
As highlighted in Figure 1.3b, antigenic peptide presentation by HLA class-II 
molecules, to the TCR of CD4 expressing (CD4+) T cells, requires the exogenous 
processing of phagocytised antigens (18, 20-22). Unlike HLA class-I, HLA class-II 
molecules present peptides 12 to 25 amino acids in length (17, 18). 
1.2.2.3 Cross-presentation 
Cross-presentation of antigenic peptides differs from the classical antigen presentation 
models as it involves exogenous derived antigenic peptides being presented on HLA 
class-I molecules (Figure 1.2c) (20, 23-25). Cross-presentation plays an essential role 
in the defence against several viruses, bacteria; and tumours which have shown an 




Figure 1.2: Side view of (A) HLA class-I and (B) HLA class-II molecules. Also represented are the top 
view of the (C) HLA class-I peptide-binding cleft pockets A-F and (D) HLA class-II peptide-binding 
groove pockets 1-9. Adapted from Cole DK, 2013 (17). 
 
Figure 1.3: Human leukocyte antigen (HLA) and the processing and presentation of antigens. (A) 
Endogenous antigen processing and HLA class-I presentation. (B) Exogenous antigen processing and 
HLA class-II presentation. (C) HLA class-I cross-presentation of exogenous antigens derived via 
endocytosis. β2M, Beta 2-Microglobulin; TCR, T- cell Receptor; ER, endoplasmic reticulum; TAP 1 and 
TAP 2, transporter associated with antigen processing 1 and 2; CLIP, Class-II-associated invariant 
chain peptide. Adapted from, Guermonprez P, et al. 2002, Heath WR and Carbone FR, 2001, Braciale 
et al. 1987, Boesteanu A et al. 1998, and Kobayashi KS et al. 2012 (18, 20-22, 25) 
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1.2.3 T Cells 
The generation and regulation of T-cell immune responses is directed by the HLA-
associated antigen processing and presentation, and recognition by the TCR. The 
TCR plays an essential role in the development and selection of T cells with enough 
TCR diversity while eliminating any TCR which may interact with self-peptides leading 
to autoimmune and unwanted responses. Here we will concentrate on the α- and  
β-chain derived TCR (αβTCR) development. 
1.2.3.1 Thymic development 
The lymphoid precursor cells move from the bone marrow to the thymus, where the 
TCR is formed by the rearrangement of variable (V) segments with the joining (J) 
and/or diverse (D) TCR gene segments (Figure 1.4) (26-28). This process of 
recombination, transcription, splicing and translation, protein folding, and the formation 
of the TCR heterodimer produces three unique variable regions within the TCR 
molecule, the complementarity determining region (CDR) loops (26). 
The three hypervariable CDR loops of both the α- and β-chains within the αβTCR are 
essential in the interaction with the peptide-HLA complex. The CDR3 loop interacts 
with the peptide in the peptide-HLA complex and its variability come from the D and/or 
J gene segments rearrangement during recombination (Figure 1.4) (17, 28, 29). As 
highlighted in Figure 1.5, the TCR CDR3 α-chain (Orange α3) interacts with the N-
terminus and the TCR CDR3 β-chain (Orange β3) with the C-terminus of a bound 
peptide (17). The other variable regions within the TCR, the CDR1 and CDR2 loops, 
are encoded within the V gene segments and interact with the HLA molecule in the 
peptide-HLA complex, next to the peptide interacting CDR3 loops, with the CDR1 and 
CDR2 loops on the TCR α-chain (blue α1 and α2) interacting with the HLA class-I α2 
domain and the HLA class-II β1 domain and the CDR1 and CDR2 loops on the TCR β-
chain (Green β1 and β2) interacting with the HLA class-I and HLA class-II α1 domain 
(Figure 1.5) (17, 30, 31). This rearrangement of TCR DNA and the variability in the 




Figure 1.4: Germline DNA T-cell receptor (TCR) rearrangement, translation, splicing and transcription. 
Variable alpha (Vα), Variable beta (Vβ), Joining alpha (Jα), Joining beta (Jβ), diverse beta (Dβ), 
Constant alpha (Cα) and Constant beta (Cβ) DNA chains, adapted from Janeway CA et al. 2001 (26) 
 
Figure 1.5: Peptide-loaded human leukocyte antigen (HLA) molecule (A) class-I and (B) class-II 
complexes and T-cell receptor (TCR) complementarity-determining region (CDR) loop interactions. 
CDR3 (Orange α3 and β3), CDR1 and CDR2 β-chains (Green β1 and β2) CDR1 and CDR2 α-chains 
(Blue α1 and α2). Figure adapted from Cole DK, 2013 (17). 
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In the thymus, T-cell development leads to CD8+ / CD4+ double positive T cells which 
express a mature αβTCR that interacts with the self-peptides presented by HLA class-I 
or HLA class-II being expressed on the surface of the thymus cortical epithelial cells 
(32-35). A double positive T cell which expresses a TCR that has either a high or low 
affinity for the self-peptide being presented in a peptide-HLA complex undergoes 
apoptosis. A TCR exhibiting an appropriate affinity for self-peptides presented on 
either the HLA class-I or HLA class-II molecules, become single positive, naive CD8+ 
or CD4+ T cells, respectively. These single positive naive T cells then migrate out of 
the medulla of the thymus to secondary lymphoid tissues such as the lymph nodes, 
tonsils, spleen, Peyer’s patches and mucosa-associated lymphoid tissue (32-35). 
1.2.3.2 Activation 
Once in the secondary lymphoid tissue, a naive T cell becomes activated once it 
interacts with the appropriate HLA-antigen presented by an APC, which has moved to 
the secondary lymphoid tissue after encountering an antigen (Figure 1.6) (36-38). 
Following activation, T cells undergo clonal expansion which produces numerous 
activated effector T cells, expressing cell-surface molecules that allow them to leave 
secondary lymphoid tissues and move to the site of inflammation (Figure 1.6). The 
differentiation and effector functions of both, CD8+ T cells and CD4+ T cells, differ (39, 
40). Effector CD4+ T cell or helper T (Th) cells direct immune responses by regulating 
macrophages and B-cell antibody production, maintaining CD8+ T-cell responses, and 
the recruitment and direction of innate response cells like neutrophils, eosinophils and 
basophils to sites of infection and inflammation (41-43). The cytokine environment and 
the initial antigen interaction dictates how the naive CD4+ T cell will differentiate into 
one of several CD4+ Th cells, including Th1, Th2, Th17, regulatory T cells (Tregs), 
Th22 or Follicular Th cells (41, 42, 44). 
Effector CD8+ cytotoxic T cells migrate out of the secondary lymphoid organs and 
move to the site of infection, interacting with cells expressing HLA class-I molecules 
presenting specific antigen-peptides (41-43). Once an infected cell(s) is identified, 
apoptosis is induced eliminating the infected cell. Effector T cells then undergo 
apoptosis-dependent programmed contraction, an important phase in immune 
homeostasis (41-43, 45). A small proportion of pathogen-specific T cells not 
programmed for apoptosis will populate a pool of memory T cells, whose numbers are 
sustained by low-level homeostatic proliferation (46, 47). 
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1.2.3.3 Memory 
Memory T cells continue to act in a surveying manner, reacting when exposed to the 
same specific antigen. Understanding into CD4+ memory T cell remains elusive when 
compared to CD8+ memory T cells. CD8+ memory T cells are composed of central 
memory T cells which remain in the secondary lymphoid organs, effector memory  
T cells which circulate through non-lymphoid tissue, and the resident memory T cells 
which remain in the tissue of the primary infection (Figure 1.6) (34, 48-50). Memory  
T cells require a lowered activation threshold and do not require the same co-
stimulator signals governing naive T-cell activation (34). 
 
Figure 1.6: Naive CD8+ T-cell activation, proliferation and clonal expansion. Tcm, central memory T 
cells; Tem, effector memory T cells; Trm, resident memory T cells; DC, dendritic cells. Adapted from 
Kaech S and Weiguo C, 2012 (51) 
1.2.4 Heterologous Immunity 
Heterologous immunity describes the immune response by antigen-specific memory  
T cells from a previously encountered pathogen, cross-recognising, and influence the 
immune response to a new or neo-antigen (52). Heterologous immunity uses a 
restricted TCR repertoire directed at cross-reactive derived, subdominant epitopes 
compared to homologous immunity in which a diverse TCR repertoire is directed at 
specific epitopes maintained from primary infection (52). Heterologous immunity is 
considered not as efficient and effective as homologous immunity, yet the severity and 
course of infection may be reduced because of heterologous immunity (13, 14). 
Diverging from normal immunity to a partial and non-protective immune response can 
also result in altered immunopathology and even increased morbidity and mortality 
(52, 53). 
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A considerable amount of evidence supports the heterologous immune model as a 
mediator of organ transplant rejection (9, 10, 12, 16-19). Organ transplant offers the 
unique circumstance where an abundance of neo-antigens, for which the host has no 
tolerance to, are presented to the immune system and cross-recognised by pre-
existing HLA-restricted memory T cells, derived in response to and maintained by 
prevalent viral infections, like those of the human herpesvirus (HHV) family, including 
Herpes Simplex Virus-1 and Herpes Simplex Virus-2 (HSV-1 and HSV-2, 
respectively), Epstein-Barr virus (EBV), and cytomegalovirus (CMV) (54-60). 
1.3 Immunopathogenesis of Delayed 
Immunologically Mediated-Adverse Drug 
Reactions 
Delayed IM-ADR involves a range of phenotypes of differing severity that are defined 
by their clinical presentation. T cell-mediated reactions can often be defined by their 
immunopathogenesis at a tissue level and by the effector cell involved. Stevens - 
Johnson syndrome (SJS) / Toxic Epidermal Necrolysis (TEN) and drug reaction with 
eosinophilia and systemic symptoms (DRESS) are among the severest of IM-ADR 
with the former having up to 50% mortality (Table 1.1) (1, 2, 61, 62). 
In SJS/TEN patients develop a widespread erythematous rash with flat or macular 
atypical targets and bullae blisters with sections or sheets of the epidermis separating 
from the dermis (2, 62-64). The spectrum of severity includes the percentage of body 
surface epidermal detachment associated with bullae blister development. SJS 
involves extensive small blisters with less than 10% epidermal detachment, SJS-TEN 
overlap 10–30% epidermal detachment, and TEN involves greater than 30% 
epidermal detachment (Table 1.1) (2, 62-65). In SJS/TEN short-term complications 
include organ involvement and sepsis and longer-term complications involve the eyes 
(adhesions or blindness), loss of nails, adhesions and structures throughout the 
respiratory, gastrointestinal and urogenital tract and neuropsychiatric complications 
including post-traumatic stress disorder and depression (Table 1.1) While only 0.4-6 
incidences of SJS/TEN occur per million persons per year, SJS/TEN is a severe, life-
threatening ADR, with mortality rates ranging from 5 to 12.5% for SJS and 30 to 50% 
for TEN and is associated with over 200 different drugs including several antiepileptic 
drugs like carbamazepine (CBZ) (Table 1.1) (2, 63, 65, 66). 
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DRESS has a longer latency period than SJS/TEN with the first manifestation being 
fever, followed by a rash of varying severity and involvement of organs such as the 
liver. Besides fever, rash and organ involvement, other symptoms include 
lymphadenopathy and haematological abnormalities including eosinophilia and/or 
lymphocytosis (Table 1.1). Up to 80% of DRESS cases involve the liver. However, 
DRESS can also include kidney damage (40%), and/or the lungs, heart, and the 
pancreas (67). Symptoms appear within a two- to eight-week window after starting the 
culprit drug and can persist after drug discontinuation or withdrawal (2, 68-70). Like 
SJS/TEN, DRESS is associated with numerous drugs including the antiretroviral 
(ARV) medication, nevirapine (NVP) (Table 1.1) 
Despite not being a SCAR, delayed rash or maculopapular eruption (MPE) deserves a 
brief mention (Table 1.1). Delayed rash often presents as macules or papules 
erythematous, without other systemic features, appearing on the face and torso, 
before becoming generalised (71, 72). Delayed rash has been associated with many 
drugs, including NVP and CBZ, and symptoms appear at the end of the first week or 
beginning of the second week of treatment with the culprit drug (Table 1.1) (71, 72). 
Delayed drug-rash reactions have been associated with drug-viral interactions, for 
example, the interaction between aminopenicillins and EBV (73). 
In the last decade, the association between HLA alleles and severe delayed 
IM-ADR has led to a greater understanding into the immunopathogenesis of these 
diseases and the ability to use these specific HLA alleles as biomarkers. This began 
with the association between HLA-B*57:01 and abacavir (ABC) associated 
hypersensitivity syndrome (HSS) (Table 1.1). 
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Table 1.1: Delayed IM-ADR and their significant features. Adapted from Rive C et al. 2013, Phillips EJ 





Symptoms/features Associated drugs 
Delayed Rash 
/ MPE 






Maculopapular rash appears on 
the  
face / torso, becoming 
generalised.  
No associated fever or systemic 
symptoms.  
Antiepileptic drugs (including 
CBZ), aminopenicillins. 
antibacterial sulphonamides, 
ARV (NVP), Allopurinol 
DRESS 
 
2-8 weeks  
Fever, rash, lymphocytosis  
(eosinophilia), lymphadenopathy, 
Liver / organ involvement. 
Viral reactivation of HHV6/7, EBV 
or CMV,  
2 weeks or more. 
Possible delayed autoimmune 
disease. 








Fever, malaise, Gastrointestinal 
symptoms, 70% develop late mild 
to moderate rash. ABC 
rechallenge results in 
Hypotension, shock and even 
death.  







SJS 1–10% body surface area 
SJS/TEN overlap 10–30% body 
surface area 
TEN >30% body surface area 
Fever and mucosal tissue 
involvement (precede rash), 
Hepatitis, jaundice, increased liver 
transaminases 
Eye involvement (post reaction 
complications), 
Gastrointestinal and respiratory 
manifestations, anaemia, 
lymphocytosis (neutropenia).  
> 200 drugs 
Antiepileptic drugs (including 
CBZ, antibacterial 
sulphonamides, NSAID’s, 
ARV’s (NVP), and 
Allopurinol. 
HSR, hypersensitivity reaction; MPE, maculopapular eruption; DRESS, drug reaction with eosinophilia 
and systemic symptoms; HSS, hypersensitivity syndrome; SJS, Stevens-Johnson syndrome; TEN, toxic 
epidermal necrolysis, HHV, human herpesvirus; EBV, Epstein-Barr virus; CMV, cytomegalovirus;, CBZ, 
carbamazepine; ARV, antiretroviral; NVP, nevirapine; NSAID, non-steroidal anti-inflammatory drugs. 
1.3.1 Abacavir 
ABC is a guanosine analogue ARV agent used in combination treatment of human 
immunodeficiency virus (HIV). ABC is a nucleoside that inhibits the reverse 
transcriptase enzyme, resulting in chain termination. Since the approval of ABC in 
1998, 4-8% of patients receiving ABC would also experience the delayed IM-ADR, 
now identified as ABC-HSS (67, 74, 75). The clinical presentation of ABC-HSS 
includes symptoms such as fever, malaise, as well as respiratory and gastrointestinal 
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symptoms. (Table 1.1) (67, 68, 74, 76). A mild to moderate rash develops in 70% of 
cases, which appears late in disease (Table 1.1) (67, 74, 76). White cell count 
abnormalities like eosinophilia and hepatitis are uncommon (67, 68, 74). ABC-HSS 
symptoms can appear within 36 hours to 6 weeks of ABC initiation, although most 
cases occur within 2 weeks of first ABC exposure (74) The majority of ABC-HSS 
symptoms are resolved within 72 hours of ABC discontinuation, when rechallenged 
with ABC, patients experience extreme hypotension, shock and, even death (Table 
1.1) (67, 68, 74, 76). 
A genetic link to ABC-HSS was hypothesised with reports of a lowered frequency of 
ABC-HSS in Asian and African populations. The report of ABC-HSS occurring in two 
members of the same family added to this idea of a genetic association (67, 74, 76, 
77). The association between HLA-B*57:01 carriage and ABC-HSS was reported by 
two separate research groups. False positive clinical diagnosis minimised “true ABC-
HSS” in non-Caucasian patients where the carriage of HLA-B*57:01 is low (74, 76-78). 
The specificity of ABC skin patch testing increased the negative predictive value of 
HLA-B*57:01 in ABC-HSS to 100% (74, 79, 80). Further validation of the 100% 
negative predictive value was seen in a case-controlled study called the Study of 
Hypersensitivity to ABC and Pharmacogenetic Evaluation (SHAPE) (81). SHAPE 
showed that both African (African-American) and Caucasian patients who tested 
positive in patch tests all carried HLA-B*57:01 (74, 76-78). In a randomised clinical 
trial, the Prospective Randomised Evaluation of DNA Screening in a Clinical Trail 
(PREDICT-1), showed that screening for HLA-B*57:01 eliminated patch test positive 
ABC-HSS patients and HLA-B*57:01 carriage has a 55% positive predictive value for 
ABC-HSS (74, 76-79). 
Figure 1.7 denotes how the genetic association of the HLA-B*57:01 allele with  
ABC-HSS, lead to HLA-B*57:01 genetic screening in clinical practice and improved 
treatment guidelines (Figure 1.7) (2, 78). The 100% negative predictive value 
associated with HLA-B*57:01 in ABC-HSS showed that the underlying 
immunopathogenesis of ABC-HSS is HLA-driven. The incomplete positive predictive 
value of 55% associated with HLA-B*57:01 in ABC-HSS, suggests that 
immunopathogenesis is driven by other factors, besides HLA-B*57:01 carriage. 
A large body of experimental work supports the model that ABC-HSS is driven by 
HLA-B*57:01-restricted, CD8+ T-cell response (2, 67, 82). CD8+ T-cell responses can 
be seen in the peripheral blood mononuclear cells (PBMC’s) of HLA-B*57:01 positive, 
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ABC-naive Donors by culturing the cells and stimulating them with ABC-pulsed  
HLA-B*57:01 transfected APCs (67, 82, 83). Changing a single amino acid in the 
peptide-binding domain, like changing the serine at position 116 of the HLA-B*57:01 
molecule, to a tyrosine, abolishes ABC-CD8+ T-cell recognition (67, 82, 83). 
Virtual modelling data have provided insight into the underlying pathogenesis of HLA-
B*57:01-restricted ABC-HSS, by providing evidence that ABC binds non-covalently to 
the peptide-binding cleft of HLA-B*57:01, altering its chemistry and shape (2, 68, 83-
85). The alteration of the peptide-binding cleft changes the repertoire of self-peptides 
presented by HLA-B*57:01, from peptides with a tryptophan (W) or a phenylalanine (F) 
at the C-terminus, to small aliphatic residue such as valine (V), alanine (A) or 
isoleucine (I) at the carboxyl terminus (2, 68, 83-85). These altered peptides presented 
when ABC is non-covalently bound to the peptide-binding cleft of HLA-B*57:01, were 
not presented during T-cell thymic development and therefore a proportion of these 
self-peptides are recognised by T cells of hypersensitive patients (2, 21, 87-89). 
 
Figure 1.7: Abacavir (ABC) translational roadmap Showing how the discovery of the association 
between HLA-B*57:01 carriage and ABC- HSS lead to the incorporation of HLA-B*57:01 genetic 
screening into clinical practice. Figure adapted from Rive C et al. 2013 and Phillips EJ et al. 2011(2, 78). 
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1.3.2 Carbamazepine 
An iminodibenzyl derivative, CBZ was developed in 1960 to treat trigeminal neuralgia 
before the discovery of its antiepileptic properties (86). Besides its antiepileptic 
properties and its ability to ease neuropathic pain accompanying diseases such as 
Herpes Zoster (HZ), CBZ is used to treat a variety of “off-label” disease and conditions 
including attention deficit hyperactive disorder, schizophrenia, bipolar disorder, 
borderline personality disorder, phantom limb syndrome, and post-traumatic stress 
disorder (87-91). The World Health Organization has placed CBZ on the essential 
medication list due to its relative costs and multiple uses (92). CBZ-HSR include 
maculopapular eruption and DRESS restricted to HLA-A*31:01 in Caucasian and other 
ethnicities, however this body of research will concentrate on HLA-B*15:02-restricted 
CBZ-SJS/TEN. 
1.3.2.1 CBZ-SJS/TEN HLA associations 
SJS/TEN is a rare disease with less than 10 in 10 thousand people experiencing the 
disease. CBZ-specific SJS/TEN was found to have a strong association with the HLA-
B*15:02 allele in Han Chinese populations (19% of the world’s total population), where 
the prevalence of the allele is approximately 10.2% (Figure 1.8) (2, 67). Similar to 
ABC-HSS, studies have shown a negative predictive value of 99-100% for HLA-
B*15:02-restricted CBZ-SJS/TEN in Han Chinese populations (93-96). Unlike HLA-
B*57:01 and ABC-HSS, the positive predictive value of HLA-B*15:02 in CBZ-SJS/TEN 
is lower (3.0-7.7%) (2). Given that 10.2% of Han Chinese carry the HLA-B*15:02 and 
that 19% of the total world’s population (7.125 billion as of 2013) is of Han Chinese 
ancestry, this places upwards of 4 to 9 million people worldwide at risk of experiencing 
SJS/TEN reaction if given CBZ (97-99). 
The CBZ-SJS/TEN-HLA-B*15:02 association has is significant in South and South-
east Asian populations where the HLA-B*15:02 allele frequency is high, with highest 
incidence in Han Chinese (10.2%) and Taiwanese (10%) populations, while the 
frequency of HLA-B*15:02 carriage in Hong Kong, Thailand, Malaysia, Vietnam, 
Philippines, India, and Indonesia is 5% (2, 67, 100). The frequency of HLA-B*15:02 is 
low in other populations, including African Americans (0.1-1%) and Caucasians (0.1%) 
(2, 67, 100). There is an identified association with other derivatives of CBZ like 
oxcarbazepine, and a weaker association between HLA-B*15:02-SJS/TEN and other 
Antiepileptic drugs like phenytoin, and lamotrigine. 
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Figure 1.8: The frequency of HLA-B*15:02 allele carriage most prevalent in those of South and South-
east Asian ethnic groups. (2, 67, 100) 
Based on the strong negative predictive value associated with CBZ-SJS/TEN and the 
carriage of HLA-B*15:02 in South and Southeast Asians, the Food and Drug 
Administration (USA) and similar regulatory agencies of different countries have 
recommended that genetic screening for HLA-B*15:02 in those of South and South-
east Asian ancestry before CBZ therapy and that all HLA-B*15:02 carriers, should not 
be administered CBZ, unless the benefits outweigh the risks (101). 
Besides the HLA-B*15:02 allele association, other B75 serotype HLA alleles, including 
HLA-B*15:08, -B*15:11, and -B*15:21, have been associated with CBZ-SJS/TEN, in 
different populations, with the rationale being that the B75 serotype alleles share high 
amino acid sequence homology that may resemble structural features of HLA-B∗15:02 
and therefore may trigger a similar cutaneous adverse reaction to CBZ (102). Other 
associations also include HLA-B*15:18, -B*59:01 and -C*07:04 (103-106). 
Studies involving European and Japanese populations have suggested an association 
between the HLA-A*31:01 allele and CBZ-SJS/TEN (107, 108). However, subsequent 
studies involving both Taiwanese and European populations have shown a stronger 
association between the HLA-A*31:01 allele and CBZ-DRESS / CBZ-MPE reactions 
and only a weak to insignificant association with CBZ-SJS/TEN (107-110). This 
inconsistency with HLA-A*31:01 might be due to several factors and stresses how 
important it is to define the clinical presentation of delayed IM-ADR phenotypes and 
eliminating false positive clinical diagnosis, which was clear in the association between 
HLA-B*57:01 and “true” ABC-HSS (75). 
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The high negative predictive and incomplete/low positive predictive values associated 
with carrying an at-risk HLA allele, like HLA-B*15:02 shows that while specific HLA 
allele carriage is a necessary factor, it alone does not explain drug-SJS/TEN 
immunopathogenesis. 
1.3.2.2 Other factors driving CBZ-SJS/TEN 
immunopathogenesis 
Immune cells 
Multiple studies have emphasised the prominence of T cells found in the blister fluid of 
SJS/TEN patients (111-114). In early stages, CD8+ cytotoxic T cells are found in blister 
fluid and epidermal layers of the skin, while CD4+ T cells are found in the dermal 
layers of the skin (115). This contradicts the common finding that CD4+ T cells are 
commonly found early in allergic reactions involving the epidermis, and not CD8+ T 
cells (115). An increase in the interleukin (IL)-2 associated, soluble IL-2 receptors 
within patient blister fluid and serum further support the role of CD8+ T cells in 
SJS/TEN, as they are a marker for activated T cells and levels correlate to disease 
activity (111, 113). Activated T cells expressing the cutaneous lymphocyte antigen skin 
homing receptor, are elevated in the peripheral blood of patients with SJS/TEN, which 
also correlates to disease activity and returns to normal with disease resolution (111, 
113, 114). 
Other immune cells found in the epidermis of SJS/TEN patients include natural killer 
(NK) cells and natural killer T (NK-T) cells which can be identified in the blister fluid of 
SJS/TEN patients (111, 116). Several pathogenic models highlighting the role of CD8+ 
cytotoxic T cells, NK, and NK-T cells in inducing the keratinocyte death seen in 
SJS/TEN have been published (63, 111, 117). These models have theorised that the 
death of keratinocytes is triggered through the various cellular apoptotic mechanisms. 
More recent evidence suggests the cytotoxic effector molecule granulysin is involved 
in the disseminated keratinocyte death in SJS/TEN (117). 
Granulysin 
Granulysin is a novel effector molecule that exhibits cytotoxic activity against several 
pathogens and tumours, while also possessing chemoattractant and proinflammatory 
abilities. (118-125). The cytotoxic effector molecule granulysin can be expressed by 
several cells, including CD8+ cytotoxic T cells, CD4+ cytotoxic-like T cells, NK cells and 
NK-T cells (2, 119, 125-127). Granulysin is a useful transplantation biomarker as 
granulysin expression in-situ is a marker for acute rejection and steroid resistance 
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(128). Granulysin is also an important cytotoxicity mediator in several skin diseases 
besides SJS/TEN including acne, psoriasis and folliculitis (119, 125, 129-132). CD4+ 
memory T cells that express granulysin are candidate marker in Mycobacterium 
tuberculosis infection (119, 133). 
Studies have shown that the 15kDa form of granulysin, found within the epidermal 
blister fluid of SJS/TEN patients, show a similar cytotoxicity to the 9kDa form secreted 
by both NK cells and CD8+ T cells (93, 103, 117). Exposing a mouse model to the 
15kDa form of granulysin induces considerable cutaneous blistering and necrosis in 
the mouse. These findings show that higher levels of extracellular secretory 15kDa 
granulysin can lead to a rapid development of epidermal necrosis. It has also been 
shown that the lower granulysin concentrations found in SJS lesions is due to an 
increase in mononuclear cell infiltration when compared to the granulysin 
concentrations of TEN lesions (93, 103, 117). This observation would explain the 
observations in SJS/TEN histopathology, showing that infiltration of sparse dermal 
mononuclear cells results in extensive epidermal necrosis (93, 103, 117). 
In 2014, a case study of one patient with lamotrigine-induced TEN, HLA types 
unknown, showed an increase CD56+ NK cell granulysin expression, when the 
patients PBMC’s were exposed to lamotrigine ex-vivo over a four-day period (134). 
Another finding by Porebski et al. 2013 showed an increase in granulysin expression 
by CD4+ memory T cells from patients with lamotrigine-induced SJS/TEN when 
exposed to lamotrigine ex-vivo (135). Chung et al. 2015 produced evidence that 
besides HLA-B*58:01 carriage, oxypurinol-induced granulysin expression in T cells 
contribute to the immunopathogenesis in allopurinol-SJS/TEN (116) 
Granulysin is an important biomarker in the diagnosis and progression of SJS/TEN. A 
robust granulysin-specific assay would offer further insight into drug-SJS/TEN 
immunopathogenesis, which could be translated into clinical practice helping to better 
predict and reduce incidences of drug-SJS/TEN. 
1.3.3 Nevirapine 
The ARV drug NVP is a non-competitive reverse transcriptase inhibitor that has been 
effective in HIV treatment. The use of NVP as a prophylactic has proven to be 
successful in reducing mother to child vertical transmission rates of HIV-1 in lower 
socio-economical populations (136, 137). NVP is also effective in salvage regimens 
after virological failure, especially in those who have not taken non-nucleoside reverse 
transcriptase inhibitors. Approved for use in combination with dual nucleoside reverse 
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transcriptase inhibitors, NVP is listed on the List of Essential Medications by the World 
Health Organization (92). 
1.3.3.1  NVP-SCAR and HLA allele associations 
NVP has been associated with inducing several IM-ADR, including delayed rash, the 
more severe cutaneous reactions DRESS and SJS/TEN. NVP-SCAR 
immunopathogenesis is driven by both CD8+ T-cell / HLA class-I responses and CD4+ 
T-cell /HLA class-II responses. Studies have shown that the response to NVP, ex-vivo 
can be abrogated by removing CD8+ or CD4+ T cells (138). The ex-vivo NVP-
stimulated responses diminish over time after first in-vivo reaction/exposure. The 
primary focus of this work will be on the diversity and complexity of HLA alleles 
associated with NVP-SCAR phenotypes while exploring this diminished ex-vivo 
responses associated with NVP-DRESS. 
Up to 5% of patients who start NVP will experience a DRESS reaction (138-141). An 
increased risk of NVP-DRESS has been associated with the HLA-DRB1*01:01 
coupled with CD4+ T cells greater than 25% (CD4+ T-cells counts > 250 cells/μL in 
women and > 400 cells/μL in men) (Table 1.2) (74, 142). While not a SCAR, NVP and 
efavirenz delayed rash was observed in French patients who carried the HLA class-II 
allele, HLA-DRB1*01 (Table 1.2) (143, 144). A study involving a South African cohort, 
found that carriage of the HLA class-II allele HLA-DRB1*01:02 and the HLA class-I 
allele HLA-B*58:01 was associated NVP-hepatotoxicity (Table 1.2) (145). 
HLA class-I allele associations to NVP-DRESS include HLA-Cw*8 in an Italian cohort 
and the HLA-Cw*8 / B*14 haplotype among the Japanese (Table 1.2) (146, 147). The 
HLA-C*04 allele was shown to increase the risk of NVP-DRESS in the Han Chinese. 
The HLA-B*35:01 and HLA-B*35:05 alleles were a significant risk factor for NVP-
DRESS in Caucasian and Asian populations, respectively (Table 1.2) (138, 148-150). 
Again, the NVP-delayed rash, while not a SCAR reaction has also been linked to the 
carriage of, HLA-C*04 and HLA-B*35:05, in Asian populations (Table 1.2). (144, 151-
153) NVP-SJS/TEN accounts for less than 1.5% of NVP-HSR (67, 76, 154). In terms 
of SJS/TEN, a recent study has shown that carriage of the HLA-C*04:01 allele 
increased the risk of NVP-SJS/TEN in a Malawian cohort (Table 1.2) (155). 
Table 1.2: Genetic (HLA alleles) and tissue specificity variation seen in different ethnic groups 
associated with the NVP-HSRs. Table adapted from Rive C et al. 2013 and Phillips EJ et al. 2011(2, 
150) 
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IM-ADR Ethnic association  Genetic association (HLA)  
DRESS 
Rash associated hepatitis 
CD4+ > 25% in Caucasians  
DRB1*01:01 and DRB1*01:02 
Italian (Sardinian)  Cw8-B*14 haplotype 
Japanese  Cw8 
Han Chinese  Cw*4 and DRB1*15 
Asian  B*35:05 




French population DRB1*01 
African, Asian, European and Thai  Cw*04 
Thai  
B*35:05, 
rs1756*G CCHCR1 (GWAS) 
 




SJS/TEN African  
HLA-C*04:01(needs 
confirmation)  
IM-ADR; Immunologically mediated-adverse drug reaction, DRESS, drug reaction with eosinophilia and 
systemic symptoms; DILI; drug-induced liver injury, SJS, Stevens-Johnson syndrome; TEN, toxic 
epidermal necrolysis, GWAS; genome-wide association study. 
 
1.4 Established Models of HLA-driven delayed 
Immunologically Mediated-Adverse Drug 
Reactions 
As highlighted earlier, specific HLA alleles, like HLA-B*15:02 in  
CBZ-SJS/TEN in Southeast Asians and HLA-B*57:01 in ABC-HSS have a negative 
predictive value of 100%. How these specific HLA alleles and drugs interact to elicit  
T cell-mediated immune responses, leading to the associated IM-ADR phenotypes 
described above is still an area of debate. Three hypotheses or models have been 
proposed to explain HLA-driven delayed IM-ADR and possible that no single 
hypothesised model is mutually exclusive. These three HLA-drug-binding models 
proposed include the hapten/prohapten model, the pharmacological interaction (P-I) 
model, and the altered peptide repertoire model (67, 74, 76, 156). 
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1.4.1 The Hapten / Prohapten Model 
The hapten/prohapten model involves drug (or a metabolite) modifying host proteins to 
creating a neo-antigen (Figure 1.9). The hapten model features chemically reactive 
drugs covalently binding to high molecular weight proteins, forming a hapten-protein 
complex (67, 157, 158). This modification can affect any autologous protein, including 
extracellular, intracellular, and membrane-bound proteins. The hapten-protein 
complexes are then processed and presented by the HLA molecule on the surface of 
the cell forming a stable HLA-hapten-peptide complex (67, 157, 158). The location, 
nature, and amount of the proteins modified influence the IM-ADR, leading to several 
immune responses. The prohapten extension to the hapten model was used to explain 
how chemically inert drugs can still elicit a delayed IM-ADR. The prohapten model 
involves the metabolism of the inert parent drug into a reactive metabolite which then 
becomes antigenic through the process mentioned. 
1.4.2 The Pharmacological Interaction Model 
The Pharmacological Interaction (P-I) model proposes that a non-covalent interaction 
between the culprit drug and TCR / HLA molecules can activate certain T cells (Figure 
1.9) (67, 74, 76, 156). This reversible reaction is comparable to the interaction of a 
ligand with its receptor. Evidence of this P-I model exists in observations of aldehyde-
fixed APCs which cannot process or present any peptides but still have the ability to 
activate specific T-cell clones (159-161). 
1.4.3 The Altered Peptide Repertoire Model 
The altered peptide repertoire model can be considered a refinement of the P-I model. 
In-silico modelling has shown how certain drugs can to fit into an “empty” HLA 
molecule, through a non-covalent bond to key residues and the occupation of anchor 
sights within the HLA peptide-binding groove (2, 83-85, 162). This non-covalently 
binding and occupation of anchor sites within an “empty” HLA protein, alters the 
repertoire of peptides capable of binding within the drug-modified HLA (2, 83-85, 162). 
Memory CD8+ T-cell responses derived from HLA-B*57:01-restricted EBV epitopes, 
can also recognise endogenous ABC-HLA-B*57:01-restricted endotopes (83). 
Evidence supporting this model comes from three independent studies that put 
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forward that the altered peptide repertoire model is the underlying mechanism in  
ABC-HSS (83-85). 
1.4.4 The Heterologous Immunity Model 
The interactions of drugs with specific HLA alleles can be explained by neo-antigen 
generation through the hapten/prohapten, the P-I and/or the altered peptide repertoire 
models (Figure 1.9). These off-target interactions with specific HLA molecules or HLA-
presented peptides are not enough to explain several factors identified with various 
delayed IM-ADR. For example, these models fail to explain how reactions can 
sometimes manifest within days after the first drug exposure or the long-lasting 
memory T-cell responses in drug-induced SJS/TEN and ABC-HSS reactions, for 
example. The models fail to explain why different drug-HLA allele combinations can 
produce different IM-ADR phenotypes, for example, why ABC-HLA-B57:01-HSS 
differs from CBZ-HLA-B*15:02-SJS/TEN which differs again from the varied IM-ADR 
phenotypes associated with NVP.(68) 
The hapten/prohapten, the P-I and/or the altered peptide repertoire models fail to 
account for the complete negative predictive value and low or incomplete positive 
predictive values associated with carrying an at-risk HLA allele. This suggests that 
while carrying an at-risk HLA allele is necessary, it alone does not explain the 
immunopathogenesis. The heterologous immune model attempts to explain the 
shortcomings. 
Similar to organ transplantation, IM-ADR presents a novel situation in which neo-
antigens are created through one of the three HLA-drug-binding models, as described 
earlier. Organ rejection is mediated by pre-existing HLA class-I–restricted effector 
memory T-cell responses to prevalent viral infections (24, 54, 56, 59, 163-166). In this 
setting memory T cells that interact with persistent viruses, for example, HHV 
epitopes, may cross-react with neo-antigens are created through one of the three 
HLA-drug-binding models (Figure 1.9) (68). Therefore, a pre-existing heterologous 
immune response could decide whether an individual with a high-risk HLA allele 
develops an IM-ADR. Heterologous immunity could also explain why IM-ADR can 
manifest within days after the first drug exposure, and the variation in tissue specificity 
and the long-lasting memory T-cell responses in drug-induced SJS/TEN and ABC-
HSS reactions, for example (68). 
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Figure 1.9: Graphical representation published by White et al., 2015 of the heterologous immunity 
model with the three neo-antigen generating, HLA-drug binding models (A) hapten/prohapten model, 
the (B) P-I model, and the (C) altered peptide repertoire model.(167) 
1.5 Scope of this Thesis 
A goal of IM-ADR research includes the ability to identify patients or specific 
population(s) who is at risk of experiencing a drug-specific IM-ADR, before 
administering the drug to prevent the resultant morbidity or mortality that could ensue. 
To achieve this, an understanding of the immunopathogenesis underlying these 
reactions is required. Both CBZ-SJS/TEN and NVP-SCAR are distinct clinical and 
immunological syndromes, but they share are several significant similarities which 
suggest that the underlying immunopathogenesis driving SCARs may share 
commonalities. Both CBZ-SJS/TEN and NVP-SCAR offer important examples for the 
immunopathogenesis of severe T cell-mediated drug reactions. 
Chapter 1 has summarised ADR and delayed IM-ADR, a smaller subset of ADR, 
driven by T cell-mediated immune responses. This chapter further explained the 
reactions and interactions of T cell-mediated immunity before moving into what is now 
known about immunopathogenesis of delayed IM-ADR. This chapter highlighted the 
ABC-HSS example, before leading into the two drugs of interest, CBZ and NVP. 
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Following this, Chapter 2 will focus on the Materials and Methods utilised to discuss 
the limitations to the established models of HLA-driven delayed drug hypersensitivity 
and answer the hypotheses proposed in the following Chapters. 
1.5.1 NVP-Induced HSR 
NVP-HSR has been associated with a variety of HLA alleles. To understand the 
immunopathogenesis driving NVP-HSRs, the question of varied tissue specificity and 
HLA alleles are associated with NVP-HSR, needs answering. Chapter 3 will look at 
examining two aspects of NVP-SCAR immunopathogenesis. HLA class-I alleles and 
their binding cleft characteristics associated with NVP-SCAR and the diminishing 
Gamma Interferon (IFN-γ) responses in NVP-stimulated, PBMC’s from NVP-DRESS 
patients. 
1.5.1.1 NVP-HSR and the shared HLA binding cleft specificities 
 The tissue specificity and varied HLA allele associations related to NVP-HSR might 
be explained by the similarities in the HLA peptide-binding cleft structure and predicted 
peptide/NVP-binding capabilities. Chapter 3 will analyse HLA class-I alleles identified 
as statistically significant in NVP-SCAR and NVP-SCAR with hepatitis, within a cohort 
of ethnically diverse, defined NVP-HSR cases and matched controls. HLA alleles will 
be analysed to see if they share similarities in peptide-binding cleft structures by 
grouping HLA alleles according to; shared key amino acid residues which make up the 
HLA class-I binding cleft pockets (A-F), validated cross-reactive group (CREG) HLA 
supertypes which groups HLA alleles based on similarities in cross-reactivity of public 
epitopes among HLA class-I alleles and binding cleft pocket chemistry, and the 
MHCcluster algorithm, which seeks to group HLA molecules based on their peptide-
binding (pb-) specificity as predicted by NetMHCpan 2.8 (168-172). Confirmation of the 
HLA shared binding cleft specificities would explain many outstanding observations 
regarding T cell-mediated delayed NVP-HSR including the low or incomplete 
negative/positive predictive values for the various HLA alleles already associated. This 
approach could apply to other delayed IM-ADR which exhibits an association to a 
varied number of HLA alleles. 
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1.5.1.2 Diminishing ex-vivo PBMC’s responses and NVP-HSR 
Immunopathogenesis 
Unlike several well characterised delayed IM-ADR, ex-vivo NVP-stimulated, PBMC’s 
IFN-γ responses diminish over time after first in-vivo reaction/exposure. Keane et al. 
2014 explored the hypothesis that in cases of the NVP-SCAR DRESS phenotype, the 
diminishing NVP-stimulated, PBMC IFN-γ responses was due to an increase in CD4+ 
Tregs levels, during the recovery period of NVP- DRESS. This increase in CD4+ Tregs 
levels has been reported in other drug-induced IM-ADR (173). In the paper by Keane 
et al. 2014, one patient exhibited an increase in Tregs that corresponded with the 
waning IFN-γ, Enzyme-Linked ImmunoSpot (ELISpot) responses (138). In this section 
of the chapter, we will expand on this hypothesis. However, as most of the NVP-
DRESS patient PBMC’s samples had been used in the initial study by Keane et al. 
2014, cytokine plasma profiles of the same NVP-DRESS patients, used in the Keane 
et al. 2014, were analysed. It is expected that the cytokine environment within the 
donor’s plasma, over the time course of a NVP-DRESS reaction and recovery period, 
alongside the Keane et al. 2014 data, might show changes in specific T-cell 
subpopulations further explaining the diminishing NVP-stimulated, PBMC IFN-γ 
responses 
1.5.2 Carbamazepine-Induced SJS/TEN  
Toxic Epidermal Necrolysis unlike NVP-SCAR and their varied HLA allele 
associations, a 100% negative predictive value has been linked with HLA-B*15:02 
carriage among those of Han Chinese and South-east Asian ancestry and CBZ-
SJS/TEN (174). Chapter 4, Chapter 5, and Chapter 6 will look at CBZ-SJS/TEN 
immunopathogenesis. Chapter 4 and 5 will explore the hypothesis which states that 
HLA-B*15:02-restricted CBZ-SJS/TEN is driven by memory T cells which expresses 
the specific cross-reactive TCR, in a heterologous immune response, explaining the 
tissue distribution of the clinical symptoms and the low or incomplete positive 
predictive value associated with HLA-B*15:02-restricted CBZ-SJS/TEN. 
1.5.2.1 CBZ-SJS/TEN and Herpes simplex virus 
Chapter 4 involves assessing several in-silico derived HSV-1 and/or HSV-2, HLA-
B*15:02-restricted peptides, ex-vivo (186-190). Identifying HLA-B*15:02-restricted 
peptides, shared and restricted to CBZ-SJS/TEN patients, is an essential step in 
assessing the heterologous immune model as it relates to HLA-B*15:02-restricted 
CBZ- SJS/TEN. 
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If a HHV-specific memory T cell is cross-recognising a neo-antigen created by one of 
the three proposed HLA-drug-binding models, then it would stand to reason that the 
immune response to the persistent pathogen should share similarities to the clinical 
presentation of CBZ-SJS/TEN. Reactivation of HSV-1 and HSV-2 involve skin and 
mucosal tissues. The skin and mucous membrane phenotype associated with HLA-
restricted CBZ-SJS/TEN might result from cross-reactive memory T cells primed for a 
specific HSV epitope(s) and activated by the neo-antigen created by one of the HLA-
drug-binding models; the subsequent drug-related immune response becomes widely 
distributed, resulting in expansive tissue involvement as seen in SJS/TEN. Besides the 
persistent pathogen immune response sharing similarities to the clinical presentation 
of SJS/TEN, the seroprevalence of the persistent pathogen within HLA-B*15:02 
positive CBZ-SJS/TEN cases should differ from HLA-B*15:02 positive CBZ-tolerant 
and naive populations. 
1.5.2.2 CBZ-SJS/TEN and T-cell receptor clonotype 
The highly variable TCR repertoire is defined through TCR gene rearrangement and 
selection in the thymus also governed by HLA molecules, self-peptide repertoires, and 
earlier exposure to pathogenic derived epitopes. Potentially dangerous TCR repertoire 
may be selected in those with at-risk HLA alleles (175). 
Ko et al. 2011 examined the CD8+ TCR repertoire in patients with CBZ-SJS/TEN 
(176). The authors showed a T-cell repertoire containing the public sequences Vβ 25-
1*01 (Vβ 11s1) CDR3 CASSISGSY and CASSGLADVDN within the PBMC’s and 
blister fluid of CBZ-SJS and CBZ-SJS-TEN overlap patients. Cellular based assays 
have shown anti-Vβ-11 antibodies can block CBZ-associated cytotoxicity and both a T-
cell clonotype and transfectants, expressing a TCR with the Vβ 25-1*01 CDR3 
CASSISGSY sequence and Vβ 25-1*01 CDR3 CASSISGSY, displayed cytotoxicity 
against HLA-B*15:02 expressing APCs in the presence of CBZ (139). The authors 
concluded that besides HLA-B*15:02 carriage, Vβ 25-1*01 CDR3 CASSISGSY and 
CASSGLADVDN TCR expression could be another factor in HLA-B*15:02-specific 
CBZ-SJS/TEN development (176). 
Chapter 5 will involve developing methods and assays to assess before identified 
specific Vβ CDR3 TCR sequence expression (161). The primary aim is to expand 
CBZ-specific T cells and identify the expression of specific vβ CDR3 sequences using 
the new and sensitive droplet digital (dd) polymerase chain reaction assay (PCR) (Bio-
Rad QX100/200 ddPCR system) (176). 
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1.5.2.3 Granulysin expression 
Chapter 6 will look granulysin expression, another established factor in CBZ-SJS/TEN 
immunopathogenesis and analysis granulysin expression in PBMC’s from patient 
donors that had experienced a SJS/TEN reaction to CBZ. Cell-based assays have 
shown that CBZ-SJS/TEN patient PBMC’s responses can be detected in PBMC’s 
acquired years after CBZ withdrawal, further supporting the responses seen in-vivo 
when a patient is rechallenged with CBZ. The overall aim is to characterise the cell 
type that is expressing granulysin when re-exposed to pharmacological relevant doses 
of CBZ ex-vivo to better understand CBZ-SJS/TEN immunopathogenesis. 
1.5.3 Final Summary and Conclusion 
Chapter 7 will summarise the findings within this body of work, highlighting the main 
findings and offering recommendations and considerations for future research into the 
underlying mechanisms governing both CBZ-SJS/TEN and NVP-HSR 
immunopathogenesis. Chapter 8 includes the bibliography highlighting the associated 


















2.1 Samples, Ethics and Limitations 
2.1.1 Nevirapine-Induced HSR 
2.1.1.1 NVP-SCAR associated HLA class-I binding cleft 
characteristics 
Samples 
Consenting participants from 11 countries (Argentina, Australia, Canada, France, 
Germany, Netherlands, Spain, Taiwan, Thailand, United Kingdom and The United 
States of America) were recruited for this study in collaboration with colleagues at 
Vanderbilt University, School of Medicine and Boehringer Ingelheim. (ClinicalTrials.gov 
NCT00310843). Cases were selected based on donors experiencing cutaneous and/or 
hepatic symptoms 8 weeks after beginning NVP. Symptoms include: 
1. NVP-induced severe cutaneous toxicity, characterised as a grade III or IV rash 
(National Institute of Allergy and Infectious Disease, Division of acquired 
immunodeficiency syndrome criteria) (149). 
2. Acute hepatic failure or symptomatic grade 3 or higher hepatic transaminase 
elevation (including aspartate transaminase and alanine transaminase) 5 times 
or more upper limit of normal (149). 
Cases and controls were excluded if donors had experience: 
3. A CD4+ T-cell count of 150 cells/μL or lower 6 months prior to beginning NVP. 
An acute viral hepatitis and/or no record of hepatic transaminase data 6 months 
leading up to NVP initiation. 
4. Received immunomodulatory drugs within the first 8 weeks of starting NVP 
and/or was part of the two nucleoside analogue reverse transcriptase inhibitor 
long-term study; Participants were given stavudine and lamivudine along with 
either NVP and/or Efavirenz depending on test parameters (149, 177). 
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Ethical considerations and approvals 
Project Title: The immunopathogenetic basis of nevirapine 
hypersensitivity 
Project No.: 2012/163 Murdoch University Human Research 
Ethics Committee 
Dates: 28 August, 2012 renewed until August 2015  
Listed as: Student researcher 
Limitations 
Limitations included the incomplete nature of the initial demographic, phenotypic, and 
sample information. Due to the study design, it was not possible to clarify any 
ambiguous or unclear information. Prior to any analysis, the demographic, phenotypic, 
and sample information for each donor was examined, organised, and confirmed 
before being included. Several samples were excluded because; no sample was 
available for HLA typing or issues with sample identity were identified (n=101) and 
either no clinical data was reported (n=22) or ambiguous clinical data was reported 
(n=62). The final analysis included 210 NVP-HSR cases (152 cutaneous adverse 
events, 58 hepatic adverse events) with 468 controls. 
2.1.1.2 Diminishing ex-vivo PBMC’s responses and NVP-HSR 
Immunopathogenesis 
Samples 
Donor 1 (NVP-HSR), Donor 2 (NVP-HSR), and Donor 3 (NVP-HSR) were kindly 
provided by The Institute for Immunology and Infectious Diseases, Murdoch 
University, Perth, Australia. Patient 2, Patient 3 and Patient 4 used in HLA Class-I 
Restricted CD8+ and Class-II Restricted CD4+ T Cells Implicated in the Pathogenesis 
of Nevirapine Hypersensitivity, by Keane et al. 2014 (Appendix 9, Section 9.2 
Publications Highlights), were renamed Donor 1 (NVP-HSR), Donor 2 (NVP-HSR), 
and Donor 3 (NVP-HSR), respectively for this body of work (138).  
Donor 1 (NVP-HSR), a Caucasian male (HLA-A*29:02, -A*31, -B*14:01, -B*44:03,  
-C*08:02, -C*16:01, -DR*07:01:01) carried the HLA-B*14 / HLA-C*08 haplotype and 
presented with rash, fever and eosinophilia two weeks after beginning a highly active 
antiretroviral therapy (HAART) regime that included NVP, ABC, and lamivudine. Donor 
1 (NVP-HSR) was positive for IgG to Varicella zoster virus (VZV), EBV, CMV, and 
HHV-6 but showed no evidence of viral reactivation (no IgM). 
Donor 2 (NVP-HSR), a 5-month-old infant with Asian ancestry (HLA-A*02:06,  
-A*34:01, -B*1521, -B*5601, -C*04:03, -C*07:01, -DR*04:06, -DR*15:02), carried the 
33 
HLA-B*56:01 and HLA-C*04:03 alleles and experienced fever, rash, eosinophilia and 
hepatitis on day 7 of a HAART regime containing NVP, ABC, and lamivudine. Donor 2 
(NVP-HSR) at the time of NVP-HSR was only 2 months of age and was positive for 
IgG to EBV, CMV and HHV-6 however, at 14 months of age only remained positive for 
IgG to HHV-6, consistent with waning of passive immunity and lack of infection with 
EBV and CMV. Donor 2 (NVP-HSR) showed tested negative for IgM and showed no 
signs of an activated virus. 
Donor 3 (NVP-HSR), Female of Asian ancestry (HLA-A*11, -A*24, -B*13:01,  
-B*35, -C*03, -C*04, -DR*11, -DR*16), carried the HLA-B*35 and HLA-C*04 allele, and 
presented with fever, rash, altered liver function and eosinophilia 14-15 days after 
starting NVP and was immediately taken off NVP. Donor 3 (NVP-HSR) was positive 
for IgG to EBV, CMV and HHV-6 but showed no evidence of viral reactivation (no 
IgM). Donor 3 (NVP-HSR) also experienced a trimethoprim-sulfmethoxazole related 
HSR, 2-3 months prior to the NVP HSR and showed evidence of elevated and 
activated CD4+ and CD8+ T cells in a sample tested 1 month post NVP HSR compared 
to a sample tested 4 months later.  
Controls included several NVP-tolerant and NVP-naive donors. 
Ethical considerations and approvals 
Project Title: Pharmacogenomics and mechanistic basis of 
drug hypersensitivity 
Project No.: 2014/20 Murdoch University Human Research 
Ethics Committee 
Dates: 22 January, 2014 until December 2016  
Listed as: Student researcher 
Limitations 
Limitations included sample size, an issue in much of research involving delayed IM-
ADR. Another limitation includes obtaining enough patient PBMC’s/plasma samples 
from various time points pre, during and post NVP-HSR. The initial study by Keane et 
al. 2014, required the majority of the NVP-DRESS patient PBMC’s, therefore we 
decided to assess the cytokine plasma profiles of the same NVP-DRESS patients, 
used in the Keane et al. 2014, to see if they show changes in specific T-cell 




Table 2.1: List of samples used in Diminishing ex-vivo PBMC’s responses and NVP-HSR 
Immunopathogenesis 
Samples Drug HSR phenotype HHV serology HLA  







A*29:02, -A*31,  
-B*14:01, -B*44:03,  
-C*08:02, -C*16:01,  
-DR*07:01:01 
Donor 2  
(NVP-HSR) 
NVP DRESS 




After 14 months 
of age 
HHV-6 IgG+ only  
A*02:06, -A*34:01,  












 -B*13:01, -B*35,  









- - - 
NVP tolerant 
Controls  NVP - - - 
HSR, hypersensitivity reaction; NVP, nevirapine; DRESS, Drug rash with eosinophilia and systemic 
symptoms; HHV, Human herpesvirus; VZV, Varicella zoster virus; EBV, Epstein-Barr virus; CMV, ; HLA, 
Human leukocyte antigen.   
2.1.2 Carbamazepine - Induced SJS/TEN 
Carbamazepine SJS/TEN samples 
Patients, who had experienced a CBZ-SJS/TEN reaction, gave informed consent to 
use their blood and products within in this study. The Controls and Donors are listed in 
Table 2.2, briefly: Donor 1 (CBZ-TEN), a female with South-east Asian ancestry (HLA-
A*11:01, -B*15:02, -B*58:01, -C*08:01, -C*03:01, -DRB1*12:02, -DRB1*03:01), carried 
the HLA-B*15:02 allele and experienced a TEN reaction to CBZ.  
Donor 1 (CBZ-TEN), diagnosed with HIV-1 infection, had also experienced an acute 
HZ with post-herpetic neuralgia, which was managed with CBZ along with other 
regular pain medications and NSAIDs. Within 9-14 days of CBZ initiation, Donor 1 
(CBZ-TEN) developed symptoms including fever, elevated transaminase levels, and 
cutaneous symptoms consistent with TEN. Donor 1 (CBZ-TEN) tested positive for IgG 
to HSV-2 and negative to HSV-1 while produced a positive CBZ cutaneous patch test 
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response 9.5 years after the original CBZ-TEN reaction, and produces positive CBZ-
stimulated, ex-vivo responses 17 years after the original CBZ-TEN reaction. 
Donor 2 (CBZ-SJS), a female of South-east Asian ancestry (HLA-A*11:01 -B*15:02, -
C*08:01, -DRB1*12:02 common haplotype with 11.6-19.7% frequency in Han Chinese 
populations), carried the HLA-B*15:02 allele, tested positive for IgG to HSV-1 and 
negative to HSV-2 and experienced a SJS reaction to CBZ (144). 
Donor 3 (CBZ-SJS), a female of Caucasian ancestry (HLA-A*26:12, -A*02:05,  
-B*15:02, -B*41:01 -C*08:01, -C*07:01, -DRB1*12:02, -DRB1*01:01), carried the HLA-
B*15:02 allele, tested positive for IgG to HSV-1 and HSV-2, and experienced a SJS 
reaction to CBZ. 
Donor 4 (CBZ-SJS non-B*15:02), a female of Caucasian ancestry (HLA-A*01:01  
-A*32:01/24, -B*35:03, -B*51:01 -C*01:02, -C*04:01, -DRB1*01:01, -DRB1*13:02), 
tested positive for IgG to HSV-1 and was retroactively diagnosed with an earlier SJS 
reaction to CBZ. Donor 4 (CBZ-SJS non-B*15:02) did not carry the HLA-B*15:02 
allele, but carried several delayed IM-ADR alleles including the NVP-SCAR associated 
HLA-C*04:01 allele and other IM-ADR associated alleles. 
Whole blood samples from healthy donors were obtained through the Australian Bone 
Marrow Donor Registry. The donors had given informed consent. CBZ-naive donors 
included; 
Control 1 (CBZ-naive) carried the HLA-B*15:02 allele (HLA-A*02:03:01, -A*24:07,  
-B*15:02, -B*56:01, -DRB1*04, -DRB1*09), was serologically positive for HSV-1 and 
negative for HSV-2, and was CBZ-naive. 
Control 2 (CBZ-naive non-B*15:02) did not carry the HLA-B*15:02 allele (HLA-A*02, 
-B*15:11, -B*38, -DRB1*11, -DRB1*16:02:01), was serologically positive for HSV-1 
and negative for HSV-2, and was CBZ-naive. 
Control 3 (CBZ-naive) carried the HLA-B*15:02 allele (HLA-A*11, -A*33:03:01,  
-B*15:02, -B*58, -DRB1*03, -DRB1*15) and was CBZ-naive. Control 3 (CBZ-naive) 
was also serologically negative for HSV-1 and HSV-2.  
Control 4 (CBZ-naive non-B*15:02) did not carry the HLA-B*15:02 allele (HLA-A*02 -
A*322012, -B*35:01, -B*51, -C*04:01, -DRB1*01:01, -DRB1*03:02) and was CBZ-




Ethical considerations and approvals 
Project 
Title: 
Pharmacogenomics and mechanistic basis of drug 
hypersensitivity 
Project No.: 2014/20 Murdoch University Human Research Ethics 
Committee 
Dates: 22 January, 2014 until December 2016  
Listed as: Student researcher 
Limitations 
The limitations associated with sample size listed previously (Materials and Methods, 
Section 2.1.1.2) also apply to CBZ-associated studies. A unique limitation with CBZ-
HSR samples includes the inability to get follow-up samples. Once a patient has 
recovered from an SJS/TEN reaction, they are not required to return for ongoing 
medical attention and as long as they avoid the culprit drug. This makes retaining 
multiple Donor samples problematic. CBZ-tolerant, HLA-B*15:02 positive patients 
have also been hard to obtain. 
Table 2.2: List of samples used in CBZ-HSR immunopathogenesis associated studies. 
Samples Drug 
HSR 
phenotype HHV serology Other 
Donor 1 (CBZ-TEN) CBZ TEN 
HSV-2 IgG + 
Acute HZ and PHN  
Patch test + 
HLA-B*15:02 + 
Donor 2 (CBZ-SJS) CBZ SJS HSV-1 IgG + HLA-B*15:02 + 
Donor 3 (CBZ-SJS) CBZ SJS 
HSV-1 IgG + 
HSV-2 IgG + 
HLA-B*15:02+ 
Donor 4 (CBZ-SJS 
non-B*15:02) 
CBZ SJS HSV-1 IgG + Non-HLA-B*15:02  
Control 1 
(CBZ-naive)  
CBZ-naive - HSV-1 IgG + HLA-B*15:02 + 
Control 2 (CBZ-
naive non-B*15:02) 
CBZ-naive - HSV-1 IgG + Non-HLA-B*15:02 
Control 3 
(CBZ-naive)  
CBZ-naive - Negative HLA-B*15:02+ 
Control 4 (CBZ-
naive non-B*15:02) 
CBZ-naive - Unknown Non-HLA-B*15:02 
CBZ, carbamazepine; SJS, Stevens-Jonson syndrome; TEN, toxic epidermal necrolysis; HSR, 
hypersensitivity reaction; HHV, human herpesvirus; HZ, Herpes Zoster, PHN, post-herpetic neuralgia;  
HSV-1, Herpes simplex virus-1; HSV-2, Herpes simplex virus-2; 
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2.2 Cellular Assays 
Table 2.3 List of reagents used in Stimulation and Expansion, flow cytometry, and Lymphoblastic cell 
lines (LCL) generation assays. Flow cytometry antibodies are included on Table 2.4, tetramer reagents 
included in Tables 2.5-2.7 and ELISpot associated reagents and materials are included in Table 2.8 
Reagent  Manufacture  Catalogue Number 
RPMI-1640 with phenol red Gibco 21-870-076 





DNase Promega RQ1 
L-glutamine  Gibco 25030-081 
Penicillin / Streptomycin Gibco 15-140-148 
Sodium pyruvate Gibco 25030-081 
Invitrogen Countess Invitrogen C10227 
RNAlater stabilisation solution Life technologies AM2070 
Recombinant human (rh) IL-2 R&D systems  
Recombinant human (rh) IL-7 R&D systems 207-IL 
Recombinant human (rh) IL-15 R&D systems 247-IL 





Extracted from Viramune 
Phosphate-buffered saline  
(1 x PBS) 
Gibco 70013032 
6-well flat-bottom culture plates  BD Falcon 353046 
12-well flat-bottom culture plates BD Falcon 353043 
96-well U-bottom plate BD Falcon 353077 
Brefelden A Sigma B7651 
IsoFLOW Sheath fluid Beckman Coulter 8546859 
IntraPrep Reagent kit Beckman Coulter A07802 
Safe-Lock 1.5mL Eppendorf Tubes Crown Scientific 0030.120.086 
Cryotubes  Nunc Bank-It 374078 
PE-streptavidin   BD Biosciences 554061 
BD Cytokine Bead Array (CBA)  BD Scientific  560484 
T-25 and T-75 culture flasks  BD Falcon 353108 and 353136 
0.45μm sterile filter with plunger Sigma  CLS431225 
Mycoplasma plus PCR primer kit  Agilent  302008 
Lectin Phytohemagglutinin (PHA-P) Sigma  L8754 
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2.2.1 Drug Stimulation and Cellular Expansion 
Day 0 - Cryopreserved PBMC’s were thawed and washed with RPMI-1640 media 
(Gibco; Cat. No. 21-870-076) medium containing 10% heat-inactivated foetal calf 
serum (FCS) (Invitrogen and Serana; Cat. No. C8056 and S-FBS-AU-015, 
respectively) and 10U/mL DNase (Promega; Cat. No. RQ1) being added between the 
first and second washes, as highlighted by Garcia-Piñeres et al. 2006) (178, 179). 
PBMC’s were then resuspended in R10 media, which contained RPMI-1640 media, 
10% heat-inactivated FCS, 1μM L-glutamine (Gibco; Cat. No. 25030-081), 50 U/mL of 
penicillin, 50 μg/mL of streptomycin (1% v/v Gibco; Cat. No. 15-140-148), and 1μM 
sodium pyruvate (Gibco; Cat. No. 25030-081) and incubated at 37°C overnight (Figure 
2.1) (83). 
Day 1 – recovery and viability of PBMC’s was determined by staining a 10μL aliquot of 
PBMC’s with 0.4% Trypan Blue solution and counting cells via the Invitrogen Countess 
method (Invitrogen; Cat. No. C10227). An appropriate aliquot of cells were removed 
for pre-stimulation IFN-γ ELISpot, intracellular cytokine staining (ICS) and 
immunophenotyping flow cytometry assays or stored in RNAlater stabilisation solution 
(Life technologies; Cat. No. AM2070) until the Ribonucleic acid (RNA) extraction could 
be performed. 
10 million cells per mL (1 x 107 cells/mL) were resuspended in R10 media (Section 
2.2.1, Drug Stimulation and Cellular Expansion) containing 50 μg/mL of recombinant 
human (rh) IL-7 (R&D systems; Cat. No. 207-IL) (Figure 2.1). The cells were split into 
three aliquots for control and test assays. R10 media (Section 2.2.1, Drug Stimulation 
and Cellular Expansion), supplemented with 50 μg/mL of rhIL-7 containing and either 
the control drug stimulant, or test stimulant (CBZ [Sigma; Cat. No. C4024]) was added 
to the aliquots, giving a final stimulant concentration of 10 μg/mL, (unless otherwise 
stated). For the unstimulated control, additional R10 media (Section 2.2.1, Drug 
Stimulation and Cellular Expansion), supplemented with 50 μg/mL of rhIL-7 containing 
was added to give the same final volume across all three aliquots (Figure 2.1). Cells 
were than incubated at 37°C for 1-2 hours. 
After stimulation, the cells were washed with a volume of cold RPMI-1640 media and 
resuspended in R10 media (Section 2.2.1, Drug Stimulation and Cellular Expansion) 
supplemented with 50 μg/mL of rhIL-7, giving a final concentration of 5 million cells per 
mL (5 x 106 cells/mL). Cells were seeded into labelled wells of a 6- or 12-well flat-
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bottom culture plates (BD Falcon; Cat. No. 353046 and 353043, respectively) and 
incubated at 37°C for up to 48 hours. 
Day 3 - 50% of the culture supernatant was removed and replaced with new R10 
media (Section 2.2.1, Drug Stimulation and Cellular Expansion) supplemented with 50 
μg/mL of rhIL-7 and with 50 μg/mL rhIL-15 (R&D systems; Cat. No. 247-IL). The 
cultures were incubated at 37°C for another 48 hours. 
Day 5 - Cultures were split, and cultures made up to the first volume by new R10 
media (Section 2.2.1, Drug Stimulation and Cellular Expansion) containing rhIL-7 and 
rhIL-15 as previously stated (Figure 2.1). The cultures were incubated at 37°C for 
another 5 days. 
Day 10 - cells were transferred to labelled 15 mL falcon tubes, washed and 
resuspended in R10 media (Section 2.2.1, Drug Stimulation and Cellular Expansion). 
The cultures were incubated at 37°C for another 4 days so they could stabilise. 
Day 14 - cell viability and counts were performed and cells washed in RPMI-1640 
media, centrifuged, and resuspended in the appropriate media for IFN-γ ELISpot, ICS 
and immunophenotyping flow cytometry assays or stored in RNAlater stabilisation 
solution until the RNA extraction could be performed (Figure 2.1). 
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Drug stimulation and cellular expansion protocol 
 
Figure 2.1: Timeline of the stimulation and cellular expansion culture protocol for analysis of CBZ-
specific polyclonal T cells. 
2.2.2 Flow Cytometry 
The mutlicolour flow assays and reagent panel combinations were carefully selected 
using spectralviewer anaylsis provided online by BD Biosciences (180). Instrament set 
up controls inculded BD CompBeads (BD Biosciences, Cat. No. 644204). The 
fluorescence minus one, single colour stained controls and unstained control methods 
were also employed for compensation and adjusting photomultiplier tube voltages. All 
flow cytometry experiments were analysed with specific biological controls like 





Removed cells from Liquid N2. Cells were thawed, washed, and resuspend in F10 
media. Cells were rested overnight in the cellular incubator (37˚C with 5% CO2)
Cells were counted, washed, and aliquoted appropriately  for  
-ICS, -ELISpot, -Storage in RNAlater stabilising solution for later RNA extraction 
and TCR analysis 
Remaining cells were aliquoted appropriately, washed and resuspended in 
rhIL-7-F10 media with the 10μg/mL of CBZ, control drug, or left unstimulated.  
After 1-2 hours of test/control stimulation, cells were washed, resuspended in 
rhIL-7-F10 media and incubated for 48 hours. 
50% of the culture media was removed and replaced with rhIL-7-F10 media 
further supplemented with rhIL-15. 
Cultures were split into 2 and the culture media  replenished with rhIL-7-F10 
media further supplemented with rhIL-15. 
1 aliquot was stored in RNAlater stabilising solution. 
Remaining cells were washed, resuspended in F10 media, and rested in the 
cellular incubator for 48 hours. On day 12 this was repeated. 
Cells were washed, counted, and resuspended in the appropriate media for 
ELISpot and ICS analysis.   
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Table 2.4: Flow cytometry Fluorochrome conjugated antibodies. 




Filter (nm) Cat. 
No 
Anti – Human 
CD3 
V450 405/448 405 450 BP *50 
#
560373 






575 BP *30 
#
340419 









Anti – Human 
CD8 













575 BP *30 #555413 






660 BP *20 
#
555518 






660 BP *20 
+
306718 
Anti – Human 
IFN-γ 







Anti – Human 
Granulysin 
(15- and 9 kDa) 









Multiple fluorochrome - Ig 
κ anti-human Ab 
- - - #644204 
*The number after the filter represents band width in nanometres (nm). #BD Bioscience and +Bio Legend Cat. 
No., catalogue numbers. BP, band pass filter; LP, long pass filter; EXmax, excitation maximum; Emmax, 
emission maximum. 
 
2.2.2.1 Intracellular cytokine staining 
Cryopreserved PBMC’s were thawed, washed, and resuspended in R10 media 
(Section 2.2.1, Drug Stimulation and Cellular Expansion). Cells were incubated 
overnight and viability and cell number determined. Cells were resuspended in R10 
media (Section 2.2.1, Drug Stimulation and Cellular Expansion) giving a final 
concentration of 0.5-1.0 x 107 cells/mL. Unlike the ELISpot and the Drug Stimulation 
and Cellular Expansion protocols, R10 media (Section 2.2.1, Drug Stimulation and 
Cellular Expansion) was not supplemented with cytokines as rhIL-2 and rhIL-15 have 
been associated with the activation of granulysin expression within CD8+ T cells (181). 
100 μL of cells were seeded into labelled wells of a sterile 96-well U-bottom plate (BD 
Falcon; Cat. No. 353077). A further 80 μL of R10 media (Section 2.2.1, Drug 
Stimulation and Cellular Expansion), either containing the appropriate test drug (CBZ) 
or control drug was added to the 100 μL of cells, to obtain a final stimulant 
concentration higher than 10 μg/mL, which would be rectified with the addition of 
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Brefelden A (Sigma; Cat. No. B7651). For the unstimulated control cells, 80 μL of R10 
media (Section 2.2.1, Drug Stimulation and Cellular Expansion) was added. Cells were 
incubated at 37°C for 2 hours, before adding 20 μL of Brefelden A giving a final 
concentration 10 μg/mL. The cells were incubated at 37°C for 6 hours (unless 
otherwise stated) 
After incubation, the cells were washed with 200 μL of IsoFLOW Sheath fluid 
(Beckman Coulter; Cat. No. 8546859) and the supernatant removed. The appropriate 
cell-surface fluorochrome-conjugated antibodies, listed in Table 2.3 was added to the 
cells and incubated in the dark (plate wrapped in aluminium foil) at 4˚C for 15 minutes. 
Cells were then fixed and permeabilized using the IntraPrep Reagent kit, following the 
protocol outlined by the manufacture (Beckman Coulter; Cat. No. A07802) (182).The 
appropriate fluorochrome labelled cytokine antibody, was added and the cells 
incubated at 24○C, in the dark (plate wrapped in aluminium foil) for 15 minutes (Table 
2.3). Cells were washed and resuspended in 200 μL of IsoFLOW. Flow cytometry was 
performed on the stained cells using the Gallios Flow Cytometer and the raw data 
analysed using the Kaluza flow cytometry software. 
2.2.2.2 Surface Marker staining and Immunophenotyping 
Similar to the ICS flow cytometry assay (Section 2.2.2.1) The multicolour flow assays 
and reagent panel combinations were carefully selected using spectralviewer anaylsis 
provided online by BD Biosciences. Instrament set up controls inculded BD 
CompBeads (BD Biosciences, Cat. No. 644204), fluorescence minus one and 
unstained controls, and specific biological controls like unstimulated samples. Cells 
were seeded into labelled wells, stained with cell-surface marker fluorochrome-
conjugated antibodies, listed in Table 2.3 and incubated on ice in the dark for 25-30 
minutes. After incubation, the cells were washed and resuspended in 200 μL of 
IsoFLOW reagent. Flow cytometry was performed on the stained cells using the 
Gallios Flow Cytometer and the raw data analysed using the Kaluza flow cytometry 
software. 
2.2.2.3 Tetramers 
Tetramer folding and construction 
HLA class-I complex folding mixture was made as outlined in Table 2.4 and by Leisner 
et al. and Svitek et al. (183, 184). The β2M and B*1502 reagents were supplied by our 
colleagues and made as outlined in Leisner et al. and Svitek et al. (183, 184). After 
incubating the HLA class-I complex folding mixture for 48 hours at 18-24 C, it was 
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filtered through a 0.5 mL 100kD membrane spin filter by centrifuging at 15,000 relative 
centrifugal force (RCF) or 14245 revolutions per minute (RPM) (FX241.5P rotor in 
Microfuge 16) for 2 minutes at 4-6◦C. 
The folded peptide/HLA class-I complex was taken through tetramer production 
process. 100 μL of the peptide/HLA class-I complex was added to separate labelled 
sterile Safe-Lock 1.5mL Eppendorf Tubes (Crown Scientific; Cat. No. 0030.120.086) 
and streptavidin-PE (1.85 μM BD Bioscience; Cat. No. 554061) was added in 
sequential aliquots as highlighted Table 2.6 with a final concentration of streptavidin-
PE being 4.10% of the starting peptide/HLA class-I complex volume. The PE-
tetramers were aliquoted into labelled cryotubes (1 mL, Nunc Bank-It; Cat. No. 
374078) at a smaller working volume of 10-20 μL to limit the amount of freeze/thawing 
and stored at -80’C until required. 
Table 2.5: Tetramer folding mix. 
Reagents  Stock Conc. (μM) Final Conc. (μM) Volume (μL)  
x1 reaction 
Sterile deionised H2O - - 294 
Tris/maleate 
(pH 6.6) 
6 1 67 
Lutrol (F68) 1 0.03 12 
*Protease inhibitors 100 1 4 
Peptide  500 6 5 
β2M (FN345-346) 80.6 3 15 
B1502 (FN286) 32.7 0.3 37 
Total  - - 400 
*Outlined in Table 2.4 μM, micromolar; μL, microliter; β2M, Beta 2-2-Microglobulin; B1502, light chain 
B*15:02 sequence 
Table 2.6: Protease inhibitor mix. 
Protease inhibitor mix (100x concentration) Volume (μL) 
Sterile deionised H2O 37.50 
EDTA 14.80 
Pepstatin A  4.80 
1,10- phenantroline  4.80 
NEM  7.40 
TLCK  1.30 
TPCK  1.30 
PMSF  2.10 
Total volume 74.00 
EDTA, Ethylenediaminetetraacetic acid; NEM, N-Ethylmaleimide; TLCK, Tosyl-L-lysine chloromethyl 




Table 2.7: Addition of streptavidin-PE labelled to peptide/HLA class-I complex. 
Time (minutes) Volume of streptavidin-PE (1.85 μM) added to 100 μL of 
peptide/HLA class-I complex  
0 1.2 μL 
15 0.60 μL 
25 0.60 μL 
35 0.60 μL 
45 0.60 μL 
55 0.60 μL 
Total streptavidin-PE 4.10 μL 
μM, micromolar; μL, microliter; PE, phycoerythrin; HLA, human leukocyte antigen 
Tetramer staining 
Tetramer staining followed the same basic flow cytometry protocol seen in Section 
2.2.2.2 Surface Marker staining and Immunophenotyping, with the exception that 5 μL 
of the PE-tetramer was added and the cells incubated in the dark (plate wrapped in 
aluminium foil) at 24 C for 20 minutes before the cells were stained with appropriate 
cell-surface fluorochrome-conjugated antibodies, listed in Table 2.3 to the appropriate 
samples. Once stained, cells were washed and resuspended in 200 μL of IsoFLOW 
reagent. Flow cytometry was performed on the stained cells using the Gallios Flow 
Cytometer and the raw data analysed using the Kaluza flow cytometry software. 
2.2.2.4 Cytometric Bead Array cytokine assay 
The Cytometric Bead Array (CBA) Th1/Th2/Th17 kit (BD Scientific; Cat No. 560484) 
included capture beads for the cytokines; IL-2, IL-4, IL-6, IL-10, TNF, IFN-γ, and IL-
17A, each of which has a unique fluorescence intensity so that beads can be mixed 
and the assay performed in a single tube. This assay was performed on plasma 
samples, as outlined by the manufacture. Plasma samples were serial diluted with the 
supplied assay diluent, to find the optimal plasma to assay diluent ratio. The optimal 




2.2.3 Enzyme-Linked ImmunoSpot 
Table 2.8 List of reagents and materials used in ELISpot assay.  
Reagent  Manufacture Catalogue Number  
MutliScreen-IP Hydrophobic PVDF 




anti–IFN-γ antibody  Mabtech 1-D1k 
Dimethyl sulfoxide (DMSO) Sigma 472301 
N-N-Dimethylformamide (DMF) Sigma 140732 
Anti-human CD3 monoclonal 
antibodies  
Mabtech 3605-1-50 
CEF peptide pool  Mabtech 3615-1 
Staphylococcal enterotoxin B (SEB) Sigma S4881-1MG 
anti–IFN-γ biotinylated antibody Mabtech 7-B6-1 
streptavidin-HRP Mabtech 3310-9 
3’, 3’, 5’, 5’-tetramethylbenzidine (TMB) Mabtech 3652-R10 
AID automated microplate ELISpot 
reader and associated software 
AID V 5.0 - B7337 
 
2.2.3.1 ELISpot assay 
IFN-γ ELISpot assay was performed following the manufacturer’s instructions (R&D 
Systems). Cells were resuspended in R10 media (Section 2.2.1, Drug Stimulation and 
Cellular Expansion) supplemented with 10U/mL of rhIL-2 at 2x106 cells/mL. The 2x105 
cells (100 μL), in duplicate/triplicate, were seeded into the appropriate wells of a 
MultiScreen-IP, Hydrophobic PVDF Sterile Filter ELISpot Plate(s) (Mabtech; Cat No.  
MAIPS4510), coated with 2 μg/mL of anti–IFN-γ antibody (Mabtech; Cat. No. 1-D1k), 
then incubated overnight or for a minimum of 18 hours, at 4°C and blocked with R10 
media (Section 2.2.1, Drug Stimulation and Cellular Expansion). 
Negative controls included the unstimulated controls in which 100 μL of R10 media 
(Section 2.2.1, Drug Stimulation and Cellular Expansion) supplemented with 10U/mL 
of rhIL-2 was added to the seeded cells. The solvent controls included adding 100 μL 
of R10 media (Section 2.2.1, Drug Stimulation and Cellular Expansion) supplemented 
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with 10U/mL of rhIL-2 media containing Dimethyl sulfoxide (DMSO) / 
Dimethylformamide (DMF) (Sigma; Cat No. 472301 and 140732, respectively), giving 
a final concentration 0.1 μL/200 μL. The negative controls were performed in triplicate 
(unless otherwise stated). 
The positive controls (duplicate) included, adding 100 μL R10 media (Section 2.2.1, 
Drug Stimulation and Cellular Expansion) supplemented with 10U/mL of rhIL-2 with 
Anti-human CD3 monoclonal antibodies (Mabtech; Cat. No. 3605-1-50), giving a final 
concentration of 0.1 μg/mL per well. Secondary positive controls included 100 μL R10 
media (Section 2.2.1, Drug Stimulation and Cellular Expansion) supplemented with 
10U/mL of rhIL-2 with 1 μg/mL of either CEF peptide pool (Mabtech; Cat. No. 3615-1) 
or Staphylococcal enterotoxin B (SEB) (Sigma; Cat No. S4881-1MG). 
Drug-stimulated IFN-γ ELISpot assays involved control drugs (acyclovir) and the drugs 
being analysed, CBZ or NVP (Sigma; Cat. No. SML0097 or Boehringer Ingelheim; 
VIRAMUNE 200mg immediate release tablets (Appendix 9, Section 9.1 Nevirapine 
isolation from Viramune tablets)). Drugs and synthesised peptides were stored in 
DMSO or DMF at a stock concentration of 10 mg/mL were diluted with R10 media 
(Section 2.2.1, Drug Stimulation and Cellular Expansion) supplemented with 10U/mL 
of rhIL-2 and added (in triplicate) to seeded cells, to give a final concentration of 10 
μg/mL (unless otherwise stated). 
After incubation, ELISpot plates were washed with sterile Phosphate-buffered saline (1 
x PBS) solution (Gibco, Cat. No. 70013032) and incubated with anti–IFN-γ biotinylated 
antibody (Mabtech, Cat. No. 7-B6-1) for 2 hours. After incubation with the anti–IFN-γ 
biotinylated antibody, ELISpot plates were washed, and incubated for 1 hour with 
streptavidin-HRP (Mabtech, Cat. No. 3310-9), and then washed again. Plates were 
substrated for 8-12 minutes using the 3’, 3’, 5, 5’-Tetramethylbenzidine substrate 
(Mabtech, Cat. No.3652-R10). Once the plates were air-dried, counts were evaluated 
with an AID automated microplate ELISpot reader and associated software (AID 
ELISpot Version 5.0, B7337). The AID reader was staged, calibrated, and set to the 
manufactures default settings. Files were saved as raw images and a PDF file was 
created using the Nitro PDF created with the details of the time, date, cytokine being 
analysed, media used, and the sample(s) identifying number. 
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2.2.4 Lymphoblastic Cell Lines 
2.2.4.1 EBV supernatant 
Lymphoblastic cell lines (LCL) were generated from patient peripheral B cells using 
EBV B95-8 strain. EBV supernatant was generated from cryopreserved EBV B95-8 
cells. Each vial was thawed and resuspended in RPMI-1640 media, which was added 
in a drop wise fashion to make a final volume of 10 mL. EBV cells were centrifuged, 
the supernatant removed, and cells resuspended in 10 mL of RPMI-1640 media 
supplemented with sterile filtered, non-heat inactivated FCS (v/v 20%), sodium 
pyruvate (1μM), and L-glutamine (1μM) (185). 
The EBV cells were transferred to a labelled, sterile, T-25 culture flask (BD Falcon; 
Cat. No. 353108) and incubated at 37°C, until an appropriate amount of cells were 
acquired and/or a change in the phenol red pH indicator from red to yellow, indicating 
the change of phenol to phenolic acid, (7-10 days). The supernatant was collected, 
and filtered through a 0.45μm sterile filter (Sigma; Cat. No. CLS431225). The sterile 
supernatant was then aliquoted into sterile 1.8 mL cryotubes and frozen to -80◦C 
before transfer into liquid nitrogen storage. The EBV cells were also resuspended in 
cryopreservation media (heat-inactivated FCS with 10% DMSO) and stored in liquid 
nitrogen. Up to 5 million (5x106) cells were used to for Mycoplasma testing using the 
Mycoplasma plus PCR primer kit (Agilent; Cat. No. 302008). (186, 187) 
2.2.4.2 Lymphoblastic cell line generation 
PBMC’s were thawed and washed with non-heat inactivated FCS based F20 media 
(Section 2.2.4.1, EBV supernatant) and incubated at 37°C overnight (185). The 
following day cell viability and counts were performed using 0.4% Trypan Blue solution 
and the Invitrogen Countess method (Chapter 2, Section 2.2.1 Drug Stimulation and 
Cellular Expansion). Cells were resuspended in non-HI serum based F20 media at 0.5 
to 1 million (0.5x106 to 1x106) cell per mL 
2.5 mL of PBMC’s / F20 were aliquoted into labelled wells of a 6-well flat-bottom 
culture plate and a further 0.5 mL of EBV supernatant was added to make a final 
volume of 3 mL15 μL of the Lectin Phytohemagglutinin from Phaseolus vulgaris  
 or PHA-P (Sigma; Cat No. L8754) at a concentration of 2.5 mg/mL was then added to 
the 3 mL of PBMC’s / EBV supernatant sample. The cells were incubated at 37°C, for 
up to 14 days, with an extra 1 mL of in non-heat inactivated FCS F20 media being 
added at day 4 and 12 (185). 
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After 14 days the cells were counted, centrifuged, and resuspended in F20 media 
made with components as mentioned in Section 2.2.4 Lymphoblastic Cell Lines 
Lymphoblastic Cell Lines, except for the addition of sterile filtered, heat-inactivated 
FCS (20% v/v) and Penicillin-Streptomycin (1% v/v). Cells were transferred to a T-25 
culture flask and monitored as they grew, with cell counts being performed and the 
appropriate amount of F20 (with heat-inactivated FCS and Penicillin-Streptomycin) 
being added to keep a concentration of 1 million (1 x 106) cells per mL. Cultures were 
transferred to sterile T-75 culture flasks (BD Falcon; Cat. No. 353136) when required 
and once the suitable numbers of LCLs were generated, they were cryopreserved until 
required. A 5 million (5x106) cells aliquot was used for Mycoplasma testing and a 
further 1-2 million (1-2 x 106) cells were used to determine the B-cell and T-cell 
frequencies in the flow cytometry LCL cultures at various stages (186, 187). 
2.3 Virtual Modelling and in-silico Peptide Design 
The virtual modelling of HLA molecules and drug/peptide interactions was performed 
by Dr David Ostrov and colleagues, University of Florida College of Medicine, 
Gainsville, Florida, USA Several 9-11mer, HLA-B*15:02-restricted HSV-1 (strain 17) 
and HSV-2 (strain HG52) peptides were synthesised based on the in-silico epitope 
mapping predictions performed by colleagues at The Institute for Immunology and 
Infectious Diseases, Murdoch University, Perth, Australia using Net-MHC3.2 based 
algorithms, combined with a novel measure of “targeting efficiency” developed in 
collaboration with Microsoft research. (169, 170, 188-190) 
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2.4 Molecular Assays 
Table 2.9 List of reagents and materials used in molecular assays. Specific PCR associated reagents 
and concentrations are listed in the relevant tables.  
Reagent  Manufacture Catalogue Number  
Maxwell 16 Total RNA purification kit  Promega 1050  
RNeasy mini-kit QIAGEN  74104 
Tris-EDTA (TE) buffer  Sigma 93283 
4% E-gel  Invitrogen G700892 
QIAGEN MinElute PCR purification kit  QIAGEN 28604 
NanoDrop DNA quantification  Thermo Fisher  ND-1000 with v3.2.1 
software 
Axygen 96-well PCR Half Skirt plate  VWR PCR-96-HS-C 
DG8 Cartridge and gaskets  Bio-Rad 186-4007 
DG8 Cartridge holder Bio-Rad 186-3051 
QX100/200 ddPCR Droplet Generator  Bio-Rad  186-4002  
VIAFLOW Electronic pipette  




(replacement tips 4445) 
Hard-Shell 96-Well PCR plate Bio-Rad HSP 9601 
Peirceable foil heat seal Bio-Rad 181-4040 
ddPCR Droplet reader oil Bio-Rad 186-3004 
C1000 Thermal Cycler 96-Deep Well Bio-Rad 185-1197 
QuantaSoft, QX100/200 ddPCR reader Bio-Rad 186-4003 
QuantaSoft, QX100/200 ddPCR 
analysing software 
Bio-Rad Version 1.5.38.1118 
 
2.4.1 RNA isolation and complementary DNA conversion 
Cells isolated from cell culturing assay’s (Section 2.2.1 Drug Stimulation and Cellular 
Expansion) were stored in RNAlater stabilisation solution, following the manufactures 
instructions. When ready for RNA extraction, the cells were removed from RNAlater 
suspension and resuspended in the appropriate amount of 1 x PBS. RNA was 
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extracted from the cells using either the Maxwell 16 Total RNA purification kit 
(Promega; Cat. No. 1050) or the RNeasy mini-kit (QIAGEN; Cat. No. 74104) and 
following the appropriate protocol outlined by the manufacture. For the ddPCR, a two-
step reserve transcriptase PCR approach was used to assess RNA expression. RNA 
conversion to complementary DNA (cDNA) was performed by preparing the reagent 
mix and following the protocol outlined in Table 2.10 while following the thermocycling 
conditions outlined in Table 2.11 





Oligo d(T) 20mer (50 µM) 
(Invitrogen; Cat. No. N8080128) 
2.5 µM 1 
RNA - 10 
Samples incubated at 65◦C for 5 minutes 
5x first strand buffer 
(Invitrogen; Cat. No. 18080-093) 
1x 4 
dNTPs (40mM) 
(Invitrogen; Cat. No. 10297-117) 
4 mM 2 
dithiothreitol (0.1mM) 
(Invitrogen; Cat. No.15508-013) 
5 μM 1 
Sterile deionised Water 
(Sigma; Cat. No. W3500-1L) 
- 0.5 
RNase out (40 U / μL) 
(Invitrogen, Cat. No.10777-019) 
20 U 0.5 
Samples then incubated at 37◦C for 5 minutes 
SSIII Reverse Transcriptase  
(200 U / μL) (Invitrogen; Cat. No. 18080-093) 
200 U 1 
dNTPs, Deoxyribonucleotide triphosphates (dATP, dCTP, dGTP, and dTTP); μM, micromolar; μL, 
microliter. 
 
Table 2.11: Cycling conditions for complementary DNA (cDNA) conversion 
Cycle Temperature (°C) Time 
Cycle 1 x 42 5 minutes 
Post cycle 10 infinite 
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2.4.2 Digital Droplet PCR 
2.4.2.1 Reference sequence Amplification, Purification, and 
Quantitation 
As TCRs are highly variable and it is difficult to have a positive control for all the TCR 
combinations. A synthetic construct was designed as a positive control and for the 
assay workup. The g-Blocks gene fragment reference sequence incorporated the 
various primer sequences to be used in the amplification and identification Vβ TCR 













 Table 2.12: M13F and M13R primers used to amplify the reference sequence to use the amplicons to 
as a positive control. 
Primer  Primer Sequence (5’-3’) Length  GC% Tm (°C) 
M13-Fw 
(Forward) 
TGTAAAACGACGGCCAGT 18 50 63.59 
M13-Re 
(Reverse) 
CAGGAAACAGCTATGACC 18 50 63.59 
GC%, percentage of cytosine and guanine within primer; Tm (°C), calculated melt temperature; and bp, 
base pairs. 
The reference cDNA sequence was resuspended in Tris-EDTA (TE) buffer (Sigma; 
Cat no. 93283) giving at 10 ng / μL. The M13 primers listed in Table 2.12 and the 
mastermix reagents and concentrations highlighted in Table 2.13 were used, along 
with the PCR thermocycling conditions, highlighted in Table 2.14, to amplify the 
reference gene. Amplified products were then analysed via electrophoresis on either a 
4% E-gel run for 20 minutes (Invitrogen; Cat No.G700892) and purified using the 
52 
QIAGEN MinElute PCR purification kit (QIAGEN; Cat. No. 28604) following the 
manufacture protocols. 
Table 2.13: Reference sequence amplification reagent Mastermix to amplify the reference sequence to 
use the amplicons to as a positive control. 
Reagent Final 
concentration 
x1 reaction volumes 
(µL) 
*PCR buffer (10x) 
(Invitrogen; Cat. No. 18067-017) 
*1x *2 
MgCl2 (50 mM) 
(Invitrogen; Cat. No. 18067-017 
1.5 mM 0.6 
dNTP (40 mM) 
 (Invitrogen; Cat. No. 10297-117) 
2 mM 1 
Forward primer (25 µM) 0.625 nM 0.5 
Reverse primer (25 µM) 0.625 nM 0.5 
*Platinum Taq (5U / µL) 
(Invitrogen; Cat. No. 10966-026) 
*2.5 Units *0.5 
Sterile deionised H2O  - 13.2 
Ref sequence cDNA (10 ng / µL) 10 ng / μL 1 
*1-2.5 Units recommended by Invitrogen for use of Platinum Taq DNA polymerase 
#Reference sequence was resuspended in TE buffer at 10ng/μL. IDT, the manufacture recommends 
using 0.1-10 ng for amplification. mM, millimolar; µM, micromolar; nM, nanomolar; U, units; cDNA, 
complementary DNA; PCR, polymerase chain reaction. 
 
Table 2.14: Reference sequence amplification PCR cycling conditions for the amplification of the 
reference sequence to use the amplicons to as a positive control. 
Cycle Temperature (°C) Time 










Extension 72 5 minutes 
Post cycle 15 Infinite 
 
Quantification of the reference sequence amplicons was done using NanoDrop DNA 
quantification (Thermo Fisher; Cat. No. ND-1000 with v3.2.1 software) and the DNA 
copy number calculated using the following equation; The amplicons were diluted with 
TE buffer to obtain a range of copy number concentrations ranging from 7.48 x 1011 
copies per μL to 7.48 copies per μL. 
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 Copy No. =   Amount of DNA (ng) x 6.022x1023  
  ((length (bp) x 1x10
9
(ng/g) x 650 (g/mole of bp)) 
 
2.4.2.2 Digital droplet PCR protocol  
The forward and reverse primers listed in Table 2.17 were validated using the 
reference cDNA sequence (Appendix 9, Section 9.2). The validated primers were 
added to into labelled sterile Safe-Lock 1.5mL Eppendorf Tubes, to give a final 
concentration of 100 nM per primer, along with the 2x EvaGreen supermix for ddPCR 
and sterile deionised water (Table 2.15). To automate the addition of mastermix and 
samples, to an Axygen 96-well PCR Half Skirt plate (VWR: Cat. No. PCR-96-HS-C), 
the Beckman Coulter Biomek FXP automated workstation requires the relevant 
position, size, and volumes data, be saved into a comma-separated values (CSV) file, 
which the robot can read and perform accordingly. This CSV file is simple file format 
used to store tabular data which can be converted and saved in plain text.  
For each sample, 22.5 μL of the mastermix was added to each well of an along with 
2.5 μL of sample cDNA, or the appropriate control. The positive control reference 
sequence amplicons were added manually in the designated Post-PCR Laboratory or 
the laboratory designated for all samples that have already undergone PCR 
amplification in order to prevent cross contamination of amplified PCR products in 
samples being prepared in the designated Pre-PCR Laboratory or the laboratory 
designated for all samples which have not undergone PCR amplification. Once 
complete, plates were sealed using adhesive PCR film samples centrifuged 
(Eppendorf Centrifuge) and droplet generation was performed in the Post-PCR 
Laboratory. 
The DG8 cartridge was placed into the ddPCR cartridge holder and 20 μL of the 25 μL 
PCR was loaded into the middle sample well section of the DG8 Cartridge, in the 
appropriate order. Then 70 μL of the ddPCR Droplet Reader Oil was loaded into the 
first, reader oil well and the DG8 gasket added to the ddPCR cartridge holder with the 
loaded ddPCR cartridge (Figure 2.2). The cartridge was then placed into the 
QX100/200 ddPCR Droplet Generator and droplet generated (Figure 2.2). 
After droplet formation, 40 μL of the sample droplets were transferred to the Hard-
Shell 96-Well PCR plate (Bio-Rad, Cat. No. HSP9601), in the same order as 
highlighted in the CSV file generated for the automated process. The plates were 
sealed with a peirceable foil heat seal, then plates placed into C1000 Thermal Cycler 
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96-Deep Well and exposed to the thermocycling conditions outlined in Table 2.16. 
After thermocycling the plate was placed into the ddPCR droplet reader and the raw 
data analysed using the QuantaSoft, QX100/200 ddPCR analysing software (Figure 
2.2). 
 
Figure 2.2: General overview of digital droplet PCR (ddPCR) assay workflow from PCR mastermix 
generation through to droplet generation, amplification, QX100/200 plate reading and analysis. 
Table 2.15: Reagent mastermix for EvaGreen ddPCR. 
Reagent Final concentration x1 reaction volumes 
(µL) 
ddPCR EvaGreen supermix (2x)  
(Bio-Rad Cat No. 186-4033) 
*1x *12.5 
Forward primer (25 µM) 100 nM 0.1 
Reverse primer (25 µM) 100 nM 0.1 
Sterile deionised H2O - 13.2 
Ref sequence cDNA - 2.5 
µM, micromolar; nM, nanomolar; µL microliters; cDNA, complementary DNA; ddPCR, digital droplet 






Table 2.16: Digital droplet PCR (ddPCR) cycling conditions for the amplification of Variable beta (vβ)-
25-1*01 and -12-3/4*01 CDR3 specific sequences, constant beta (Cβ), and ribonuclease P RNA 
component H1 (RPPH1) reference gene sequences. 




 95 30 seconds 
Cycle (40x) 58 30 seconds 




4 5 minutes 








Table 2.17: vβ 25 and 12 CDR3 specific, and reference gene primers. 




Vβ25– ISGSY fwd. CDR3 
Specific primer 
TTGTAGGAACCTGAGATGGAA 21 57.1 63.65 
Vβ25 – GLAGVDN fwd. CDR3 
Specific primer 
TTGTTGTCAACTCCCGCTAACCCACT 26 50.0 63.87 
Vβ25 – ISGSY and GLAGVDN 
rev 
GGTGTGGGAGATCTCTGCTTC 21 57.1 63.79 
Vβ12 Fwd. Primer TGAAGATCCAGCCCTC 16 56.3 63.53 
Vβ12 CDR3 specific rev AAACAGCTCCCCGGCTAAA 19 52.6 63.66 
Cβ fwd TCCAGTTCTACGGGCTCTCG 20 60.0 63.78 
Cβ rev GACGATCTGGGTGACGGGT 19 63.2 63.77 
RPPH1 F AGTGAGTTCAATGGCTGAGG 20 50.0 63.68 
RPPH1 R  GGCGGAGGAGAGTAGTCT 18 61.1 63.70 
Vβ, Variable beta; Cβ, constant beta; and RPPH1, ribonuclease P RNA component H1 gene primers. GC%, 
percentage of cytosine and guanine within primer; Tm (°C), calculated melt temperature; and bp,  
 
2.4.2.3 QX100/200 ddPCR raw data analysis 
The analysis of the QX100/200 raw data output and statistical parameters of the 
ddPCR system is dependent on the partitioning of the template DNA/cDNA into 
uniform droplets. The QuantaSoft software (Version 1.5.38.1118) measures the 
amount of positive and negative droplets based upon the fluorophore in each sample. 
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The fraction of positive droplets is then fitted into a Poisson distribution algorithm to 
determine the starting concentration of the Target DNA/cDNA template as copies per 
μL and copies per reaction (copies per 20 μL). For accurate quantitation with a 95% 
confidence level, a minimum of 14,000-15,000 total droplets are required when using 
the EvaGreen ddPCR method. For the ddPCR specific Vβ CDR3 TCR mRNA analysis, 
TCR mRNA expression levels were normalised using the expression of the 
ribonuclease P RNA component H1 (RPPH1) gene and reporting Vβ CDR3 TCR 




















Based on established drug-HSR models, which illustrates the importance of the HLA 
peptide-binding cleft in specific drug interactions, this chapter will explore the notion 
that NVP-HSR tissue specificity and varied HLA allele associations explained in 
Chapter 1, Section 1.3.3 Nevirapine, Table 1.2, can be explained by similarities in HLA 
peptide-binding cleft structures and predicted peptide specificity and chemistry. We 
sought to compare significant NVP-HSR HLA alleles across ethnic groups by grouping 
NVP-HSR significant HLA alleles according to shared key amino acid residues which 
make up the HLA class-I binding cleft pockets (A-F), based on similarities in cross-
reactivity of public epitopes among HLA class-I alleles and binding cleft pocket 
chemistry (CREG HLA supertypes), and based on MHCcluster algorithm grouping 
(pb), which groups HLA molecules on their peptide-binding specificity as predicted by 
NetMHCpan 2.8, (Table 3.1) (168-172, 191). 
This chapter will also explore the characteristic unique to NVP-SCARs, the diminishing 
ex-vivo NVP-stimulated, PBMC’s IFN-γ responses in patients as they recover from 
DRESS. As identified by Keane et al. 2014, the NVP-stimulated IFN-γ responses in 
NVP-DRESS patient PBMC’s, diminish over time, becoming undetectable after 
recovery. Keane et al. 2014 explored the hypothesis that these diminishing responses 
were due to an increase in CD4+ Tregs levels after NVP withdrawal and during the 
recovery period. In the paper by Keane et al. 2014, one patient exhibited an increase 
in Tregs that corresponded with the waning IFN-γ ELISpot responses (138). 
In this section of the chapter, this hypothesis will be investigated further. However, as 
most of the NVP-DRESS patient PBMC’s samples had been used in the first study by 
Keane et al. 2014, we analysed the cytokine plasma profiles of the same NVP-DRESS 
patients, used in the Keane et al. 2014. We expected that the cytokine environment 
within the donor’s plasma, over the time course of a NVP-DRESS reaction and 
recovery period, alongside the Keane et al. 2014 data, might show changes in specific 




Table 3.1 HLA cross-reactive group (CREG) supertypes and MHC Cluster peptide-binding (pb-) groups 
HLA grouping  HLA alleles (HLA-) Grouping characteristics 
CREG B*07 
supertype 
B*07, B*08, B*13, B*54, B*55, B*56, 
B*27, B*60, B*61, B*41, B*42, B*47, 
B*48, B*59, B*67, B*81, and B*82  
Grouped based on similarities in 
cross-reactivity of public epitopes 
among HLA class-I alleles and 
binding cleft pocket chemistry  
(171, 172, 191) 
CREG B*05 
supertype 
B*18, B*35, B*46, B*49, B*50, B*51, 
B*52, B*53, B*57, B*58, B*62,-B*63, 
B*71, B*72, B*73,B*75, B*76, B*77  
and B*78  
pb-B*35 B*35:(01/05/08), -B*53:01 
Grouped based on their peptide-
binding specificity as predicted by 
NetMHCpan 2.8 (160-162) 
pb-B*78 B*78:01, B*55:01, B*56:01 
pb-C*05 
C*04:(03/06) C*05:(01/09)  
C*08:(01/02) C*17:01 
pb-C*18 C*04:(01/05/07), C*18:01 
 
3.2 Hypothesis and Aims 
Hypothesis 1 
The predicted peptide-binding properties, the structure of the HLA class-I molecule 
peptide-binding cleft, in particular, the B- and F-pockets, and predicted NVP-binding 
properties may be shared between the various HLA alleles associated with 
NVP-SCAR with hepatitis and NVP-SCAR without hepatitis. 
Aim 1 
Retroactively analysing the patient and demographic data from a NVP-HSR 
associated cohort with controls (ClinicalTrials.gov NCT00310843 Chapter 2, 
Nevirapine-Induced HSR 2.1.1) and the NVP-SCAR and NVP-SCAR with hepatitis 
DNA samples will be sequenced and HLA typed. The data will then be analysed to 
identify significant HLA alleles and grouping associations, their predicted peptide-
binding properties, the structure of the HLA class-I molecule peptide-binding cleft, in 
particular, the B- and F-pockets, and predicted NVP-binding properties. 
Hypothesis 2 
The cytokine plasma profiles of NVP-SCAR patients over the time course of the 
reaction represents the changes in T-cell subpopulations, explaining the diminishing 




The CBA Th1/Th2/Th17 kit (BD Scientific; Cat No. 560484) and the method outlined in 
Chapter 2 Materials and Methods, Section 2.2.2.4 Cytometric Bead Array cytokine 
assay will be used to analyse the cytokine profiles of the Plasma from NVP-DRESS 
patents obtained over the time course of their NVP-DRESS reaction. 
3.3  Methods 
3.3.1 NVP-SCAR Associated HLA Class-I Binding Cleft 
Characteristics 
3.3.1.1 HLA four digit typing and Samples 
On the samples highlighted in Chapter 2 Materials and Methods Section 2.1.1.1 NVP-
SCAR associated HLA class-I binding cleft characteristics, HLA-A, HLA-B,  
HLA-C, and HLA-DR PCR amplification was performed by myself in conjunction with 
staff at The Institute for Immunology and Infectious Diseases, Murdoch University, 
Perth, Australia. Using the next generation sequencing 454 FLX+ sequencer platform, 
the amplified products were sequenced and the raw data analysed using accredited 
HLA allele caller software that uses the latest IMGT HLA allele database as the allele 
reference library by colleagues at The Institute for Immunology and Infectious 
Diseases, Murdoch University, Perth, Australia (Table 3.2).  
3.3.1.2 Statistical analysis and virtual modelling 
Both univariate and multivariate analyses were performed and stratified for race 
according to HLA class-I alleles, HLA CREG supertypes, and peptide-binding groups 
assigned from MHC Cluster binding specificities (Table 3.1) (168, 169, 171) In this 
study, clinical notes were re-evaluated by and myself, Dr Rebecca Pavlos, and 
Professor Elizabeth Phillips (Table 3.2). Samples were excluded from this analysis 
because no sample was available for HLA typing or issues with sample identity were 
identified (n=101) and either no clinical data was reported (n=22) or ambiguous clinical 
data was reported (n=62). The final analysis included 210 clinically defined NVP-HSR 
cases (152 SCAR, 58 HSR with hepatitis) with 468 controls. The statistical analysis 
was performed in conjunction with colleagues at The Institute for Immunology and 
Infectious Diseases, Murdoch University, Perth, Australia and Vanderbilt University, 
Nashville Tennessee, USA in particular Dr Elizabeth McKinnon, Dr Rebecca Pavlos 
and Professor Elizabeth Phillips (Table 3.2). Virtual modelling of NVP-binding in the 
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HLA-C*04:01 allele, was performed by Dr David Ostrov and colleagues, University of 
Florida College of Medicine, Gainsville, Florida, USA (Table 3.2). 
3.3.2 Diminishing IFN-γ Responses in NVP-stimulated, 
PBMC’s from NVP-DRESS Patients 
 A complete description of the Controls and Donors is given in Chapter 2 Materials and 
Methods, Section 2.1.1.2 Diminishing ex-vivo PBMC’s responses and NVP-HSR 
Immunopathogenesis. The CBA flow cytometry methods, outlined in Chapter 2, 
Materials and Methods, Section 2.2.2.4 Cytokine Bead Array, were used to assess the 
cytokine plasma profiles of NVP-DRESS patients. This study was part of a larger 
retrospective cohort study that involved the analysis of HLA class-I and class-II alleles 
association and examined NVP specific CD4+ and CD8+ T-cell responses by IFN-γ 
ELISpot assay and flow cytometry. The results of this larger study were published in 
AIDS: HLA Class-I Restricted CD8+ and Class-II Restricted CD4+ T Cells Implicated in 
the Pathogenesis of Nevirapine Hypersensitivity by Keane et al. 2014 (Appendix 9, 
Section 9.2 Publications Highlights) (138). Statistical analysis and graphical 
representations were calculated using GraphPad Prism software Version 5.02 
(GraphPad Software Inc., California USA). 
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Table 3.2 Distribution of the work within Chapter 3 and accreditation to those who contributed 
Work performed  Accreditation 
PCR amplification of HLA target sequences 
from DNA 
Craig Rive and staff at IIID  
(NATA and ASHI accredited) 
Sequencing of HLA amplicons  Staff at IIID  
(NATA and ASHI accredited) 
Analysis of sequencing data and assigning of 
HLA 4-digt types 
Staff at IIID  
(NATA and ASHI accredited) 
Evaluation of clinical data  Craig Rive 
Rebecca Pavlos 
Elizabeth Philips 
NVP-SCAR analysis Rebecca Pavlos 
Elizabeth McKinnon 
NVP-HSR with Hepatitis analysis Craig Rive 
Rebecca Pavlos 
Elizabeth McKinnon 
Virtual modelling of HLA-C*04:01 and NVP-
binding 
David Ostrov, University of 
Florida College of Medicine, 
Gainsville, Florida, USA 
NVP associated ELISpot, Treg flow cytometry, 
and clinical data associated with  
Donor 1 (NVP-HSR)  
Niamh Keane and contributors 
to the publication by  
Keane et. al 2014 (138) 
Cytokine analysis of NVP-DRESS patient 
plasma 
Craig Rive 
PCR, Polymerase Chain Reaction; HLA, Human Leukocyte Antigen; DNA, deoxyribonucleic 
acid; NVP, nevirapine; SCAR, Severe cutaneous adverse reaction, IIID, Institute for 
Immunology and Infectious Diseases; NATA, National Association of Testing Authorities; 
ASHI, American Society for Histocompatibility and Immunogenetics. 
 
3.4 Results 
3.4.1 NVP-HSR Associated HLA Class-I Binding Cleft 
Characteristics 
3.4.1.1 NVP-HSR with hepatitis 
The CREG B*07 and pb-B*78 groupings of HLA alleles as highlighted in Table 3.3 
were both found to be significant in predicting NVP-HSR with hepatitis in Caucasians 
(OR 2.18, p value 0.040 and OR 2.15, p value 0.016, respectively (Table 3.3). (168-
172, 191). 
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Table 3.3: NVP-HSR with hepatitis and statistically significant HLA CREG supertype and pb-groups 
Phenotype Race Group P Value OR 
Hepatitis Caucasian 
CREG B*07 0.016 2.150 
pb-B*78 0.040 2.180 
CREG, cross-reactive group; pb-, peptide-binding. 
Associated HLA-B peptide-binding properties and MHC Cluster analysis 
The MHCcluster analysis of the pb-B*78 group was compared to other common HLA 
alleles identified within this cohort. Several HLA alleles belonged to the MHC Cluster 
assigned pb-B*46 and pb-B*18 groups, as well as the pb-B*35 group (Table 3.1).The 
MHCcluster analysis shows the pb-B*78 group alleles HLA-B*55:01,  
-B*56:01, and -B*78:01 share close predicted peptide-binding capabilities (HLA-
B*55:01 to -B*56:01 distance = 0.093, HLA-B*55:01 to -B*78:01 distance = 0.111). 
The pb-B*35 group alleles are represented by the HLA-B*35:01, -B*35:05, and -
B*53:01 alleles also share close predicted peptide-binding capabilities with (HLA-
B*35:01 to -B*35:05 distance = 0.039, HLA-B*35:01 and HLA-B*35:05 to HLA-B*53:01 
distance = 0.254 and 0.273, respectively) (Figure 3.1 and Figure 3.2). 
The MHCcluster tree and heatmap both show the pb-B*78 and pb-B*35 groups are 
distinctly separate in terms of their predicted peptide-binding capabilities (distances 
ranging from 0.361 to 0.539) (Figure 3.1 and Figure 3.2). The peptide-binding motifs in 
Figure 3.1 shows how the pb-B*78 and pb-B*35 grouped alleles prefer to bind 9mer 
peptides with a proline (P) or an alanine (A) at position 2 (P2 from the NH2 terminus of 
the peptide) (168). We hypothesised that the HLA alleles within the pb-B*78 and pb-
B*35 groups would share structurally similar B-pockets. 
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Figure 3.1: MHCcluster tree created for the functional clustering of HLA-B alleles. Depicted are the 
peptide-binding groups, pb-B*78 (red), pb-B*35 (orange), pb-B*46, and pb-B*18. (blue), with 
representative predicted peptide-binding motifs (168). 
 
Figure 3.2: MHCcluster heatmap representation for the functional clustering of HLA-B alleles, Depicted 
are the peptide-binding groups, pb-B*78 (red), pb-B*35 (orange), pb-B*46, and pb-B*18 using the 
MHCcluster algorithm (168). 
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Associated HLA-B binding cleft B-pocket. 
While the MHCcluster analysis shows the pb-B*78 and pb-B*35 allele grouping are 
distinctly different in their predicted peptide-binding capabilities, they both show a 
tendency to bind a 9mer with a proline (P) or an alanine (A) at P2. The amino acid at 
P2 of a HLA class-I bound peptide interacts with the HLA class-I binding cleft  
B-pocket. An analysis of the binding cleft B-pocket structure was performed by 
analysing the particular amino acids present in key positions that make up the binding 
cleft B-pocket and therefore interact with the P2 amino acid of a bound peptide. 
Multiple virtual modelling studies have shown that the amino acids at positions 7, 9, 
24, 34, 41, 45, 63, 66, 67, 70, and 99 in the binding cleft B-pocket of the HLA-B 
molecule are essential in the interaction with the P2 amino acid of a bound peptide 
(171, 192-195). The HLA-B*55:(01/02), -B*56:(01/03/04) alleles of the MHCcluster 
assigned pb-B*78 group, share the same amino acids sequence YYAVAENIYQY at 
the binding cleft B-pocket positions 7, 9, 24, 34, 41, 45, 63, 66, 67, 70, and 99, 
respectively. However, HLA-B*78:01 also grouped into pb-B*78 by MHCcluster, does 
not share the same B-pocket amino acid sequence as the other pb-B*78 grouped 
alleles but shares the same amino acid sequence as the MHCcluster pb-B*35 grouped 
alleles (Table 3.4). The pb-B*78 alleles, HLA-B*55:01 and HLA-B*56:01 (minus HLA-
B*78:01) also belong to the validated HLA supertype CREG B*07 group, which was 
also identified as significant in Table 3.1. This analysis has highlighted the potential for 
the association of both HLA-B*55:01 and HLA-B*56:01 with NVP-HSR with hepatitis. 
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Table 3.4: HLA-B, B-pocket key amino acid residues YYAVAENIYQY at positions 7, 9, 24, 34, 41, 45, 
63, 66, 67, 70, and 99 respectively for the CREG B*07 and pb-B*78 alleles HLA-B*55:(01/02), 
B*56:(01/03/04), compared to the amino acid sequence of other HLA-B alleles. 
HLA-B* Amino acid position B-pocket 
7 9 24 34 41 45 63 66 67 70 99 
55:(01/02),56:(01/03/04) YY Y A V A E N I Y Q Y 
78:01,53:01,51:(01/02/04/08), 
35:(01/02/03/04/05/08/43) 
- - - - - T - - F - - 
18:(01/02) - H S - - T - - S N - 
44:(02/03/05) - - T - T K E I S N - 
57:(01/02/03/04) - - - - - M E N M S - 
58:(01/02) - - - - - T E N M S - 
15:(01/12/24/25/35) - - - - - M E I S N - 
15:02 - - - - - M - I S N - 
15:03 - - S - - E - - - - - 
46:(01/02) - - - - - M E K - - - 
 
3.4.1.2 NVP-SCAR 
The HLA-C*04:01 allele was significant in predicting NVP-SCAR, across all the broad 
ethnic groups within this study, Asian (OR 5.73, p value < 0.0001), Caucasian (OR 
1.92, p value 0.048) and, African (OR 4.00, p value 0.02) ancestry (Table 3.5). Ethnic-
specific analysis showed several HLA-C alleles to be significant in predicting NVP-
SCAR. These included HLA-C*05:01 in Caucasians/Hispanics when compared to non-
HLA-C*04:01 / non-HLA-C*05:01 carriers (OR 2.55, p value 0.004) and HLA-C*18:01 
in African descendants, compared to non-HLA-C*04:01 / non-HLA-C*18:01 carriers 
(OR 5.70, p value 0.007) (Table 3.5). 
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Table 3.5: NVP-SCAR statistically significant HLA-C alleles. 
Phenotype Race/ethnicity Allele (HLA-) P Value OR 
Rash Caucasian  
C*04:01 0.048 1.92 
C*05:01 0.004 2.55 
Rash African 
C*04:01 0.020 4.00 
C*18:01 0.007 5.70 
Rash Asian C*04:01 <0.0001 5.73 
 
HLA-C peptide-binding properties and MHC Cluster analysis 
The HLA-C*04:01, -C*05:01, and -C*18:01 alleles, and other common HLA-C alleles 
identified within the cohort were analysed and assigned to specific peptide-binding 
groups by the MHC Cluster program based on the NetMHCpan 2.8 (176, 177, 181). As 
shown in Figure 3.3, the HLA-C*04:(01/05/07) alleles shared predicted peptide-binding 
capabilities (distance < 0.0001). (168) The HLA-C*04:(01/05/07) alleles also shared 
closely related predicted peptide-binding capabilities to the HLA-C*18:01 allele 
(distance = 0.277). For this study, the HLA-C*04:(01/05/07) and HLA-C*18:01 alleles 
were assigned to one peptide-binding group pb-C*18 (Figure 3.3 and Figure 3.4) 
(168). The peptide-binding group pb-C*05 included the HLA-C*04:03, -C*05:(01/09) 
alleles (HLA-C*04:03 to C*05:(01/09) distance = 0.0046). (168) Also identified in the 
pb-C*05 group was HLA-C*08:(01/02) (in relation to HLA- C*05:(01/09) distance = 
0.129), HLA-C*04:06 (in relation to HLA-C*05:(01/09) distance = 0.276), and HLA-
C*17:01 (in relation to HLA-C*05:(01/09) distance = 0.246) (Figure 3.3 and Figure 3.4) 
(168). The peptide-binding motifs in Figure 3.3 show the predicted peptide-binding 
capabilities of the MHCcluster assigned pb-C*18 and pb-C*05 HLA alleles. Both 
MHCcluster assigned pb-C*18 and pb-C*05 group HLA alleles prefer to bind 9mer 
peptides with either a leucine (L), phenylalanine (F), valine (V), isoleucine (I), or a 
methionine (M) at P9 of the peptide which interacts with the binding cleft F-pocket of 
the HLA class-I molecule (168). Given that the MHCcluster assigned pb-C*18 and pb-
C*05 HLA alleles are predicted to bind a 9mer similar amino acids at P2, we 





Figure 3.3: MHCcluster tree created for the functional clustering of HLA-C alleles. Depicted are the 
various predicted peptide-binding groups, pb-C*05 and pb-C*18 (blue), with representative peptide-
binding motifs (168). 
 
Figure 3.4: MHCcluster heatmap representation for the functional clustering of HLA-C alleles. Depicted 
are the various predicted peptide-binding groups, including pb-C*05 and pb-C*18 (blue), using the 
MHCcluster algorithm (168). 
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Associated HLA-C binding cleft F- and B-pocket 
While the MHCcluster analysis showed that the HLA alleles assigned to the  
pb-C*05 and pb-C*18 allele groups are different in their predicted peptide-binding 
capabilities, they have the tendency to bind 9mer peptides with either a leucine (L), 
phenylalanine (F), valine (V), isoleucine (I), or a methionine (M) at P9 of the peptide 
which interacts with the binding cleft F-pocket of the HLA class-I molecule. Therefore, 
analysis of the binding groove F-pocket structure was performed by analysing the 
particular the amino acids in key positions of the binding cleft F-pocket (Table 3.6). 
Multiple virtual modelling studies have shown that the amino acids at positions 74, 77, 
80, 81, 84, 95, 97, 114, 116, 123, 133, 143, 146, and 147 in the F-pocket of the HLA-C 
molecule, are essential in the interaction with the amino acid at P9 of a HLA class-I 
bound peptide (171, 192-195). Table 3.4 shows the HLA alleles within the MHCcluster 
assigned pb-C*18 and pb-C*05 groups share the same F-pocket amino acid sequence 
DNKLYLRNFYWTKW at positions 74, 77, 80, 81, 84, 95, 97, 114, 116, 123, 133, 143, 
146, and 147, respectively (171, 192-195). This analysis also looked at the key amino 
acid residues of the binding cleft B-pocket amino acid residues positions 7, 9, 24, 34, 
41, 45, 63, 66, 67, and 70. The B-pocket residue sequences of the MHCcluster 
defined pb-C*18 and pb-C*05 grouped HLA alleles shared no significant similarities 
(Table 3.6). The B-pocket residue sequences of the MHCcluster defined pb-C*18 and 
pb-C*05 grouped HLA alleles are shared with by other HLA alleles identified in this 
cohort, but not significant in NVP-SCAR. For example, the pb-C*18 alleles HLA-
C*04:(01/07) share the same B-pocket residues as HLA-C*14:(02/04) and the pb-C*05 
alleles HLA-C*05:(01/09), share the same B-pocket residues as HLA-C*03:(03/04) and 
HLA-C*08:(01/02/03) (Table 3.7). 
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Table 3.6: HLA-C F-pocket key amino acid residues, DNKLYLRNFYWTKW at positions 74, 77, 80, 81, 
84, 95, 97, 114, 116, 123, 133, 143, 146, and 147, respectively for the HLA-C*04:(01/03/06/07), HLA-




Amino acid position F-pocket 
74 77 80 81 84 95 97 114 116 123 133 143 146 147 
04:(01/03/06/07), 
05:(01/09),18:01 
D N K L Y L R N F Y W T K W 
02:(02/10) - - - - - - - D S - - - - - 
06:02, 16:02 - - - - - - W D S - - - - - 
17:01 - - - - - I - - - - - S - L 
15:02 - - - - - I - D L - - - - - 
15:05 - - - - - I - D - - - - - - 
15:06 - - - - - I - D Y - - - - - 
01:(02/08) - S N - - - W D Y - - - - - 
3:05 - S N - - - S D Y - - - - - 
12:03,14:02, 
16:(01/04) 
- S N - - - W D S - - - - - 
14:04 - - N - - - W D S - - - - - 
03:02, 12:02 - S N - - - - D S - - - - - 
07:(01/02) - S N - - - - D S - - - - L 
7:04 - S N - - F - D - - - - - L 
7:12 - S N - - F - D - - - - - - 
03:(04/02) - S N - - I - D Y - - - - - 
1:03 - S N - - - W - - - - - - - 




Table 3.7: HLA-C, B-pocket key amino acid residues YSAVGEKYQF at the B-pocket positions 7, 9, 24, 
34, 41, 45, 63, 66, 67, and 70 respectively for the HLA-C*04:(01/03/06/07), HLA-C*05:(01/09) and HLA-
C*18:01 alleles, compared to the amino acid sequence of other HLA-C alleles. 
HLA-C* 
 
Amino acid position B-pocket 
7 9 24 34 41 45 63 66 67 70 
04:(01/07), 14:(02/04) Y S A V G E K Y Q F 
05:(01/09), 03:(03/04),  
08:( 01/02/03) 
- Y - - - - - - - Y 
04:(03/06) - Y - - - - - - - - 
18:01 - D S - - - - - - - 
 
Virtual modelling 
The MHCcluster and HLA class-I binding cleft F- and B- pocket structure analysis 
showed that the NVP-SCAR associated HLA-C alleles share the same binding cleft F-
pocket, but different B-pockets. Virtual modelling analysis performed and analysed by 
colleagues at the University of Florida, showed that NVP preferentially interacts near 
the binding cleft B-pocket of the HLA-C*04:01 molecule and not the F-pocket (Figure 
3.5). 
 
Figure 3.5: Virtual modelling of NVP and HLA-C*04:01 potential interaction, which indicates the 
preferential docking or binding of NVP near the B-pocket of the HLA-C*04:01 molecule. 
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Multivariate analysis and HLA predictive values 
The HLA-C*04:01 allele was significant in NVP-SCAR, when analysing the whole 
cohort and remaining significant in all populations (Table 3.8). The MHCcluster pb-
C*18 and pb-C*05 grouped HLA alleles, which share the same binding groove  
F-pocket amino acid residues, were also significant in predicting NVP-SCAR, when 
analysing the whole cohort (OR 2.73, p value 0.0003) but only remained significant in 
Caucasians, when each race was analysed separately (OR 3.35, p value 0.002) 
(Table 3.8) (171). 
Table 3.8: Multivariate model of predictive and protective NVP-rash associated SCARs HLA alleles, 
adjusted for ethnicity. 
MULTIVARIATE 
(+ adjusted for race) 
ALL CAUCASIAN ASIAN BLACK 
OR P OR P OR P OR P 
HLA-C*04:01 4.28 <0.0001 3.00 0.002 8.23 <0.0001 6.38 0.006 
 
pb-C*18 and pb-C*05 group 
sharing the same F-pocket 
 
2.73 0.0003 3.35 0.002 1.51 0.4 3.27 0.1 
 
Table 3.9 shows the positive and negative predictive values calculated based on 
sample prevalence of NVP-SCAR and the conserved estimates of 5% prevalence 
cited in the literature (138-141). HLA-C*04:01 allele possessed a positive predictive 
value ranging from 4.6% in Taiwanese to 26.7% in Southeast Asians, and a negative 
predictive value ranging from 94.7% in Taiwanese to 96.4% Africans, adjusted for a 
prevalence of 5% NVP-SCAR (Table 3.9) (138-141). Carriage of a HLA allele that 
shares the same key binding cleft F-pocket residues as HLA-C*04:01, possessed a 
positive predictive value between 2.7% and 11.0% and a negative predictive value 
between 94.5% and 97.4% was determined, depending on ethnicity and adjusted for 







Table 3.9: Positive and negative predictive values for carriage of the identified predicted and/or 
protective NVP-SCAR associated HLA class-I alleles, adjusted for 5% prevalence. 
  
Controls NVP- rash 
HSR 
    Sample 
prevalence 
























African 44 8 11 8 42.1 84.6 50.0 80.0 12.6 96.5 
European 115 29 26 16 38.1 79.9 35.6 81.6 9.1 96.1 
Hispanic 52 14 19 6 24.0 78.8 30.0 73.2 5.6 95.2 
SEA 154 6 40 14 25.9 96.2 70.0 79.4 26.7 96.1 
Taiwanese 36 4 10 1 9.1 90.0 20.0 78.3 4.6 95.0 
Predictive HLA-C allele 
African 38 14 7 12 63.2 73.1 46.2 84.4 11.0 97.4 
European 95 49 15 27 64.3 66 35.5 86.4 9.0 97.2 
Hispanic 43 23 12 13 52 65.2 36.1 78.2 7.3 96.3 
SEA 132 28 34 20 37 82.5 41.7 79.5 10.0 96.1 
Taiwanese 33 7 10 1 9.1 82.5 12.5 76.7 2.7 94.5 
 
3.4.2 Diminishing Ex-vivo PBMC’s Responses and NVP-HSR 
Immunopathogenesis 
3.4.2.1 IFN-γ ELISpot and CBA flow cytometry analysis 
Work performed by Niamh Keane et al. 2014 showed that NVP-restricted responses 
were detected by IFN-γ ELISpot assay in PBMC’s from the three donors; but these 
responses waned and diminished becoming undetectable in PBMC’s shortly after the 
first presentation of NVP-SCAR, DRESS phenotype (Figure 3.6) (138). Looking at the 
cytokine plasma profiles of the same NVP-DRESS patients, used in Keane et al. 2014, 
we expected that the cytokine environment within the donor’s plasma, over the time 
course of a NVP-DRESS reaction and recovery period, might show changes in specific 
T-cell subpopulations, further explaining the diminishing NVP-stimulated, PBMC IFN-γ 
responses. For example an increase in IL-10 during the recovery period might disrupt 
the Treg/Th17 balance and add weight to the first hypothesis proposed by Keane et al. 
2014, that the diminishing NVP-stimulated, PBMC IFN-γ responses were due to an 
increase in CD4+ Tregs levels after NVP withdrawal and during the recovery period. 
Keane et al. 2014 proposed this hypothesis, based on Figure 3.7 which shows the 
percentage of Tregs 8 days after NVP cessation, which matched the non-HSR control 
Treg percentages and NVP IFN-γ responses were still detectable in Donor 1 (NVP-
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HSR). As the IFN-γ response diminished, the percentage of Tregs became elevated 
(Figure 3.6 and Figure 3.7) (138). 
 
Figure 3.6 Timeline of diminishing IFN-γ responses SFU/million cells in Donor 1 (NVP-HSR), Donor 2 
(NVP-HSR), and Donor 3 (NVP-HSR) Figure from Keane et al. 2014 (138) 
 
Figure 3.7: Regulatory T cells expressed at a % of CD4 T cells are shown in the plot where clear 
symbols indicates samples from Donor 1 (NVP-HSR) and the time after NVP cessation. The filled in 
symbols indicate samples from controls (black, blue) and HIV patient not on medication (red symbol). 
Figure from Keane et al. 2014 (138). 
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Donor 1 (NVP-HSR) showed a reduced IFN-γ ELISpot response in NVP-exposed 
PBMC’s acquired 18 days post NVP-DRESS. Donor 1 (NVP-HSR) showed an IFN-γ 
ELISpot response to NVP in the order of 1600 SFU/million cells, in PBMC’s acquired 5 
post NVP-DRESS which had reduced to 150 SFU/million cells in PBMC’s acquired day 
8 post NVP-DRESS (138). PBMC’s from Donor 1 (NVP-HSR) acquired 18 days post 
NVP-DRESS, showed no IFN-γ ELISpot response (138). The cytokine plasma profile 
of Donor 1 (NVP-HSR) also showed detectable IFN-γ release at day 1 post NVP-
DRESS which then decreased. The cytokine IL-6 was detected at day 1 and day 5 in 
the plasma of Donor 1 (NVP-HSR) which decreased to become undetectable by day 8 
post NVP-DRESS (Figure 3.8) (138). 
 
Figure 3.8: Cytokine plasma profile of Donor 1 (NVP-HSR), plasma obtained pre-NVP-HSR to day 102 
post NVP-HSR. Concentrations were determined by using the CBA kit internal standard controls and 
normalised against the NVP-tolerant and NVP-naive healthy controls. Statistical significance was 
determined using an analysis of variance (ANOVA) statistical analysis (p < 0.0001) and multiple 
comparison tests (***p < 0.0001) to compare the concentration of each cytokine in Donor 1 (NVP-HSR) 
to the concentration of the responding cytokine in the NVP-tolerant and NVP-naive healthy controls. 
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Donor 2 (NVP-HSR) showed an IFN-γ ELISpot response in the order of 300 
SFU/million cells in NVP-exposed PBMC’s acquired 2 days post NVP-DRESS. 
PBMC’s acquired 62 days post NVP-DRESS showed no detectable IFN-γ ELISpot 
response (138). The cytokine plasma profile of Donor 2 (NVP-HSR) also showed 
significant IL-6 release at day 1 post NVP-HSR which increased day 2 post NVP-
DRESS (Figure 3.9). 
 
 
Figure 3.9: Cytokine plasma profile of Donor 2 (NVP-HSR) plasma obtained pre-NVP-DRESS to day 
330 post NVP-DRESS. Concentrations were determined by using the CBA kit internal standard controls 
and normalised against the NVP-tolerant and NVP-naive healthy controls. Statistical significance was 
determined using an analysis of variance (ANOVA) statistical analysis (p < 0.0001) and multiple 
comparison tests (***p < 0.0001) to compare the concentration of each cytokine in Donor 2 (NVP-HSR) 




Donor 3 (NVP-HSR), showed an IFN-γ ELISpot response in the order of 400 
SFU//million cells in PBMC’s collected 97 days post NVP-DRESS induced and by day 
476 post NVP-DRESS, no IFN-γ ELISpot response was detected. The cytokine 
plasma profile of Donor 3 (NVP-HSR) showed no significant release of the cytokines 
being analysed (Figure 3.10). 
 
 
Figure 3.10: Cytokine plasma profile of Donor 3 (NVP-HSR) plasma obtained day 7 to day 727 post 
NVP-HSR. Concentrations were determined by using the CBA kit internal standard controls and 
normalised against the NVP-tolerant and NVP-naive healthy controls. 
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Analysis of the IL-6 plasma profile over the time course of a NVP-DRESS is shown in 
Figure 3.11. Detectable levels of IL-6 in the plasma of the Donors at day 1 decreased 
to insignificant levels in the Donors' plasma by day 12, post NVP cessation. 
 
 
Figure 3.11: Plasma IL-6 cytokine profile of Donor 1 (NVP-HSR) and Donor 2 (NVP-HSR) (Donor 3 
(NVP-HSR) not included), highlighting the potential of IL-6 having a role in NVP-HSR. Concentrations 
were determined by using the CBA kit internal standard controls and normalised against the NVP-
tolerant and NVP-naive healthy controls. Statistical significance was determined using an analysis of 
variance (ANOVA) statistical analysis (p < 0.0001) and multiple comparison tests to compare the 
concentration of each cytokine to their respective pre-NVP plasma cytokine concentration  
(***p < 0.0001). 
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3.5 Discussion 
3.5.1 NVP-SCAR Associated HLA Class-I Binding Cleft 
Characteristics 
3.5.1.1 NVP- SCAR with hepatitis 
A larger proportion of NVP-HSR involve the liver, with 80% of DRESS cases 
presenting with clinical hepatitis (67). The validated HLA CREG supertype B*07, which 
consists of a group of HLA alleles that share similarities in cross-reactivity of public 
epitopes and binding cleft pocket chemistry and the MHCcluster pb-B*78 grouped 
alleles, which share similar peptide-binding specificity, as predicted by NetMHCpan 
2.8, showed a significant predictive association with NVP-HSR with hepatitis. After the 
MHCcluster and binding cleft B-pocket structural analysis of the pb-B*78 group, the 
HLA-B*55:01 and HLA-B*56:01 alleles both belonging to the CREG B*07 and pb-B*78 
groups were found to be significant 
Donor 2 (NVP-HSR) from the cytokine profile analysis, also possessed the  
HLA-B*56:01 along with the HLA-C*04:03 allele also significant in NVP-SCAR. Donor 
2 (NVP-HSR), experienced a fever, rash, eosinophilia and hepatitis, typical of DRESS, 
on day 7 of a HAART regime containing NVP. Further analysis of the HLA-B*55:01 
and HLA-B*56:01 alleles is required and future studies should include virtual modelling 
to highlight the NVP-binding characteristics of HLA-B*55:01 and HLA-B*56:01. 
Following that, setting up a series of peptide elution experiments and analysing the 
peptide sequence data to show the binding characteristics of peptides would further 
our understand of any potential interaction between the drug and how it influences the 
peptides being presented. This work will lead to designing a working model for how 
NVP generates neo-antigens, which can then be tested ex-vivo. 
3.5.1.2 NVP- SCAR 
The HLA-C*04:01 was shown to have a significant predictive association to NVP-
SCAR across all the ethnic groups, despite the variations in allele frequency. The 
unique F-pocket amino acid sequence possessed by HLA-C*04:01 is also shared by 
HLA-C*05:01 and HLA-C*18:01 shown to be predictive in Caucasian and Africans, 
respectively (Table 3.5). The HLA-C*04:01, -C*05:01 and -C*18:01 alleles, and other 
common HLA-C alleles identified within the cohort were analysed and assigned to 
specific peptide-binding groups, based on the binding specificities of the MHC Cluster 
algorithm to see if they shared are similarities in their peptide-binding cleft structure 
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and/or peptide-binding capabilities which could then be translated back to increased 
risk of NVP-rash associated SCAR. 
The MHCcluster analysis the HLA-C*04:01, HLA-C*05:01, HLA-C*18:01, and other 
related alleles prevalent in the cohort showed these alleles all preferred to bind 9mer 
peptides with an Aspartic acid (D) at position 2 of the peptide (from the NH2 terminal 
end) which interacts with binding cleft B-pocket (Figure 3.3 and Figure 3.4). Further 
analysis of the MHCcluster assigned pb-C*18 and pb-C*05 groups, showed the alleles 
within both groups shared the binding groove F-pocket residues (Table 3.6). A 
multivariate analysis of the cohort showed the alleles which have a shared binding 
cleft F-pocket were predictive in NVP-SCAR, but, when each individual race was 
analysed, the F-pocket sequence remained significant only in Caucasians (Table 3.8). 
While these pb-C*18 and pb-C*05 group alleles shared the same binding cleft  
F-pocket, their binding cleft B-pocket varied. For example the pb-C*18 alleles HLA-
C*04:(01/07) share the same key B-pocket residues as HLA-C*14:(02/04) and the pb-
C*05 alleles HLA-C*05:(01/09) share the same key B-pocket residues as HLA-
C*03:(03/04) and HLA-C*08:(01/02/03) (Table 3.5). The shared binding cleft F-pocket 
and variation in binding cleft B-pocket among these NVP-SCAR associated HLA-C 
alleles would suggest the importance of the binding cleft F-pocket, in terms of NVP-
SCAR immunopathogenesis and the HLA-drug-TCR interaction. HLA-C*04:01 and the 
other predictive HLA-B and HLA-C alleles should be used in future studies to explore 
NVP-SCAR immunopathogenesis. 
Virtual modelling analysis performed by colleagues at the University of Florida show a 
preferential interaction between NVP and a region close to the B-pocket, and not the 
F-pocket as one might have predicted based on shared binding cleft F-pocket (83-85). 
Before proposing a working model for ex-vivo based analysis, more research into 
peptide-binding within this HLA and how the drug may interact is needed. One method 
includes setting up a series of peptide elution experiments and analysing the peptide 
sequence data to find the binding characteristics of peptides. This work will lead to 
designing a working model for how NVP generates neo-antigens, which can then be 
tested ex-vivo. 
3.5.2 Diminishing Ex-vivo PBMC’s Responses and NVP-HSR 
Immunopathogenesis 
This smaller study was part of a larger study involving NVP-SCAR 
immunopathogenesis (138). While the first section of this chapter looked at the binding 
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characteristics of HLA class-I alleles, the second half looked to find the immunological 
mechanism driving the NVP-DRESS by analysing the cytokine environment within the 
donor’s plasma, over the time course of a NVP-DRESS reaction and recovery period. 
We expected this might show changes in specific T-cell subpopulations, further 
explaining the diminishing NVP-stimulated, PBMC IFN-γ responses supporting the 
data presented in the paper by Keane et al. 2014 (138, 173). 
As highlighted in Keane et al. 2014, Donor 1 (NVP-HSR) exhibited an increase in 
Tregs cell numbers corresponded with diminishing IFN-γ ELISpot responses (138). 
After this first analysis, PBMC’s samples were limiting. Therefore to discuss this 
question and offer more data to complement the data published by Keane et al. 2014, 
we assessed donor plasma over the time course of NVP-DRESS reaction to see if the 
cytokine environment reflects the changes in specific T-cell subpopulations. If the 
cytokine environment were to support the Tregs cell numbers corresponded with 
diminishing IFN-γ ELISpot responses, we suspected to see an increase in cytokines 
like IL-10, which can show changes in the IL-17/Treg balance. Several cytokines were 
measured in patients over the time course of a NVP-DRESS reaction. Furthermore, 
two of the Donors carried HLA allotypes that were identified as significant NVP-SCAR 
predictors or potential predictors in Section 3.4 Results. Donor 2 (NVP-HSR) carried 
both HLA-B*56:01 and HLA-C*04:03, and Donor 3 (NVP-HSR), HLA-C*04. Donor 1 
(NVP-HSR) however, carried the previously identified HLA-B*14 / HLA-C*08 haplotype 
alleles (146, 147) 
Donor 1 (NVP-HSR) showed a detectable IFN-γ release at day 1 post  
NVP-DRESS, which then decreased. Both Donor 1 (NVP-HSR) and Donor 2 (NVP-
HSR) both showed a significant IL-6 release within the first 8 days post NVP-DRESS. 
Elevated IL-6 levels in plasma samples can be linked to numerous different 
pathologies (196-198). 
IL-6 is a proinflammatory and the elevated levels could result from the immune 
reaction which is not particularly significant to NVP-DRESS and commonly 
concentration of IL-6 are typically below 1pg/ml due to its short plasma half-life and 
corticosteroids down regulate IL-6 expression (199). Elevated IL-6 plasma levels have 
also been shown to proceed HHV-6 reactivation and has been associated with higher 
HHV-6 viral load and progression to encephalitis and systemic inflammation in stem 
cell transplantation patients who experience HHV-6 infection-related complications 
(200, 201) This association to HHV-6 reactivation is significant as it has been 
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associated with some IM-ADR and has been linked to prolonged disease and severe 
organ involvement, fever and, cutaneous symptoms plus hepatosplenomegaly, and 
severe lymphocytopenia. The reactivation of HHV’s like HHV-6 and corresponding 
virus-specific Tregs in patients with DRESS has been reported (202). The Donors in 
this study showed no specific evidence of HSV-1, HSV-2, HHV-3 (VZV), CMV, EBV or 
HHV-6 reactivation. However, all patients possessed IgG antibodies for HHV-6, 
including Donor 2 (NVP-HSR), an infant at the time of NVP-DRESS. 
The accelerated production of IL-6, especially by cytotoxic T cells in MS patients helps 
these cytotoxic T cells to become more resistant to Tregs and is potent modifier of 
early Tregs and cytotoxic T-cell interactions and communication (203, 204). Other 
studies have also highlighted the importance of IL-6 and the balance between Tregs / 
Th17 cells (208, 210). Given this increase in IL-6 and other studies that suggest  
HHV-6 reactivation in DRESS, in particular before reactivation, and the importance of 
IL-6 in Tregs/Th17 balance, IL-6 could be a cytokine important to NVP-DRESS 
alongside other key factors like carriage specific HLA class-I alleles. One model we 
propose is that the decrease in Tregs at the time of the reaction might be  
driving NVP-DRESS and the return of Tregs during recovery, responsible for the NVP-
stimulated diminishing IFN-γ PBMC responses. 
To further analyse this proposed model, future analysis should look at the expression 
and quantification of inhibitory immune receptors; CTLA4, (cytotoxic T-lymphocyte-
associated protein 4 or CD152), PD-1 (Programmed Death 1), and/or PD-L1 
(Programmed Death Ligand 1) (205-208). Ex-vivo experiments to assess this could 
include monoclonal antibodies directed towards blocking these inhibitory immune 
receptors, to see if the ex-vivo response can be recovered (205, 207, 208). While it 
would have been preferential to perform this on the specific samples used in Keane et 
al. 2014 and within this thesis, this could not be performed as samples were limited 
and were used in the first study by Niamh Keane et al. 2014, hence the reason we 













Stevens - Johnson Syndrome 
and 
Toxic Epidermal Necrolysis:  
 








Chapter 1 (Section 1.3.2 Carbamazepine) highlighted the strong association between 
HLA-B*15:02 and other B75 serotypes, including the HLA-B*15:08, -B*15:11, and -
B*15:21 alleles and CBZ-SJS/TEN (2, 209, 210). Based on a strong negative 
predictive values associated with HLA-B*15:02 carriage (100% in Han Chinese), the 
Food and Drug Administration (USA) and similar regulatory agencies of different 
countries have recommended that genetic screening for HLA-B*15:02 for those of 
South-east Asian ancestry, before CBZ therapy and that all HLA-B*15:02 carriers, 
should not be administered CBZ, unless the benefits outweigh the risks (101). 
However, the low/incomplete positive predictive value of HLA-B*15:02 carriage (3.3-
7% in Han Chinese) illustrates how carriage is necessary but not enough to explain 
CBZ-SJS/TEN pathogenesis and other factors must also play a role in driving CBZ-
SJS/TEN. 
As explained in Chapter 1 (Section 1.4 Established Models of HLA-driven delayed 
Immunologically Mediated-Adverse Drug Reactions), a considerable amount of 
evidence supports the heterologous immune model as a mediator of organ transplant 
rejection (9, 10, 12, 16-19). In organ transplantation, an overabundance of neo-
antigens are presented to the hosts immune system, which can be cross-recognised 
by pre-existing class-I memory T cells, created in response to prevalent viruses, like 
those of the Herpesviridae family. (54-60) Similar to organ transplantation, IM-ADR 
presents a novel situation, in which neo-antigens can be created by the off-target drug-
HLA interaction, which are then cross-recognised by epitope-specific class-I memory T 
cells. Epitope-specific class-I memory T cells might determine CBZ-SJS/TEN 
development in individuals who carry the at-risk HLA allele. Increasing the ability to 
predict HLA-B*15:02-CBZ-SJS/TEN and further our understanding of the 
immunopathogenic mechanisms driving these reactions. 
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4.2 Hypothesis and Aims 
Hypothesis 
A proportion of the HSV-1 and/or HSV-2 HLA-B*15:02-restricted peptides can induce a 
specific HLA-B*15:02-epitope memory T-cell response shared in patients who 
experience a CBZ-SJS/TEN reaction. 
Aim 
To identify several in-silico predicted HLA-B*15:02-restricted HSV-1/HSV-2 peptides 
which may elicit responses in the CBZ-SJS/TEN patient’s ex-vivo. Once identified, the 
aim is to isolate and expand the HSV-1/HSV-2 specific memory T cells in-vitro for 
future analysis of the cross-reactivity model. 
4.3 Methods 
4.3.1 Samples and Controls 
The Controls and Donors used in this chapter, with a complete description, are listed 
in Table 2.2 Chapter 2 Materials and Methods, Section 2.1.2 Carbamazepine - 
Induced Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis. 
4.3.2 In-Silico HLA-B*15:02-restricted Peptide Predictions 
Several HLA-B*15:02-restricted HSV-1 (strain 17) and HSV-2 (strain HG52) 9-11mer 
peptides were predicted by Bioinformatics colleagues at The Institute for Immunology 
and Infectious Diseases, Murdoch University, Perth, Australia using in-silico epitope 
mapping methods which involved Net-MHC3.2 based algorithms, combined with a 
novel measure of “targeting efficiency” developed in collaboration with Microsoft 
research (Table 4.3) (169, 170, 188-190) Based on personal communications, 42 
predicted HLA-B*15:02-restricted peptides were synthesised for ex-vivo analysis, 
highlighted Table 4.1 and Table 4.2 (169, 170). Listed in Table 4.2, are variants of the 
HSV-1/HSV-2 shared peptide, YAHGHSLRLPY and a control peptide, which were also 
synthesised and analysed as the results dictated (211). 
  
89 
Table 4.1: In-silico predicted HSV-1 and HSV-2, HLA-B*15:02-restricted peptides which were 
synthesised and analysed ex-vivo (169, 170, 188, 189). 




FAFTINIAAY DNA packaging tegument protein UL17  ref|NP_044618.1 667-676 
FTFGGGYVY envelope glycoprotein B UL27 ref|NP_044629.1 641-649 
FVYTPSPY tegument protein UL21  ref|NP_044622.1 161-168 
HMRTLSAF tegument protein UL37  ref|NP_044639.1 773-780 
ISYSSGAIAAF capsid portal protein UL6 ref|NP_044607.1 555-565 
LAFVLDSPSAY envelope glycoprotein H UL22 ref|NP_044623.1 476-486 
LAYNGSAY envelope glycoprotein I US7 ref|NP_044669.1 172-179 
MAIAAEGTLAY envelope glycoprotein I US7 ref|NP_044669.1 164-174 
MLRRRGEAY large tegument protein UL36 ref|NP_044638.2 1926-1934 
NMYAKLSGAF helicase-primase helicase subunit UL5 ref|NP_044606.1 128-137 
SMVPTGQAF helicase-primase primase subunit UL52 ref|NP_044655.1 539-547 
YANAASGAF envelope protein UL43  ref|NP_044645.2 59-67 
YTYARVFAF helicase-primase helicase subunit UL5 ref|NP_044606.1 731-739 
















AMFAGLCAF envelope glycoprotein B UL27 ref|NP_044497.1 727-735 
FAFTINTAAY DNA packaging tegument protein UL17  ref|NP_044486.1 666-675 
FTINTAAY DNA packaging tegument protein UL17  ref|NP_044486.1 668-675 
FAREYTTLAF helicase-primase subunit UL8 ref|NP_044477.1 208-217 
FAYTPSPY tegument protein UL21  ref|NP_044490.1 161-168 
FLFYPDPTY nuclear egress lamina protein UL31 ref|NP_044501.1 201-209 
FLVAACAAAY capsid triplex subunit 1 UL38 ref|NP_044508.1 189-198 
FLWDRHAQRAY envelope glycoprotein L UL1 ref|NP_044470.1 82-92 
FQHQYIPAY capsid portal protein UL6 ref|NP_044475.1 509-517 
LAFVLDSPAAY Envelope glycoprotein H UL22 ref|NP_044491.1 476-486 
FVLDSPAAY Envelope glycoprotein H UL22 ref|NP_044491.1 478-486 
LLASSGFAF envelope glycoprotein H UL22 ref|NP_044491.1 385-393 
MAFRASGPAY membrane protein UL45  ref|NP_044515.1 1-10 
MARGAGLVF envelope glycoprotein E US8 ref|NP_044538.1 1-9 
YAQYMSRAY envelope glycoprotein H UL22 ref|NP_044491.1 352-360 
SMFAYVKPM DNA replication origin-binding helicase UL9 ref|NP_044478.1 380-388 
DTAFAFNPY large tegument protein UL36 ref|NP_044506.1 1388-1396 
TAFAFNPY large tegument protein UL36 ref|NP_044506.1 1389-1396 











Table 4.2: In-silico predicted HSV-1 and HSV-2 shared, HLA-B*15:02-restricted peptides and variants of 
the HSV-1 and HSV-2 shared peptide, YAHGHSLRLPY which were synthesised and analysed, ex-vivo 







ELFPGHPVY large tegument protein HSV 1 UL36 ref|NP_044638.2 2488-2496 
 large tegument protein HSV 2 UL36 ref|NP_044506.1 2486-2494 
EQFSLSSY envelope protein HSV 1 UL20 ref|NP_044621.1 31-38 
 envelope protein HSV 2 UL20 ref|NP_044489.1 31-38 
FAASFAAIAY ribonucleotide reductase subunit 2 HSV 1 UL40 ref|NP_044642.1 191-200 
 ribonucleotide reductase subunit 2 HSV 2 UL40 ref|NP_044510.1 188-197 
FLMHAPAF envelope glycoprotein D HSV 1 US6 ref|NP_044668.1 176-183 
 envelope glycoprotein D HSV 2 US6 ref|NP_044536.1 176-183 
YMAKLHAY helicase-primase helicase subunit HSV 1 UL5 ref|NP_044606.1 404-411 
 helicase-primase helicase subunit HSV 2 UL5 ref|NP_044474.1 403-410 
YMALVSAM envelope glycoprotein B HSV 1 UL27 ref|NP_044629.1 849-856 
 envelope glycoprotein B HSV 2 UL27 ref|NP_044497.1 849-856 
YTFKTYQVF DNA packaging protein HSV 1 UL32 ref|NP_044634.1 552-559 
 DNA packaging protein HSV 2 UL32 ref|NP_044502.1 555-562 
YAHGHSLRLPY helicase-primase primase subunit HSV 1 UL52 ref|NP_044655.1 811-821 
 helicase-primase primase subunit HSV 2 UL52 ref|NP_044523.1 823-833 
 




AHGHSLRLPY Variant of YAHGHSLRLPY UL52   
HGHSLRLPY Variant of YAHGHSLRLPY UL52 ref|NP_044655.1 811-821 
YA_G_SLRLPY Variant of YAHGHSLRLPY UL52 and  
YAHG_SLRLPY Variant of YAHGHSLRLPY UL52 ref|NP_044523.1 823-833 
YA_GHSLRLPY Variant of YAHGHSLRLPY UL52   
 
VZV (HHV3) 
   
YSHGHSLRLPF helicase-primase primase subunit ORF6 ref|NP_040129.1 855-865 
M. tuberculosis    
NIRQAGVQY  ESAT-6-like protein EsxB 
(M. tuberculosis)  
ref|WP_009937166.1 72-80 
HSV Herpes simplex virus; HLA-B, Human leukocyte antigen B. 
4.3.3 Ex-vivo analysis of in-silico derived  
HLA-B*15:02-restricted peptides. 
The IFN-γ ELISpot assays and tetramer based flow cytometry methods, outlined in 
Chapter 2, Section 2.2. Cellular assays were used to assess the  
in-silico predicted HLA-B*15:02-restricted HSV-1/HSV-2 peptides, ex-vivo. Figure 4.1 
includes an example of the raw ELISpot results from which spot forming unit/per one 
million cells (SFU/million cells) were derived. SFU/million cells were calculated based 
on the original cell number input and the spots counted, minus the background 
response determined by the negative or solvent control SFU/million result. The mean 
SFU/million cells (+/- Standard Deviation (SD)) were calculated with a minimum of 
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three replications per peptide. De novo sequencing by mass spectrum analysis was 
performed by Proteomics International (Perth, Western Australia), as the research 
dictated. Statistical analysis and graphical representations were calculated using 
GraphPad Prism software Version 5.02 (GraphPad Software Inc., California, USA). 
Table 4.3: Distribution of the work within Chapter 4 and accreditation to those who contributed. 
Work performed  Accreditation 
In-silico predictions of  
HSV-1/HSV-2 HLA-B*15:02- restricted peptides 
Bioinformatics staff at IIID  
 
Patient clinical analysis Elizabeth Phillips  
Peptide de novo Sequencing and Mass 
spectrometry analysis 
Proteomics International  
Ex-vivo analysis of predicted HSV-1/HSV-2 HLA-
B*15:02- restricted peptides 
Craig Rive 
HSV-1, HSV-2; herpes simplex virus type 1 and 2, HLA, human leukocyte antigen 
  
 
Figure 4.1: Example IFN-γ ELISpot raw data. The unstimulated background and solvent controls 
(DMSO/DMF at 1μL/mL), positive controls anti-CD3
 
antibody (wells B1 and B2 0.1μg/mL) and SEB 
(wells B3 and B4 1μg/mL) responses at 200,000 cells per well. The test positive and test negative 
responses highlight the typical positive and negative response to the test stimulant (drug or peptide 
10μg/mL) with an input of 50,000 and 200,000 cell per well. 
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4.4 Results 
4.4.1 Ex-vivo analysis of in-silico derived  
HLA-B*15:02-restricted peptides. 
4.4.1.1 IFN-γ ELISpot. 
Figure 4.2 to Figure 4.7 shows the predicted HLA-15:02-restricted peptides which 
elicited immune responses in CBZ-SJS/TEN Donor, and CBZ-naive control PBMC 
samples. Figure 4.8 emphasises the key predicted HLA-15:02-restricted peptides 
which elicited immune responses in more than one of the CBZ-SJS/TEN Donors. 
These include the YAHGHSLRLPY HSV-1/2 shared peptide (Table 4.2) and the 
LAFVLDSPSAY HSV-1 peptide (Table 4.1), compared to previously identified HLA-
B*15:(01:02)-restricted M. tuberculosis peptide, NIRQAGVQY initially used as a 
control and the FAFTINITY HSV-2 peptide which only elicited an immune response in 
Donor 2 (SJS) (211). Given the HSV-1 positive serological status for Control 1 (CBZ-
naive) (Table 2.2), the HSV-1 and shared HSV-1/HSV-2 predicted HLA-15:02-
restricted peptides could also elicit immune responses as seen in the shared 
ELFGHPVY HSV-1/2 epitope response. No responses were predicted to occur in both 
Donor 4 (CBZ-SJS non-B*15:02) (Figure 4.5) and Control 2 (CBZ-naive non-B*15:02) 
(Figure 4.7), unless the predicted HLA-B*15:02-restricted peptides exhibited HLA 
class-I allele promiscuity (212, 213). Figure 4.5 shows a response to the already 
mentioned LAFVLDSPSAY HSV-1 peptide in Donor 4 (CBZ-SJS non-B*15:02). The 
cut-off for positive response was determined to be 50 SFU/million cells. 
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Figure 4.2 The Mean (+/- SD) IFN-γ responses SFU/million cells in Donor 1 (CBZ-TEN) were 
determined using ELISpot, described in Chapter 2, Enzyme-Linked ImmunoSpot 2.2.3. Cut-off for 
positive responses, 50 SFU/million cells (red line). Error bars represent intra-sample variation (n=3). 
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Figure 4.3: The Mean (+/- SD) IFN-γ responses SFU/million cells in Donor 2 (CBZ-SJS) were 
determined using ELISpot, described in Chapter 2, Enzyme-Linked ImmunoSpot 2.2.3. Cut-off for 
positive responses, 50 SFU/million cells (red line). Error bars represent intra-sample variation (n=3). 
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Figure 4.4: The Mean (+/- SD) IFN-γ responses SFU/million cells in Donor 3 (CBZ-SJS) were 
determined using ELISpot, described in Chapter 2, Enzyme-Linked ImmunoSpot 2.2.3. Cut-off for 
positive responses, 50 SFU/million cells (red line). Error bars represent intra-sample variation (n=3). 
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Figure 4.5: Mean (+/- SD) IFN-γ responses SFU/million cells in Donor 4 (CBZ-SJS non- B*15:02) were 
determined using ELISpot, described in Chapter 2, Enzyme-Linked ImmunoSpot 2.2.3. Cut-off for 




Figure 4.6: Mean (+/- SD) IFN-γ responses SFU/million cells in Control 1 (CBZ-naive) were determined 
using ELISpot, described in Chapter 2, Enzyme-Linked ImmunoSpot 2.2.3. Cut-off for positive 




Figure 4.7: Mean (+/- SD) IFN-γ responses SFU/million cells in Control 2 (CBZ-naive non-B*15:02) were 
determined using ELISpot, described in Chapter 2, Enzyme-Linked ImmunoSpot 2.2.3. Cut-off for 




Figure 4.8: Mean (+/- SD) IFN-γ responses SFU/million cells to CBZ and predicted HLA-B*15:02-
restricted peptides identified in Figure 4.2  to Figure 4.7, determined using ELISpot, described in 
Chapter 2, Enzyme-Linked ImmunoSpot 2.2.3. Cut-off for positive responses, 50 SFU/million cells (red 
line). Error bars represent intra-sample variation (n=3). 
4.4.1.2 IFN-γ ELISpot dose-dependent responses  
The affinity of cellular responses to decreasing peptide concentrations (10, 1, and 
0.1 μg/mL) was assessed through the IFN-γ ELISpot assay. The cellular immune 
responses to the of the predicted HSV-1/2 peptide YAHGHSLRLPY and the predicted 
HSV-1 peptide LAFVLDSPSAY showed a significant decrease in SFU/million cells in 
relationship to the concentration of the peptide in all three CBZ-SJS/TEN, HLA-
B*15:02 positive Donors (Figure 4.9 and Figure 4.10). The TB peptide NIRQAGVQY 
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show a decrease in SFU/million cells in Donor 1 (CBZ-TEN) and Donor 2 (CBZ-SJS); 
but in Donor 3 (CBZ-SJS) no statistical significance was determined (Figure 4.11). No 
significant decrease was seen in SFU/million cells in relationship to the HSV-2 peptide 
FAFTINTAAY concentration in the CBZ-SJS/TEN, HLA-B*15:02 positive Donors 
(Figure 4.12). 
 
Figure 4.9: Mean (+/- SD) IFN-γ responses SFU/million cells to the increasing concentrations of the 
predicted HLA-B*15:02-restricted peptide, YAHGHSLRLPY in the three HLA-B*15:02 positive Donors  
were determined using ELISpot, described in Chapter 2, Enzyme-Linked ImmunoSpot 2.2.3 with a 
concentrations of 0.1 μg/ml, 1 μg/ml, and 10 μg/ml. Error bars represent intra-sample variation (n=3) 
and the p values were determined using the Pearson correlation test (*p < 0.05).  
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Figure 4.10: Mean (+/- SD) IFN-γ responses SFU/million cells to the increasing concentrations of the 
predicted HLA-B*15:02-restricted peptide, LAFVLDSPSAY in the three HLA-B*15:02 positive Donors  
were determined using ELISpot, described in Chapter 2, Enzyme-Linked ImmunoSpot 2.2.3 with a 
concentrations of 0.1 μg/ml, 1 μg/ml, and 10 μg/ml. Error bars represent intra-sample variation (n=3) 




Figure 4.11: Mean (+/- SD) IFN-γ responses SFU/million cells to the increasing concentrations of the 
predicted HLA-B*15:02-restricted peptide, NIRQAGVQY in the three HLA-B*15:02 positive Donors  
were determined using ELISpot, described in Chapter 2, Enzyme-Linked ImmunoSpot 2.2.3 with a 
concentrations of 0.1 μg/ml, 1 μg/ml, and 10 μg/ml. Error bars represent intra-sample variation (n=3) 
and the p values were determined using the Pearson correlation test (*p < 0.05) 
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Figure 4.12 Mean (+/- SD) IFN-γ responses SFU/million cells to the increasing concentrations of the 
predicted HLA-B*15:02-restricted peptide, FAFTINTAAY in the three HLA-B*15:02 positive Donors  
were determined using ELISpot, described in Chapter 2, Enzyme-Linked ImmunoSpot 2.2.3 with a 
concentrations of 0.1 μg/ml, 1 μg/ml, and 10 μg/ml. Error bars represent intra-sample variation (n=3).  
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4.4.1.3 Variant YAHG_SLRLPY peptide analysis 
 
Purified versions of the responsive peptides were used to make B*15:02 tetramers. 
Tetramer grade peptides were tested ex-vivo to confirm the newly synthesised peptide 
before tetramer folding and staining. The tetramer grade HSV-1/2-restricted 
YAHGHSLRLPY peptide, failed to replicate the responses seen in the original IFN-γ 
ELISpot analysis. The original and tetramer folding YAHGHSLRLPY peptides were 
analysed independently by Proteomics International and through personal 
correspondence, it was determined that the original YAHGHSLRLPY peptide product 
contained several potential variants which may be responsible for the original 
response (Figure 4.15). The MS analysis highlighted the original YAHGHSLRLPY 
product contained variants of the original peptide in which one or both the Histidine (H) 
residues were missing, as highlighted by the peaks with a mass of approximately 1176 
(>60% intensity) and 1040 (>40% intensity).  
 
Figure 4.13 MS/MS analysis of YAHGHSLRLPY, original responsive peptide (left) and pure form for 
tetramer folding (right). A Spectrum was obtained in de novo peptide analysis via the MALDI TOF MS 
(4800 Proteomics analyser).  
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A series of variant were synthesised following the same IFN-γ ELISpot analysis used 
above, it was determined the variant peptide YAHG_SLRLPY missing the 5th amino 
acid, (Histidine) was responsible for the original responses.  
The IFN-γ  ELISpot screening of the predicted HLA-B*15:02-restricted HSV-1/2 shared 
peptide, YAHGHSLRLPY and the missing histidine variants, YAHG_SLRLPY, 
YA_GHSLRLPY, and YA_G_SLRLPY in the Donor and Control PBMCs (Figure 4.14) 
highlighted the significance of the YAHG_SLRLPY variant. Figure 4.21 shows affinity 
of T cell responses to decreasing ex-vivo concentrations the variant YAHG_SLRLPY 
peptide. Following this, tetramers were made for the YAHG_SLRLPY variant, 
LAFVLDSPSAY and NIRQAGVQY as outlined in Chapter 2, Materials and Methods, 
Section 2.2.2.3 Tetramers and Flow cytometry flow cytometry assays were performed 




Figure 4.14 Mean (+/- SD) IFN-γ responses SFU/million cells in Donor 1 (CBZ-TEN) to the 
YAHGHSLRLPY peptide and the missing histidine variants, YAHG_SLRLPY, YA_GHSLRLPY, and 
YA_G_SLRLPY determined using ELISpot, described in Chapter 2, Enzyme-Linked ImmunoSpot 2.2.3. 




Figure 4.15 Mean (+/- SD) IFN-γ responses SFU/million cells in Donor 2 (CBZ-SJS) to the 
YAHGHSLRLPY peptide and the missing histidine variants, YAHG_SLRLPY, YA_GHSLRLPY, and 
YA_G_SLRLPY determined using ELISpot, described in Chapter 2, Enzyme-Linked ImmunoSpot 2.2.3. 




Figure 4.16 Mean (+/- SD) IFN-γ responses SFU/million cells in Donor 3 (CBZ-SJS) to the 
YAHGHSLRLPY peptide and the missing histidine variants, YAHG_SLRLPY, YA_GHSLRLPY, and 
YA_G_SLRLPY determined using ELISpot, described in Chapter 2, Enzyme-Linked ImmunoSpot 2.2.3. 




Figure 4.17 Mean (+/- SD) IFN-γ responses SFU/million cells in Donor 4 (CBZ-SJS  
non- B*15:02) to the YAHGHSLRLPY peptide and the missing histidine variants, YAHG_SLRLPY, 
YA_GHSLRLPY, and YA_G_SLRLPY determined using ELISpot, described in Chapter 2, Enzyme-
Linked ImmunoSpot 2.2.3. Cut-off for positive responses, 50 SFU/million cells (red line). Error bars 
represent intra-sample variation (n=3). 
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Figure 4.18 Mean (+/- SD) IFN-γ responses SFU/million cells in Control 1 (CBZ-naive)  to the 
YAHGHSLRLPY peptide and the missing histidine variants, YAHG_SLRLPY, YA_GHSLRLPY, and 
YA_G_SLRLPY determined using ELISpot, described in Chapter 2, Enzyme-Linked ImmunoSpot 2.2.3. 





Figure 4.19 Mean (+/- SD) IFN-γ responses SFU/million cells in Control 2 (CBZ-naive  
non- B*15:02) to the YAHGHSLRLPY peptide and the missing histidine variants, YAHG_SLRLPY, 
YA_GHSLRLPY, and YA_G_SLRLPY determined using ELISpot, described in Chapter 2, Enzyme-
Linked ImmunoSpot 2.2.3. Cut-off for positive responses, 50 SFU/million cells (red line). Error bars 




4.4.1.4 YAHG_SLRLPY dose-dependent IFN-γ ELISpot 
responses  
The affinity of cellular responses to decreasing variant peptide YAHG_SLRLPY 
concentrations (10, 1, and 0.1 μg/mL) was assessed through the IFN-γ ELISpot assay. 
The cellular immune responses to the of the predicted HSV-1/2 variant peptide 
YAHG_SLRLPY showed a significant decrease in SFU/million cells in relationship to 
the concentration of the peptide in all three CBZ-SJS/TEN, HLA-B*15:02 positive 
Donors (Figure 4.25), but not in Donor 4 (CBZ-SJS non-B*15:02). 
 
Figure 4.20 Mean (+/- SD) IFN-γ responses SFU/million cells to the increasing concentrations of the 
predicted HLA-B*15:02-restricted variant peptide, YAHG_SLRLPY in the three HLA-B*15:02 positive 
CBZ-SJS/TEN Donors and Donor 4 (CBZ-SJS non-B*15:02)  were determined using ELISpot, 
described in Chapter 2, Enzyme-Linked ImmunoSpot 2.2.3 with a concentrations of 0.1 μg/ml, 1 μg/ml, 
and 10 μg/ml. Error bars represent intra-sample variation (n=3) and the p values were determined using 
the Pearson correlation test (*p < 0.05) and r2 values non-linear regression analysis (n=4) 
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4.4.1.5 Predicted peptide tetramer staining 
B*15:02 tetramers where constructed using the variant YAHG_SLRLPY  
HSV-1/2 shared peptide, the LAFVLDSPSAY HSV-1 peptide, and the NIRQAGVQY 
M. tuberculosis peptide, to confirm these identified peptides are  
HLA-B*15:02-restricted and recognised by CD8+ T cells. The tetramer responses show 
that all three peptides are HLA-B*15:02-restricted epitopes, that are recognised by 
CD8+ T cells (Figure 4.21 to Figure 4.25).  
 
 
Figure 4.21: Donor 1 CBZ-TEN, B*15:02-YAHG_SLRLPY, LAFVLDSPSAY, and NIRQAGVQY tetramer 
stain, performed as outlined in Chapter 2, Tetramers 2.2.2.3. Samples were compared to negative 
control which consisted of unstained sample spiked with PE and washed out as per the Tetramer 
staining protocol. Error bars represent intra-sample variation (n=5).  
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Figure 4.22: Donor 2 (CBZ-SJS), B*15:02-YAHG_SLRLPY, LAFVLDSPSAY, and NIRQAGVQY 
tetramer stain performed as outlined in Chapter 2, Tetramers 2.2.2.3. Samples were compared to 
negative control which consisted of unstained sample spiked with PE and washed out as per the 
Tetramer staining protocol. Error bars represent intra-sample variation (n=5). 
 
Figure 4.23: Donor 3 (CBZ-SJS), B*15:02-YAHG_SLRLPY, LAFVLDSPSAY, and NIRQAGVQY 
tetramer stain performed as outlined in Chapter 2, Tetramers 2.2.2.3. Samples were compared to 
negative control which consisted of unstained sample spiked with PE and washed out as per the 
Tetramer staining protocol. Error bars represent intra-sample variation (n=5). 
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Figure 4.24: Control 2 (CBZ-naive non-B*15:02), B*15:02-YAHG_SLRLPY, LAFVLDSPSAY, and 
NIRQAGVQY tetramer stain performed as outlined in Chapter 2, Tetramers 2.2.2.3. Samples were 
compared to negative control which consisted of unstained sample spiked with PE and washed out as 
per the Tetramer staining protocol. Error bars represent intra-sample variation (n=5).  
4.5 Discussion 
This chapter examined methods to screen CBZ-SJS/TEN patients potential cross-
reactive memory T-cell responses to HLA-B*15:02-restricted HSV-1 and HSV-2 
peptides. A series of predicted HLA-B*15:02-restricted HSV-1 and/or HSV-2 peptides 
were identified through in-silico based predicted HLA-restricted epitope mapping. The 
ex-vivo analysis identified several predicted peptides which matched the hypothesis 
predictions, in that a proportion of the HSV-1 and/or HSV-2 HLA-B*15:02-restricted 
peptides can induce a specific HLA-B*15:02-epitiope memory T-cell response shared 
in patients who experience a CBZ-SJS/TEN reaction. These included the HSV-1, 
envelope glycoprotein H derived peptide, LAFVLDSPSAY (UL22, AA 476-486), the 
HSV-1/HSV-2 shared Helicase-primase-primase subunit (UL52, AA 811-821 and 823-
833, in HSV-1 and HSV-2 respectively) peptide, YAHGHSLRLPY and the previously 
identified M. tuberculosis ESAT-6-like protein EsxB derived peptide, NIRQAGVQY (AA 
72-80). 
The pure YAHGHSLRLPY peptide failed to illicit the same response the original 
peptide product in repeated IFN-γ ELISpot experiments. Both the original and pure 
116 
YAHGHSLRLPY peptide products were analysed via mass spectrometry. The mass 
spectra analysis showed that the original YAHGHSLRLPY peptide product had at least 
three possible variants of the YAHGHSLRLPY, with a loss of a histidine (H) at position 
3 and/or 5. The YAHG_SLRLPY variant, missing the 5th Histidine (H), gave the 
greatest IFN-γ ELISpot responses, ex-vivo. 
A Basic Local Alignment Search Tool (BLAST) search of the National Centre for 
Biotechnology Information (NCBI) protein database using the YAHG_SLRLPY atypical 
epitope showed the specific-YAHG_SLRLPY amino acid sequence matched none of 
the reference protein sequences in the NCBI protein database and one possibility is 
that the cellular immune response generated by this atypical epitope is an artefact of 
ex-vivo analysis (169, 188, 189, 214). The original YAHGHSLRLPY peptide originates 
from a highly conserved region of the UL52 protein in all the various strains of HSV-1 
and HSV-2 that have been identified and published. (169, 188, 189, 214). It should be 
noted that not finding a match in a BLAST search does not suggest this specific 
atypical epitope does not exist, it merely suggests it does not exist in any identified 
and published sequence contained within the specific databases. 
The identification of such an atypical epitope has a remarkable impact on our 
understanding of immunological and/or virological processes. We need to better 
understand the mechanisms behind ambiguous transcription, translation, protein 
folding, degradation, and epitope synthesis before we can understand the efficiency 
and frequency of atypical epitopes. Several debated mechanisms have been 
identified, which could cause atypical epitope generation. (215-220) These include the 
DRiP hypothesis which describes substandard polypeptides developing from 
alternative and/or defective mRNAs, ribosomal frameshifts, downstream initiation 
on genuine mRNAs, and other errors inherent in translation including tRNA-amino acid 
misacylation. (221-230) Using the netChop 3.1 program to analysing YAHGHSLRLPY 
and surrounding amino acids within the HSV-1 and HSV-2 Helicase-primase-primase 
subunit, four cleavage sites were predicted (231). The four cleavage sites included the 
5th histidine (H), and the 1st tyrosine (Y) and both leucine residues (L), but the netChop 
program is rather underdeveloped (231). 
The HLA-B*15:02-restricted peptides LAFVLDSPSAY and NIRQAGVQY produced 
positive tetramer responses, in at least one of the three CBZ-SJS/TEN, HLA-B*15:02 
positive donors. As we could not determine the M. tuberculosis serology of the Donors 
and Controls, the positive NIRQAGVQY tetramer response in Donor 2 (SJS) is of 
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interest. The majority M. tuberculosis infections are latent and asymptomatic and this 
specific epitope is not one of the 483 T-cell epitopes in 12 BCG vaccine strains, 
according to Skjøt et al., 2002. The NIRQAGVQY epitope is one of four recognised by 
CD8+ T cells that Li et al. 2014 identified as important for the development of M. 
tuberculosis peptide-based vaccines and for improved diagnosis of TB in humans 
(211, 232). The identification of NIRQAGVQY-specific CD8+ T cells either means the 
patient has or had a TB infection or the epitope is non-specific. 
The assessment of three HLA-B*15:02-restricted CBZ-SJS/TEN donors is not powerful 
enough to exclude the HLA-B*15:02-restricted peptide LAFVLDSPSAY and while the 
hypothesis originally stated that a specific HSV-1/HSV-2 epitope HLA-B*15:02-
restricted memory T-cell response shared in patients who experience a CBZ-SJS/TEN 
reaction cross-reacts with neo-antigens derived by the off-target actions of drugs with 
high-risk HLA alleles, it is also probable that several of HSV-1/HSV-2 epitope HLA-
B*15:02-restricted memory T-cell response are associated with CBZ-SJS/TEN. Ideally 
more predicted HLA-B*15:02 restricted HSV-1 / HSV-2, peptides should be screened 
before proceeding. Given the association between the CBZ-TEN reaction and the 
acute HZ experienced by Donor 1 (CBZ-TEN) in-silico epitope mapping strategies 
should also be extended to generating several HLA-restricted VZV peptides. 
Further analysis is required, involving more CBZ-SJS/TEN donors and CBZ-naive and 
CBZ-tolerant controls which have been hard to acquire. In the recent paper by Jing et 
al., 2016 showed recognition of VZV-infected cells, proteins, and peptides by 
polyclonal HSV-1–driven CD8 T cells (233). Along with the detection of cross-
reactivity, this paper also discovered several novel cross-reactive  
T-cell epitopes, including one HLA-B*15:02-restricted HSV / VZV cross-reactive T-cell 
epitope which was found using PBMC’s acquired from the same donor used in this 
study, Donor 1 (233). Future experiments should include the assessment of this newly 
identified VZV / HSV epitope, following the method and experimentation outlined in 
this chapter. If the newly identified VZV / HSV epitope can fulfil the requirements as 
the atypical YAHG_SRLPY HSV-1 / HSV-2 epitope has, both these epitopes can be 
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This chapter will continue on this exploration of the heterologous immune model by 
assessing specific cross-reactive TCR associated with HLA-B*15:02-resticted CBZ-
SJS/TEN. A strong association between HLA-B*15:02 CBZ-SJS/TEN in those of 
South-east Asian ancestry has been established (2, 209, 210). Based on a strong 
negative predictive values associated with HLA-B*15:02 carriage (100% in Han 
Chinese), the Food and Drug Administration (USA) and similar regulatory agencies of 
different countries have recommended that genetic screening for HLA-B*15:02, in 
those of South-east Asian ancestry, before CBZ therapy and that all HLA-B*15:02 
carriers, should not be administered CBZ, unless the benefits outweigh the risks (101). 
The low/incomplete positive predictive value of HLA-B*15:02 carriage illustrates how 
carriage is necessary, but not enough to explain CBZ-SJS/TEN pathogenesis and 
other factors must also play a role in driving CBZ-SJS/TEN. 
The heterologous immunity model explains, not only the variation of tissue distribution 
between different clinical delayed IM-ADR, but also the low positive predictive value of 
HLA-B*15:02 carriage in CBZ-SJS/TEN by explaining what is driving 
immunopathogenesis. This study looked at expanding CBZ-specific T cells (CD8+ T 
cells) to see if the patients in this study carried the oligoclonal CBZ-specific public TCR 
sequences previously identified in Ko et al. 2011 (176). Through the development of a 
Bio-Rad QX100/200 ddPCR assay, the mRNA expression of the CBZ-specific public 
TCR sequences, Vβ 25-1*01 (Vβ 11s1) CDR3 CASSISGSY and CASSGLADVDN 
sequences were analysed (176, 234). The Vβ 12-3/4*01 CDR3 CASSLAGELF was 
identified in the analysis of CBZ-SJS/TEN patients blister fluid by colleagues at the 
National Yang-Ming University and Chang Gung Memorial Hospital in Taiwan and 
through personal communications with them, was also assessed (Table 5.1). 
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5.2 Hypothesis and Aims 
Hypothesis 
Patients that have experienced a CBZ-SJS/TEN share a subset of oligoclonal T cells, 
previously identified CBZ-specific public TCR sequences Vβ 25-1*01 (Vβ 11s1) CDR3 
CASSISGSY / CASSGLADVDN or the newly identified Vβ 12-3/4*01 CDR3 
CASSLAGELF sequence. 
Aims 
To expand CBZ-specific T cells and identify specific CDR3 sequences in a novel 
ddPCR assay (176). 
5.3 Methods 
5.3.1 Samples and Controls 
The Controls and Donors used in this chapter, with a complete description, are listed 
in Table 2.2 Chapter 2 Materials and Methods, Section 2.1.2 Carbamazepine - 
Induced  Stevens - Johnson syndrome and Toxic Epidermal Necrolysis. 
5.3.2 Experimental Assays and Analysis 
The stimulation and expansion culture outlined in Chapter 2, Materials and Methods 
Section 2.2.1 Drug Stimulation and Cellular Expansion, was used to stimulate and 
expand polyclonal T cells. The IFN-γ ELISpot assays and ICS flow cytometry outlined 
in Chapter 2, Section 2.2 were used to assess the CBZ-associated immune 
responses. Figure 5.1 includes an example of the raw ELISpot results from which spot 
forming unit/one million cells (SFU/million cells) was derived and  an example of the 
ICS flow cytometry raw data plots from which the CD8+ T-cell IFN-γ response to CBZ 
was detected both pre- and post-stimulation is shown in Figure 5.2. Statistical analysis 
and graphical representations were calculated using GraphPad Prism software 
Version 5.02 (GraphPad software Inc., California, USA). 
RNA was extracted from T cells acquired from pre-stimulation and  
post-stimulation and expansion, and converted to cDNA as highlighted in Chapter 2, 
Section 2.4.1 RNA isolation and complementary DNA conversion. The cDNA was 
used in the ddPCR assay to amplify and detect the specific TCR Vβ CDR3 sequences. 
QX100/200 raw data output was analysed using the QuantaSoft software (Version 
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1.5.38.1118). As outlined in Chapter 2, Digital Droplet PCR 2.4.2 and in Appendix 9, 
Section 9.2 the forward and reverse primers listed in Table 2.17 were validated using 
the reference cDNA sequence. For the ddPCR specific Vβ CDR3 TCR analysis, 
expression levels were normalised using RPPH1 gene expression and reported as a 
percentage of normalised Cβ mRNA expression levels. Statistical analysis and 
graphical representations were calculated using GraphPad Prism software Version 
5.02 (GraphPad software Inc., California, USA). 
Table 5.1: Distribution of the work within this chapter and accreditation to those who contributed 
Work performed  Accreditation 
Information about the specific Vβ CDR3 TCR 
sequences to target in ddPCR assays 
Ko et al. 2011 (176) 
and personal correspondence with 
colleagues at Taipei Taiwan and 
Chang Gung Memorial Hospital  
Patient Phenotype and clinical analysis Elizabeth Philips  
Ex-vivo analysis of CBZ-stimulated T cells Craig Rive 
ddPCR assay development  Craig Rive 
Vβ, variable beta; CDR3, complementarity-determining region 3; TCR, T-cell receptor, ddPCR; 
digital droplet PCR. 
5.4 Results 
5.4.1 ELISpot and ICS Flow Cytometry responses in Donor 
and Control cells pre- and post- CBZ stimulation and 
expansion  
The IFN-γ responses to both pre- and post- cellular stimulation and expansion cultures 
were assessed using ELISpot and ICS, to show the T-cell expansion culture was 
successful in expanding polyclonal T cells, some of which are CBZ-specific CD8+ T 
cells. Statistically significant increases in T-cell IFN-γ responses were seen in the 
three CBZ-SJS/TEN Donors CBZ-stimulated and expanded culture cells, when re-
exposed to CBZ compared to the controls (Donor 1 (CBZ-TEN) and Donor 2 (CBZ-
SJS) (***) p value < 0.0001, Donor 3 (CBZ-SJS) (*) p value < 0.05 Figure 5.1). ICS 
IFN-γ flow cytometry analysis shows an increase in IFN-γ expression by CD8+ T cells 
in the three CBZ-SJS/TEN Donors CBZ-stimulated and expanded cells when re-
exposed to CBZ compared to the controls (Figure 5.1). 
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Figure 5.1: Left: Example IFN-γ ELISpot raw data. The unstimulated background and solvent controls 
(DMSO/DMF at 1μL/mL), positive controls anti-CD3
 
antibody (wells B1 and B2, 0.1μg/mL) and SEB 
(wells B3 and B4, 1μg/mL) responses at 200,000 cells per well. The test positive and test negative 
responses highlight the typical positive and negative response to the test stimulant (drug or peptide 
10μg/mL) with an input of 50,000 and 200,000 cell per well. Right: Mean (+/- SD) IFN-γ responses 
SFU/million cells in CBZ-SJS/TEN Donors and Controls, both pre- and post-CBZ stimulation and 
culture, were determined using ELISpot, described in Chapter 2, Enzyme-Linked ImmunoSpot 2.2.3. 
Error bars represent intra-sample variation (n=3) 
 
Figure 5.2: Left: Example ICS raw data plots showing the CBZ-associated cellular IFN-γ responses both 
pre- and post-stimulation (CBZ 10μg/mL) in Donor 1 (CBZ-TEN). Right: Mean (+/- SD) IFN-γ ICS flow 
cytometry analysis for CBZ-SJS/TEN Donor and controls cells both pre- and post- stimulation and 
culture were determined using the ICS method outlined in Chapter 2, Intracellular cytokine staining 
2.2.2.1. Error bars represent intra-sample variation (n=3).  
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5.4.2 TCR analysis of Donor and Control cells pre- and post- 
CBZ stimulation and expansion using digital droplet 
PCR 
The assay workup required the validation of the specific primers, the thermocycling 
conditions, constructing a positive control and assessment of the assay sensitivity. 
Using a synthetic construct which contained the relevant primer sequences, the 
ddPCR assay was validated (Appendix 9, Section 9.2).  
5.4.2.1 TCR Vβ CDR3 ddPCR RNA expression analysis 
Figure 5.3 to Figure 5.5 highlight the TCR Vβ CDR3 profile of Donor 1 (CBZ-TEN), 
Donor 2 (CBZ-SJS) and Donor 3 (CBZ-SJS), with Table 5.2 summarising the findings. 
In Donor 1 (CBZ-TEN) a significant increase in Vβ 25-1*01 (Vβ 11s1) CDR3 
CASSISGSY expression was detected in the cells stimulated with CBZ and expanded 
in culture compared to pre-stimulation, unstimulated and control drug-stimulated and 
expanded cells. Donor 2 (CBZ-SJS) showed a significant increase in Vβ 25-1*01 
CDR3 CASSISGSY expression in the CBZ-stimulated and expanded cells compared 
to cells pre-stimulation and unstimulated expanded cells. However, the increase Vβ 
25-1*01 CDR3 CASSISGSY expression, seen in CBZ-stimulated and expanded cells 
was also seen control drug-stimulated and expanded cells. 
Donor 2 (CBZ-SJS) and Donor 3 (CBZ-SJS) exhibited a significant increase in Vβ 12-
3/4*01 CDR3 CASSLAGELF expression in the cells stimulated with CBZ and 
expanded in culture compared to the three control conditions. Donor 1 (CBZ-TEN) also 
exhibited a significant increase in Vβ 12-3/4*01 CDR3 CASSLAGELF expression cells 
stimulated with CBZ and expanded in culture when compared to the control pre-
stimulated cells only. 
Vβ 25-1*01 CDR3 CASSGLAGVDN expression was found significant in Donor 3 
(CBZ-SJS) CBZ-stimulated and expanded cells when compared to cells pre-
stimulation and unstimulated expanded cells. The increase in Vβ 25-1*01 CDR3 
CASSISGSY expression seen in CBZ-stimulated and expanded cells was also seen 
control drug-stimulated and expanded cells. 
126 
 
Figure 5.3: TCR Vβ CDR3 sequence profile of Donor 1 CBZ-TEN. Raw data analysed using Bio-Rad 
QuantaSoft software, results normalised against RPHH1 expression, and calculated as a percentage 
(%) of normalised Cβ expression. Statistical significance was determined using analysis of variance 
(ANOVA) statistical analysis (p value < 0.0001) and multiple comparison tests showed significant 




Figure 5.4: Vβ TCR CDR3 sequence profile of Donor 2 (CBZ-SJS). Raw data analysed using Bio-Rad 
QuantaSoft software, results normalised against RPHH1 expression, and calculated as a percentage 
(%) of normalised Cβ expression. Statistical significance was determined using analysis of variance 
(ANOVA) statistical analysis (p value < 0.0001) and multiple comparison tests showed significant 
differences between CBZ-stimulated cells to the other 3 conditions (***p value < 0.0001). 
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Figure 5.5: Vβ TCR CDR3 sequence profile of Donor 3 (CBZ-SJS). Raw data analysed using Bio-Rad 
QuantaSoft software, results normalised against RPHH1 expression, and calculated as a percentage 
(%) of normalised Cβ expression. Statistical significance was determined using analysis of variance 
(ANOVA) statistical analysis (p value < 0.0001) and multiple comparison tests showed significant 





Table 5.2 Table 5.2 Summary of the ddPCR amplification and analysis of target Vβ CDR3 sequences as 
a percentage (%) of expression in Donor 1 (CBZ-TEN), Donor 2 (CBZ-SJS), and Donor 3 (CBZ-SJS) 
pre-stimulation cells, CBZ, control drug stimulated and expanded cells, and the unstimulated expanded 
cells.  
Sample  Vβ 25-1*01 (Vβ 11s1) CDR3 CASSISGSY 












0.73% 0.72% 0.01% 0.04% 
 Vβ 25-1*01 CDR3 CASSGLAGVDN 
 Pre-stimulation  CBZ stimulated  Control drug stimulated Unstimulated   
Donor 1 
(CBZ-TEN) 
1.94% 3.34% 4.76% 9.07% 
Donor 2 
(CBZ-SJS) 
0.44% 0.63% 1.35% 0.67% 
Donor 3 
(CBZ-SJS) 
1.44% 14.02% 10.44% 3.66% 
 Vβ 12-3/4*01 CDR3 CASSLAGELF 


















Using PBMC’s obtained from patients who had experienced a 
CBZ-SJS/TEN reaction, this study showed that CBZ induced responses can be 
expanded using a short cellular stimulation and expansion culture. CBZ-specific public 
TCR sequences, Vβ 25-1*01 (Vβ 11s1) CDR3 CASSISGSY / CASSGLADVDN or the 
130 
newly identified Vβ 12-3/4*01 CDR3 CASSLAGELF sequence expression can be 
detected using a two-step rtPCR and using the cDNA as the template in a ddPCR 
assay (176). 
The Vβ 25-1*01 (Vβ 11s1) CDR3 CASSISGSY sequence was found to be expressed 
in Donor 1 (CBZ-TEN) when cells were stimulated with CBZ and expanded in culture 
compared to the unstimulated and control drug-stimulated and expanded cells. The Vβ 
12-3/4*01 CDR3 CASSSLAGELF sequence was found to be expressed in Donor 1 
(CBZ-TEN) cells stimulated with CBZ and expanded in culture, when compared to pre-
stimulated cells and while not significant, an increase was seen when compared to the 
unstimulated and control drug-stimulated and expanded cells (Table 5.2). 
Donor 2 (CBZ-SJS) exhibited a significant increase in the Vβ 12-3/4*01 CD3 
CASSLAGELF sequence expression in cells stimulated with CBZ and expanded in 
culture compared to pre-stimulation, unstimulated and control drug-stimulated and 
expanded cells (Table 5.2). Donor 3 (CBZ-SJS) also exhibited an increase in the Vβ 
12-3/4*01 CD3 CASSLAGELF sequence expression. Cells from Donor 2 (CBZ-SJS) 
and Donor 3 (CBZ-SJS) showed a CBZ-associated Vβ 25-1*01 CDR3 CASSISGSY 
and CDR3 CASSSGLAGVDN increased expression, respectively (Table 5.2). 
However, in both cases, the increase seen in the CBZ-stimulated and expanded cells 
was also seen in the control drug-stimulated and expanded cells. It is possible the 
increase in CDR3 CASSISGSY and CDR3 CASSSGLAGVDN sequence expression 
results from a distorted representation of the T-cell repertoire driven by ex-vivo 
expansion. 
Jing et al. 2016 in collaboration with other members of our group showed recognition 
of VZV-infected cells, proteins, and peptides by polyclonal HSV-1–driven CD8+ T cells. 
In this paper, they identified several potential VZV / HSV cross-reactive Vβ TCR CDR3 
sequences specific to Donor 1 (CBZ-TEN). The expression can be assessed using the 
same method described in this chapter. Several IM-ADR studies have highlighted the 
involvement of more complex TCR repertoire (116, 235, 236). It is also possible that 
the specific Vβ or Vα TCR clonotype is not as essential as the specific-CDR3 
sequence, which interacts with the HLA-bound peptide. This could mean that the TCR 
repertoire can be heterogeneous and polyclonal, yet share the same or structurally 
similar specific-CDR3 sequences. The data presented here shows in at least Donor 1 
(CBZ-TEN) shows the CBZ-associated expansion of a polyclonal T-cell pool, each 
expressing different Vβ specific-CDR3 sequences. Specific of cross-reactive memory 
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T cells might determine tissue specificity and severity of the reaction. Recent studies 
have also highlighted how HSV-specific CD8αα+ tissue-resident T cells are persistent 
within the epidermis over a prolonged period and cause rapid cytotoxicity to cells 
expressing low levels of HSV reactivation (237). Going forward it may be prudent to 
look at epidermal tissue samples from patient blister fluid, to identify CBZ-SJS/TEN 
restricted TCR clonotype repertoire. 
What this chapter has provided is a method that is adaptable and sensitive to pick up 
the increased expression of known Vβ TCR CDR3 sequence. The method, 
experimental design and in particular the ddPCR assay performed here can be utilised 
in any study involving the quantitative assessment and expression of any known Vβ or 
Vα TCR CDR3 sequence. The ddPCR method provided here can be utilised to further 
assess Vβ TCR CDR3 sequences identified by Ko et al, the expression of VZV / HSV 
cross-reactive Vβ or Vα TCR CDR3 sequences identified by Jing et al., 2016, or 
identifying the HSV-specific CD8αα+ tissue-resident T-cell clonotype (176, 233, 237). 
The ddPCR method outlined in this chapter can also be modified and adapted to 
assess TCR expression in other delayed IM-ADR and can be used in several 
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Granulysin is an effector molecule that exhibits cytotoxic activity against several 
pathogens and tumours while also possessing chemoattractant and proinflammatory 
abilities (118-125). Granulysin can be expressed by several cells, including CD8+ 
cytotoxic T cells, CD4+ cytotoxic-like T cells, NK cells and NK-T cells (2, 119, 125-
127). Granulysin has proven to be a useful biomarker and an important cytotoxicity 
mediator in several skin diseases besides SJS/TEN including acne, psoriasis and 
folliculitis (119, 125, 129-132). In terms of SJS/TEN, granulysin has been associated 
with the disseminated keratinocyte death seen in SJS/TEN pathology. (111, 117) 
This chapter will explore CBZ-SJS/TEN immunopathogenesis through the expression 
of granulysin in the PBMC’s acquired from patient donors that had experienced a 
SJS/TEN reaction to CBZ, compared to CBZ-naive control PBMC’s. This will be 
achieved using ICS and Immunophenotyping flow cytometry assays to define the 
cellular subtypes within donor PBMC’s which show an increase in granulysin 
expression when incubated with pharmacological relevant doses of CBZ, ex-vivo. 
6.2 Hypothesis and Aims 
Hypothesis 
The analysis of CBZ-SJS/TEN patient donor PBMCs show an increase granulysin 
expression within several cellular subtypes when stimulated with pharmacological 
amounts of CBZ (10μg/mL) ex-vivo.  
Aims 
To detect granulysin expression in cellular subtypes within PBMC’s from  
CBZ-SJS/TEN Donors and Controls stimulated with pharmacological amounts of CBZ 
(10μg/mL) compared to unstimulated and control drug stimulated PBMC’s.  
6.3 Methods 
6.3.1 Samples and Controls 
The Controls and Donors used in this chapter, with a complete description, are listed 
in Table 2.2 Chapter 2 Materials and Methods, Section 2.1.2 Carbamazepine - 
Induced  Stevens - Johnson syndrome and Toxic Epidermal Necrolysis. 
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6.3.2 Experimental assays and analysis 
ICS and immunophenotyping flow cytometry assays were performed as outlined in 
Chapter 2 Materials and Methods, Section 2.2.2 Flow Cytometry. Figure 6.1 shows the 
flow cytometry gating procedure used to isolate the relevant cellular subpopulations to 
assess granulysin expression. From the forward and side scatter plots, the lymphocyte 
population was identified and labelled gate A, which was then further separated into 
CD3+ and CD3- cells (Figure 6.1B). The CD3- / CD56+ NK cell population was 
assessed for granulysin expression (Figure 6.1C), the CD3+ cells were further sorted 
into CD56+ and CD56- cells (Figure 6.1D). The CD3+ CD56- cells were sorted into 
CD8+ and CD4+ (Figure 6.1E) and each assessed for granulysin expression (Figure 
6.1E1 and E2). The CD56+ cells were sorted into CD8+ and CD4+ (Figure 6.1F) and 
each assessed for granulysin expression (Figure 6.1F1 and F2). Statistical analysis 
and graphical representations were calculated using GraphPad Prism software 
Version 5.02 (GraphPad software Inc., California, USA). Figure 6.1 Top Right 
highlights an example of negative to low Granulysin expression and Figure 6.1 bottom 
right highlights an example of positive granulysin expression. 
Table 6.1: Distribution of the work within this chapter and accreditation to those who contributed 
Work performed  Accreditation 
Patient Phenotype and clinical analysis Elizabeth Philips  
Ex-vivo analysis of CBZ-stimulated PBMC’s via 







Figure 6.1: Left: Example immunophenotyping and ICS raw data plots showing the gating procedure 
used to isolate the cellular subpopulations and determine their cytokine expression under the relevant 
conditions. Top Right: Example of negative to low Granulysin expression. Bottom Right: Example of 
positive granulysin expression.  
6.4 Results 
6.4.1 Evaluation of granulysin in CD8+ T cells obtained from 
CBZ SJS/TEN donors and naive CBZ controls 
Comparisons between unstimulated, CBZ-, and or control drug-stimulated CD8+ 
cytotoxic T cells in both CBZ-SJS/TEN Donors and CBZ-naive controls are highlighted 
in Figure 6.2 to Figure 6.5. All data points in Figure 6.2 show the mean (SD+/-) 
percentage of PBMC’s CD8+ cytotoxic T cells that express granulysin, for each sample 
(n > 3) under the specific ex-vivo stimulation condition. Figure 6.3 shows the same 
data but compares the unstimulated versus the CBZ-stimulated ex-vivo granulysin 
responses for each sample. 
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Figure 6.2: Mean (+/- SD) Granulysin expression in CD8+ cytotoxic T cells from Donor and Control 
PBMC’s incubated ex-vivo with CBZ, control drug, or left unstimulated. Statistical significance was 
determined using ANOVA analysis (p < 0.0001). Multiple comparison tests showed significance 
between unstimulated and CBZ-stimulated donor PBMC’s (* p value < 0.05), CBZ and control drug-
stimulated donor PBMC’s (*** p value < 0.0001), CBZ and the unstimulated, CBZ and control drug-
stimulated donor PBMC’s (*** p value < 0.0001). The error bars represent inter-sample variation (n=4). 
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Figure 6.3: Mean (+/- SD) Granulysin expression in CD8
+
 cytotoxic T cells in Donor and Control PBMC’s 
incubated ex-vivo with CBZ versus unstimulated PBMC’s. Statistical significance between unstimulated 
and CBZ-stimulated for each set of donors (***p value of < 0.0001), using the paired two-tailed T-test, 
compared to the controls (not significant (ns)). The error bars represent intra-sample variation (n=4).  
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Figure 6.4 and Figure 6.5 highlight IFN-γ expression in CD8+ cytotoxic T cells. The 
IFN-γ expression results were obtained by exposing PBMC’s from the Donors and 
Controls to the same conditions in which the granulysin expression results in Figure 
6.2 and Figure 6.3 were obtained. Comparing granulysin versus IFN-γ expression in 
CD8+ cytotoxic T cells, differences were observed, including the percentage of CD3+ 
CD8+ T cells expressing IFN-γ when stimulated with CBZ (10μg/mL) being only 0.1-
0.2% of total PBMC’s, compared the percentage of CBZ-stimulated CD3+ CD8+ T cells 
expressing granulysin (Figure 6.2). 
 
Figure 6.4: Mean (+/- SD) INF-γ expression in CD8
+
 cytotoxic T cells from Donor and Control PBMC’s 
incubated ex-vivo with CBZ, control drug, or left unstimulated. Statistical significance was determined 
using ANOVA analysis (p < 0.0001). Multiple comparison tests showed significance between, 
unstimulated and CBZ-stimulated donor PBMC’s (*** p value < 0.0001), CBZ and Control drug-
stimulated donor PBMC’s (*** p value < 0.0001), CBZ and the unstimulated, CBZ and Control drug-
stimulated donor PBMC’s (*** p value < 0.0001). The error bars represent inter-sample variation (n=4). 
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Figure 6.5: Mean (+/- SD) IFN-γ expression in CD8
+
 cytotoxic T cells in Donor and Control PBMC’s 
incubated ex-vivo with CBZ versus unstimulated PBMC’s. Statistical significance between unstimulated 
and CBZ-stimulated Donor 1 (CBZ-TEN) (***p value of < 0.0001), Donor 2 (CBZ- SJS) (*p value of < 
0.05) and Donor 4 (CBZ-SJS non- B*15:02) (*p value of < 0.05) using the paired two-tailed T-test. 
Donor 3 (CBZ-SJS) and Controls CBZ-naive (both HLA-B*15:02 positive and negative) were not 
significant (ns)). The error bars represent intra-sample variation (n=4). 
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6.4.2 Evaluation of granulysin in CD4+ T cells obtained from 
CBZ SJS/TEN donors and naive CBZ controls 
Comparisons between unstimulated, CBZ-, and control drug-stimulated CD4+ T cells in 
both CBZ-SJS/TEN Donors and CBZ-naive controls are highlighted in Figure 6.6. All 
data points in Figure 6.6 represents the mean (SD+/-) percentage of PBMC’s that are 
granulysin-expressing, CD4+ T cells for each sample (n > 3) under the specific ex-vivo 
stimulation condition. No significant difference in granulysin expression was seen in 
CD4+ T cells from the HLA-B*15:02 positive donors, Donor 1 (CBZ-TEN), Donor 2 
(CBZ-SJS) and Donor 3 (CBZ-SJS) and the CBZ-naive controls when stimulated with 
a pharmacological relevant dose of CBZ compared to control drug, or left 
unstimulated. Figure 6.7 shows, Donor 4 (CBZ-SJS non-B*15:02) showed a significant 
increase in granulysin expression by CD4+ T cells exposed to CBZ, compared to the 
HLA-B*15:02 donors, Donor 1 (CBZ-TEN), Donor 2 (CBZ-SJS) and Donor 3 (CBZ-
SJS) and controls. Figure 6.8 further supports this with a significant increase in IFN-γ 
expression by CD4+ T cells in Donor 4 (CBZ-SJS non-B*15:02) when exposed to CBZ. 
143 
 






 T cells in Donor and Control 
PBMC’s incubated ex-vivo with CBZ, control drug, or left unstimulated. No statistical significance was 
determined between the means of the various conditions. (ANOVA analysis and multiple comparison 
tests).The error bars represent inter-sample variation (n=4). 
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Figure 6.7: Mean (+/- SD) Granulysin expression in CD4+ T cells in Donor and Control PBMC’s 
incubated ex-vivo with CBZ versus unstimulated PBMC’s. Statistical significance was found between 
Donor 4 (CBZ-SJS non- B*15:02) unstimulated and CBZ-stimulated PBMC’s (*** p value < 0.0001). 
HLA-B*15:02 positive Donors 1 (CBZ-TEN), Donor 2 (CBZ-SJS), and Donor 3 (CBZ-SJS) unstimulated 
versus CBZ-stimulated PBMC’s, and the Controls were found to be not significant using a paired two-
tailed T-test. The error bars represent intra-sample variation (n=4). 
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Figure 6.8: Mean (+/- SD) IFN-γ expression in CD4+ T cells in Donor and Control PBMC’s incubated ex-
vivo with CBZ versus unstimulated PBMC’s. Statistical significance was found between Donor 4 (CBZ-
SJS non- B*15:02) unstimulated and CBZ-stimulated PBMC’s (*** p value < 0.0001). HLA-B*15:02 
positive Donors 1 (CBZ-TEN), Donor 2 (CBZ-SJS), and Donor 3 (CBZ-SJS) unstimulated versus CBZ-
stimulated PBMC’s, and the Controls were found to be not significant using a paired two-tailed T-test. 
The error bars represent intra-sample variation (n=4). 
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6.4.3 Evaluation of granulysin in CD56+ NK and NK-T cells 
obtained from CBZ SJS/TEN donors and naive CBZ 
controls 
The final PBMC’s cellular subsets included CD56+ NK cells and CD3+ CD56+ CD8+ or 
CD4+ cell populations. CD56+ on the CD3+ T cells could reflect T-cell activation and 
not specifically NK-T cells themselves (238). No significant correlation was seen 
between unstimulated, CBZ-, and control drug-stimulated granulysin expression in 
CBZ-SJS/TEN Donors and CBZ-naive controls as highlighted in Figure 6.9, Figure 
6.10, and Figure 6.11. All data points in the following graphs represents the mean 
(SD+/-) percentage of total PBMC’s that are granulysin-expressing, CD56+ NK cells 
(Figure 6.9), CD56+ CD8+ NK-T cells (Figure 6.10), or CD56+ CD4+ NK-T cells (Figure 
6.11) for each sample (n > 3) under the specific ex-vivo stimulation condition. 
 
Figure 6.9: Mean (+/- SD) Granulysin expression in CD56
+
 NK cells in Donor and Control PBMC’s 
incubated ex-vivo with CBZ, control drug, or left unstimulated. The error bars represent variation within 
the same sample on multiple test (N tests per sample in each condition = 4). 
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 NK-T cells in Donor and 
Control PBMC’s incubated ex-vivo with CBZ, control drug, or left unstimulated. The error bars represent 
intra-sample variation (n=4). 
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 NK-T cells in Donor and 
Control PBMC’s incubated ex-vivo with CBZ, control drug, or left unstimulated. The error bars represent 
inter-sample variation (n=4). 
6.5 Discussion 
Granulysin has been attributed to the disseminated keratinocyte death seen in 
SJS/TEN pathology. (111, 117) Granulysin in the epidermal blister fluid of SJS/TEN 
patients; predominately the 15-kDa form is secreted by both NK cells and CD8+ T cells 
via a nongranular exocytotic pathway (103, 117, 210). Lamotrigine is another 
antiepileptic drug associated with SJS/TEN. In 2014, a case study of one patient with 
lamotrigine-induced TEN showed an increase in CD56+ NK cell granulysin expression, 
when the patient PBMC’s were exposed to lamotrigine ex-vivo over a four-day period. 
(134) Another finding by Porebski et al. 2013 showed an increase in granulysin 
expression by CD4+ T cell from patients who experienced a lamotrigine-induced 
SJS/TEN, when re-exposed to lamotrigine ex-vivo (135). 
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In this specific analysis granulysin expression is not representative of disease 
progression or a prediction marker, but it does have the ability to be an important test 
in the diagnosis SJS/TEN and allow clinicians to have more confidence in identifying 
the culprit drug. The performed in this chapter differs from these and other studies 
involving antiepileptic drug-induced SJS/TEN and granulysin expression in that Figure 
6.2 and Figure 6.3 show an increase in granulysin expression in CD8+ cytotoxic T cells 
within PBMC’s exposed to CBZ, ex-vivo. These PBMC’s obtained from CBZ-SJS/TEN 
donors up to 17 years after the initial CBZ-SJS/TEN reaction. Figure 6.2 shows an 
increased expression of granulysin in unstimulated CD8+ cytotoxic T cells within the 
donor PBMC’s when compared to the controls. This suggests the Donors have an 
increased number CD8+ cytotoxic T cells already expressing granulysin, which 
supports studies that show that granulysin is produced by CD8+ T cells, unlike other 
apoptotic molecules like perforin and granzyme B (239). This increased frequency of 
CD8+ cytotoxic T cells already expressing granulysin, coupled with the further increase 
in granulysin expression by CD8+ cytotoxic T cells when PBMC’s are incubated with 
CBZ ex-vivo, supports previous data that suggests CBZ-SJS/TEN is a memory based 
immune response, with several CD8+ T cells “pre-loaded” with granulysin. This also 
explains why some patients experience a whole skin necrolysis in as little as 24-36 
hours.  
No significant increase in granulysin expression was detected in CBZ-SJS/TEN Donor 
and CBZ-naive control CD56+ cell subtypes when exposed to the various conditions 
(unstimulated, CBZ-, and control drug-stimulated) (Figure 6.9, Figure 6.10, and Figure 
6.11). This coupled with the increase in granulysin-expressing, CD8+ cytotoxic T cells 
within PBMC’s exposed to CBZ, ex-vivo, we propose that CD8+ cytotoxic T cells are 
the initial leukocyte subtype. The evidence of granulysin producing NK cells within 
patient blister fluid at the time of a reaction could result from the initial CD8+ cytotoxic 
T-cell reaction, leading to granulysin release which not only has a cytotoxic role but a 
chemotaxic role, attracting NK cells to the site of inflammation exacerbating the 
situation (239, 240). Further studies are required to verify this proposal. 
Experimentation should involve immunophenotyping skin-infiltrating lymphocytes at 
the acute phase of SJS/TEN. A recent presentation at the European Academy of 
Allergy and Clinical Immunology’s 2016 Drug Hypersensitivity Meeting in Malaga, 
Spain Villani A.P. et al. 2016 presented data which shows that CD8+ T cells and to a 
lesser extent CD4+ T cells, were the main leukocyte subsets found in acute TEN 
blisters (240). 
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Donor 4 (CBZ-SJS non-B*15:02) also showed a higher level of granulysin expression 
in CD4+ T cells, that also increased with CBZ exposure, ex-vivo (Figure 6.7). This is 
supported by the increase in IFN-γ under the same conditions (Figure 6.8). While only 
one patient, it raises interesting questions and supports the results of Porebski et al. 
2013 in lamotrigine-induced SJS/TEN (135). However, it was also noted that Donor 4 
(CBZ-SJS non-15:02) also expressed higher levels of granulysin in the CD3+ CD4+ 
CD56+ cell subpopulation, irrespective of CBZ or control drug stimulation or left 
unstimulated (Figure 6.11). Further analysis using samples acquired from  


















Studies have shown that approximately 2.2 million serious ADR occur every year in 
the United States of America, with over 100 thousand (4.5%) resulting in death (3-6). 
ADR are the fourth to sixth most common cause of mortality in the developed world. 
This places high demands on hospitals, healthcare institutions and facilities, and 
auxiliary health care services. The enormous burden and cost of ADR are incompletely 
captured and underestimated (1, 5, 7). 
The low frequency of these deadly, delayed IM-ADR means they are rarely seen in the 
pre-clinical and pre-marketing phases of testing. Delayed IM-ADR were considered 
unpredictable until researchers identified the association between carriage of the HLA-
B*57:01 allele and ABC-HSS. This pharmacogenetic association leads to HLA-
B*57:01 genetic screening been implemented globally in primary HIV clinical practice, 
allowing ABC to stay on the market, while reducing the numbers of ABC-HSS case. 
This HLA-drug association has also led to a greater understanding of the 
immunopathogenesis underlying this T cell-driven delayed IM-ADR 
7.2 Nevirapine Induced Hypersensitivity 
7.2.1 NVP-SCAR Associated HLA Class-I Binding Cleft 
Characteristics 
NVP has been associated with a diverse number of HSR clinical phenotypes and 
numerous HLA alleles. We explored the notion that tissue specificity of NVP-SCAR 
and the various HLA alleles associations can be explained by similarities in HLA 
peptide-binding cleft structures, by grouping HLA alleles according to shared key 
amino acid residues which make up the HLA class-I binding cleft pockets (A-F), 
MHCcluster algorithm, which seeks to group HLA molecules based on their peptide-
binding specificity as predicted by NetMHCpan 2.8, and looking at the validated CREG 
HLA supertypes, which groups HLA alleles based on similarities in cross-reactivity of 
public epitopes among HLA class-I alleles and binding cleft pocket chemistry. (168-
172) 
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7.2.1.1 NVP-HSR with hepatitis 
A vast majority of NVP-HSR involve hepatic symptoms, with 80% NVP-DRESS cases 
presenting with liver complications. An increased risk of NVP-HSR with hepatitis was 
associated with the validated HLA supertype CREG B*07 and the MHCcluster 
assigned pb-B*78 group. The MHCcluster assigned pb-B*78 group and binding cleft B-
pocket residue analysis of the showed the HLA-B*55:01 and HLA-B*56:01 alleles 
shared the same binding cleft B-pocket residues and were the two alleles were shared 
between the CREG B*07 and pb-B*78 groups. Further, analysis of these alleles is 
required, but Donor 2 (NVP-HSR), who experienced a NVP-DRESS reaction, 7 days 
after NVP initiation, carried the HLA-B*56:01 and HLA-C*04:03 alleles. 
7.2.1.2 NVP-SCAR 
The HLA-C*04:01 alleles was shown to be a significant predictive HLA allele in NVP-
SCAR (Table 3.8). Other significant HLA-C alleles associated with NVP-SCAR 
included the HLA-C*05:01 alleles among Caucasian and the HLA-C*18:01 among 
Africans. The HLA-C*04:01, -C*05:01, -C*18:01, and other related alleles prevalent in 
the cohort were analysed using MHCcluster to see if they shared similar predicted 
peptide-binding capabilities. MHCcluster analysis showed these alleles all preferred to 
bind 9mer peptides with an Aspartic acid (D) at position 2 of the peptide (from the NH2 
terminal end) which interacts with binding cleft B-pocket. 
HLA-C*04:01, HLA-C*05:01, and HLA-C*18:01 also shared the same binding cleft F-
pocket residue. This F-pocket structure also proved to a significant predictor for NVP-
rash associated SCAR, when the cohort was analysed together, but only remained 
significant in Caucasians, when the data was adjusted for race (Table 3.8). This group 
of alleles which share the same binding cleft F-pocket possesses varied binding cleft 
B-pocket sequences suggesting the potential importance of the binding cleft F-pocket. 
The F-pocket sequence significance and the virtual modelling analysis performed by 
colleagues at the University of Florida showed the interaction between NVP within the 
B-pocket. More research is required before a model can be formulated to further 
analyse NVP-SCAR and the significance of the shared F-pocket sequences and how 
the preferred binding of NVP near the B-pocket interacts with peptide presentation (83-
85). 
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7.2.2 Diminishing Ex-vivo PBMC’s Responses and NVP-HSR 
Immunopathogenesis 
This smaller study was part of a larger study involving NVP-SCAR 
immunopathogenesis (138). As highlighted in Keane et al. 2014, one patient exhibited 
an increase in Tregs cell numbers corresponded with diminishing IFN-γ ELISpot 
responses (138). After this first analysis, PBMC's samples were limiting, therefore to 
discuss this question and provide more data to complement the data published by 
Keane et al. 2014, donor plasma was analysed over the time course of NVP-DRESS 
to see if the cytokine environment reflects the changes in specific T-cell 
subpopulations. Several cytokines were measured in patients over the time course of 
a NVP-DRESS reaction. Donor 1 (NVP-HSR) showed a detectable IFN-γ release at 
day 1 post NVP- DRESS, which then decreased, potentially due to the withdrawal of 
NVP. Both Donor 1 (NVP-HSR) and Donor 2 (NVP-HSR) both showed significant IL-6 
levels within the first 8 days post NVP- DRESS. 
Elevated IL-6 levels in plasma samples can be linked to numerous different 
pathologies but taken in context could be significant in the immunopathogenesis of, or 
recovery from, a NVP-DRESS reaction (195-197). Given this increase in IL-6 and the 
role IL-6 plays in Tregs/Th17 balance, this cytokine alongside other key factors like 
carriage specific HLA class-I alleles could be important in NVP-DRESS 
immunopathogenesis. One model we propose is that the decrease in Tregs at the time 
of the reaction, due to IL-6 altering the Th17/Treg balance might be partially driving 
NVP-DRESS and the return of Tregs during recovery is responsible for the NVP-
stimulated diminishing IFN-γ PBMC's responses. 
While this increase in IL-6 and the fact that Keane et al. 2014 showed the removal of 
CD25+ T cells had no effect on restoring diminishing NVP-stimulated, IFN-γ ELISpot 
responses, this data combined is only from a few patients (138). To further analyse 
this proposed model, future analysis should look at the expression and quantification 
of inhibitory immune receptors; CTLA4, PD-1, and/or PD-L1 (203-206). Ex-vivo 
experiments including monoclonal antibodies directed towards blocking these 
inhibitory immune receptors to see if the ex-vivo response can be recovered or further 
rule out the role of Tregs in diminishing NVP-stimulated IFN-γ PBMC responses (203, 
205, 206). While it would have been preferential to perform this on the specific 
samples used in Keane et al. 2014 and within this thesis, this could not be performed 
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as samples were limited and used in the first study by Niamh Keane et al. 2014, hence 
the reason we analysed the Donors' plasma cytokine environment. 
7.3 Carbamazepine-Induced Stevens - Johnson 
syndrome and Toxic Epidermal Necrolysis 
A strong association between HLA-B*15:02 and other B75 serotypes, including the 
HLA-B*15:08, -B*15:11, and -B*15:21 alleles and CBZ-SJS/TEN has already been 
established (2, 207, 208). Furthermore, the HLA-B*15:02 and SJS/TEN association 
has been extended to several other Antiepileptic drugs, including phenytoin, 
lamotrigine, and oxcarbazepine. While screening for HLA-B*15:02 carriage based on 
the 100% negative predictive value is a workable option, the low positive predictive 
value of HLA-B*15:02 in CBZ-SJS/TEN (3.0-7.7% in Han Chinese) means screening 
for HLA-B*15:02 prevents large number of patients who carry an associated HLA allele 
from taking these CBZ. Limits are placed on the number of alternative drugs that can 
be prescribed. Understanding this disparity between negative and positive predictive 
values will help in our understanding of the immunopathogenesis driving HLA-
restricted drug-SJS/TEN and allow for more effective screening methods to be used. 
The heterologous immune responses have been suggested as a model to explain not 
only the low positive predictive value associated with at-risk HLA alleles and CBZ-
SJS/TEN but also explains the varied tissue distribution of IM-ADR. 
One aspect this body of work has explored involves a heterologous immune response 
explained in Chapter 1 (Section 1.4 Established Models of HLA-driven delayed 
Immunologically Mediated-Adverse Drug Reactions) which might explain the low and 
incomplete positive predictive value associated with HLA-restricted CBZ-SJS/TEN. 
The existence or nonexistence of epitope-specific class-I memory T cells which 
express a specific cross-reactive TCR, might determine CBZ-SJS/TEN development in 
individuals who carry the at-risk HLA allele. This would also go further to explain the 
low positive predictive value of HLA-B*15:02 in CBZ-SJS/TEN and further our 
understanding of the immunopathogenic mechanisms driving drug-SJS/TEN. 
7.3.1 Predicted HLA-restricted Peptide Screening 
The identification of HLA-B*15:02-restricted peptides, shared and restricted to  
CBZ-SJS/TEN patients, is an essential step assessing the heterologous immune 
model as it relates to HLA-B*15:02-restricted CBZ-SJS/TEN. This initial screening of 
HSV-1 and/or HSV-2 predicted HLA-B*15:02-restricted peptides generated by in-silico 
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epitope mapping techniques, designed and performed by colleagues at The Institute 
for Immunology and Infectious Diseases, Murdoch University, Perth, Australia, elicited 
genuine peptide IFN-γ ELISpot responses. The atypical YAHG_SLRLPY epitope, a 
variant of the HSV-1/HSV-2 shared Helicase-primase-primase subunit (UL52 amino 
acid positions 811-821 and 823-833, in HSV-1 and HSV-2 respectively) peptide 
YAHGHSLRLPY, was the only peptide that fitted the parameters outlined by the 
hypothesis. 
A protein BLAST search of this atypical epitope did not match anything within the 
NCBI databases (169, 186, 187, 212). This peptide originates from a highly conserved 
region of the UL52 protein in all the various strains of HSV-1 and HSV-2 that have 
been identified and published Specific-YAHG_SLRLPY amino acid sequence matched 
none of the reference protein sequence in the NCBI protein database (169, 186, 187, 
212). 
The identification of such an atypical epitope has a remarkable impact on our 
understanding of immunological and/or virological processes. A better understand of 
the mechanisms behind ambiguous transcription, translation, protein folding and 
degradation, and epitope synthesis is required before the efficiency and frequency of 
atypical epitopes can be determined. 
Several debated mechanisms have been identified, which could cause atypical epitope 
generation (213-218). These include the DRiP hypothesis which describes 
substandard polypeptides developing from alternative and/or defective mRNAs, 
ribosomal frameshifts, downstream initiation on genuine mRNAs, and other errors 
inherent in translation including tRNA-amino acid misacylation (219-228). Using the 
netChop 3.1 program to analysing YAHGHSLRLPY and surrounding amino acids 
within the HSV-1 and HSV-2 Helicase-primase-primase subunit, four cleavage sites 
were predicted (229). The four cleavage sites included the 5th histidine (H), and the 
1st tyrosine (Y) and both leucine residues (L), but the netChop program is rather 
underdeveloped (229). 
Continued analysis using more CBZ - SJS/TEN patients and CBZ-tolerant controls, is 
required before an atypical epitope, like YAHG_SLRLY can be considered as a 
potential epitope responsible in the primary immune response and the subsequent 
maintenance of the memory T cell which express the specific cross-reactive TCR, in a 
heterologous immune response. Future analysis should also not rule out other HHV or 
persistent pathogens to screen for cross-reactivity. Given the association between the 
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CBZ-TEN reaction and the acute HZ experienced by Donor 1 (CBZ-TEN), in-silico 
epitope mapping strategies should also be extended to generating several HLA-
restricted VZV peptides. 
As highlighted in Chapter 4, a recent paper by Jing et al., 2016 discovered several 
novel cross-reactive T-cell epitopes, including a HLA-B*15:02-restricted HSV / VZV 
cross-reactive T-cell epitope found using PBMC’s acquired from Donor 1 (CBZ-TEN) 
(231). This epitope should also be screened using the other Donors in this chapter 
which have shown responses to the atypical YAHG_SRLPY HSV-1 / HSV-2 epitope. If 
this newly identified VZV / HSV epitope meets the requirements outlined in the 
hypothesis and aims of this chapter, as the atypical YAHG_SRLPY HSV-1 / HSV-2 
epitope has, both these epitopes can be used in future studies into the 
immunopathogenesis of HLA-B*15:02-restricted CBZ-SJS/TEN. 
7.3.2 Specific T-cell Clonotype and Detection by ddPCR 
This study also showed that CBZ induced responses can be expanded from PBMC’s 
obtained from patients up to 17 years after the initial reaction. Expression of the 
previously identified CBZ-specific public TCR sequences, Vβ 25-1*01 (Vβ 11s1) CDR3 
CASSISGSY / CASSGLADVDN or the newly identified Vβ 12-3/4*01 CDR3 
CASSLAGELF sequence can be detected using ddPCR (176). 
The Vβ 25-1*01 (Vβ 11s1) CDR3 CASSISGSY sequence was found to be expressed 
in Donor 1 (CBZ-TEN), when cells were stimulated with CBZ and expanded in culture 
when compared to the unstimulated and control drug-stimulated and expanded cells. 
The Vβ 12-3/4*01 CDR3 CASSSLAGELF sequence was found to be expressed in 
Donor 1 (CBZ-TEN) cells stimulated with CBZ and expanded in culture when 
compared to pre-stimulated cells and while not significant, an increase was seen when 
compared to the unstimulated and control drug-stimulated and expanded cells. 
Donor 2 (CBZ-SJS) exhibited a significant increase in the Vβ 12-3/4*01 CD3 
CASSLAGELF sequence expression in cells stimulated with CBZ and expanded in 
culture compared to pre-stimulation, unstimulated and control drug-stimulated and 
expanded cells. Donor 3 (CBZ-SJS) also exhibited an increase in the Vβ 12-3/4*01 
CD3 CASSLAGELF sequence expression. Cells from Donor 2 (CBZ-SJS) and Donor 3 
(CBZ-SJS) showed a CBZ-associated increase in Vβ 25-1*01 CDR3 CASSISGSY and 
CDR3 CASSSGLAGVDN expression, respectively. However, in both cases, the 
increase in CBZ-stimulated and expanded cells was also seen in the control drug-
stimulated, expanded cells. It is possible the increase in CDR3 CASSISGSY and 
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CDR3 CASSSGLAGVDN sequence expression results from a distorted representation 
of the T-cell repertoire driven by ex-vivo expansion. 
This study did not confirm the findings by Ko et al, 2011, but an increase in Vβ 25-1*01 
(Vβ 11s1) CDR3 CASSISGSY expression in CBZ-stimulated cells from Donor 1 (CBZ-
TEN) was seen. In contrast to the proposal by Ko et al, 2011, several IM-ADR studies 
have highlighted the involvement of a more complex TCR repertoire (116, 233, 234). It 
is also possible that the specific Vβ or Vα TCR clonotype is not as essential as the 
specific-CDR3 sequence, which interacts with the HLA-bound peptide. This could 
mean that the TCR repertoire can be heterogeneous and polyclonal, yet share the 
same or structurally similar specific-CDR3 sequences. 
Recent studies have also highlighted how HHV can drive the production of tissue-
resident memory T cells, possessing high cytolytic potential and a low trigger threshold 
causing local tissue damage (235). One such example includes HSV-specific CD8αα+ 
tissue-resident T cells, persistent within the epidermis over a prolonged period and 
causes rapid cytotoxicity to cells expressing low levels of HSV reactivation (235). 
Going forward it will be prudent to look at epidermal tissue samples to identify both 
HLA-restricted pathogenic epitopes and to screen for potential TCR clonotypes 
involved in CBZ-SJS/TEN, to prove this heterologous immune model. 
The recent paper by Jing et al., 2016 showed the recognition of VZV-infected cells, 
proteins, and peptides by polyclonal HSV-1–driven CD8+ T cells. In this paper, they 
identified several potential VZV / HSV cross-reactive Vβ TCR CDR3 sequences 
specific the same Donor 1 (CBZ-TEN) also analysed here (231). The expression of 
these VZV / HSV cross-reactive Vβ TCR CDR3 sequences can be assessed using the 
same method described in this chapter. 
What this chapter has provided is an adaptable and sensitive experimental method to 
assess TCR expression. In particular, the ddPCR assay highlighted can be utilised in 
any study involving the quantitative assessment and expression of any known Vβ or 
Vα TCR CDR3 sequence. The ddPCR method used here can be utilised to further 
assess Vβ TCR CDR3 sequences identified by Ko et al, the expression of VZV / HSV 
cross-reactive Vβ or Vα TCR CDR3 sequences identified by Jing et al., 2016, or 
identifying the HSV-specific CD8αα+ tissue-resident T-cell clonotype. This specific 
ddPCR assay can be modified and adapted to not only assess TCR expression in 
other delayed IM-ADR, this assay can be used across several immunological research 
disciplines, including tumour T-cell immunology. 
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7.3.3 Granulysin Expression 
Chapter 4 and 5 approached the study of CBZ-SJS/TEN immunopathogenesis by 
evaluating the heterologous immunity model. Chapter 6 looked at another aspect of 
CBZ-SJS/TEN immunopathogenesis, granulysin expression. The examination of 
granulysin expression in patient PBMC’s obtained up to 17 years after the initial CBZ-
SJS/TEN reaction, involved the ex-vivo CBZ stimulation to show the relevant PBMC's 
subtypes involved. 
The granulysin analysis in this body of research differs from other bodies of work 
because it shows an increase in granulysin-expressing by CD8+ cytotoxic T cells within 
PBMC’s exposed to CBZ, ex-vivo (103, 116, 117, 134, 135). This study also shows an 
increased expression of granulysin in unstimulated CD8+ cytotoxic T cells within the 
donor PBMC’s when compared to the controls. The findings here suggest that CD8+ 
cytotoxic T cells are a primary cellular subtype within the PBMC’s that interacts with 
CBZ. This would support the current model for immunopathogenesis, in that CBZ-
SJS/TEN is driven by CD8+ T cells through a HLA-restricted TCR interaction and their 
activation recruits other granulysin producing cells into this reaction. This would also 
explain why it is common to find not only activated CD8+ cytotoxic T cells, but other 
activated granulysin excreting cells like NK and NK T cells, within the epidermal 
blisters of patients during the reaction (113, 114, 117). 
It has been shown that granulysin can cause a 2 to 7 fold increase in chemotaxis of 
monocytes, CD4+, and CD8+ memory T cells, NK cells, and mature, monocyte-derived 
dendritic cells (239, 240). While further studies are required to verify this, 
experimentation should involve immunophenotyping skin-infiltrating lymphocytes at the 
acute phase of SJS/TEN. A recent presentation at the European Academy of Allergy 
and Clinical Immunology's 2016 Drug Hypersensitivity Meeting in Malaga, Spain Villani 
A.P. et al. 2016 presented data which shows that CD8+ T cells and to a lesser extent 
CD4+ T cells, were the main leukocyte subsets found in acute TEN blisters (238). 
This study also showed an increase in granulysin expression by CBZ-stimulated CD4+ 
T cells in Donor 4 (CBZ-SJS non-B*15:02). Donor 4 (CBZ-SJS non-B*15:02), also 
exhibited an increased expression of granulysin in unstimulated CD4+ T cells, 
supported by the increase in IFN-γ under the same conditions. This is only one patient, 
but it supports what Porebski et al. 2013 showed with lamotrigine- SJS/TEN (135). 
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7.3.4 Future Experimentation for HLA-15:02-restricted CBZ-
SJS/TEN 
Future work should combine the experiments and results of Chapter 4, to see if the 
identified HLA-B*15:02-restricted epitopes elicit granulysin responses in the memory T 
cells which express the TCR sequences (Chapter 6) identified in Chapter 5. This 
would be strong evidence of the heterologous model. The preliminary work on this has 
so far failed to show the epitopes, identified in Chapter 4, elicit the same granulysin 
response as seen in CBZ stimulation highlighted in Chapter 5, in memory T cells which 
express the TCR sequences shown in Chapter 6 (Appendix 9, Section 9.3 Future 
experimentation for HLA-15:02-restricted CBZ-SJS/TEN, Figure 9.16 and Figure 9.17). 
Despite this, Chapters 4, 5, and 6 provide a way forward to continue the search for 
potential HLA-B*15:02-restricted epitope responses to prove or disprove the 
heterologous model. 
7.4 Final Conclusions 
Not only do ADRs place a great deal of demand and strain on hospitals, healthcare 
facilities, auxiliary healthcare services, they are a major cause of iatrogenic and 
preventable disease and death (1, 2). The ABC translational roadmap is a successful 
example of how the research discoveries can be translated into clinical practice 
leading to improved patient care. The ability to identify patients at risk of experiencing 
a drug-specific IM-ADR, before administering the drug is an advantageous concept. To 
achieve a greater understanding of IM-ADR immunopathogenesis is required. Both 
CBZ-SJS/TEN and NVP-SCARs are distinct clinical and immunological syndromes, 
but they share are several significant similarities which suggest that the underlying 
immunopathogenesis driving SCARs may share commonalities. Both CBZ-SJS/TEN 
and NVP-SCARs provide important examples for the immunopathogenesis of severe  
T cell-mediated drug reactions. 
As with ABC and HLA-B*57:01 genetic screening, the Food and Drug Administration 
(USA) recommends genetic screening for HLA-B*15:02 before CBZ therapy and that 
all HLA-B*15:02 carriers, should not be administered CBZ unless the benefits 
outweigh the risks (101). The low positive predictive value associated with HLA-
B*15:02 carriage alone means numerous HLA-B*15:02 carriers who would otherwise 
benefit from CBZ therapy, are required to undertake alternative treatments or risk 
experiencing an SJS/TEN reaction. Further insight into the immunopathogenesis is 
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required to improve screening methods which would increase our ability to predict and 
avoid potential CBZ-SJS/TEN reactions. 
In terms of CBZ-SJS/TEN, we have shown that that increased expression of the 
SJS/TEN associated cytotoxic molecule, granulysin in CD8+ T cells can be detected in 
an ex-vivo assay in which PBMC’s isolated from CBZ-SJS/TEN patients are exposed 
to CBZ. Future experimentation should include CBZ-naive and CBZ-tolerant controls 
to determine if the flow cytometry ICS assay described in this body of work is useful in 
improving CBZ-SJS/TEN prediction in conjunction with HLA-B*15:02 carriage. The 
ddPCR method developed in this body of research should be used in further analysing 
the TCR sequences identified in Jing et al. 2016 (231). A greater understanding of 
cross-reactive memory T-cell responses would help us understand why not all patients 
who carry at-risk alleles develop an IM-ADR. Continued research into the specificities 
of the T cells involved in CBZ-SJS/TEN is required, however, the ddPCR method 
outlined here can be translated into clinical practice, in conjunction with genetic 
screening for HLA-B*15:02 to improve the predictability of IM-ADR. 
Future research into the CBZ-SJS/TEN associated T cells should focus on advances 
in the ability to characterise individual patient TCR repertoires by means of deep 
sequencing, targeting the Vα and Vβ TCR genes and gene expression, and 
sequencing based assays which can show paired TCR α- and β-chain sequences. 
To add to our understanding of CBZ-SJS/TEN specific cross-reactive memory T-cell 
responses we looked at potential epitope-specific T-cell responses. We have also 
identified specific HSV-1/HSV-2 responses, with one atypical epitope being shared 
among the HLA-B*15:02-CBZ-SJS/TEN patients. We propose that further 
experimentation to answer the question of cross-reactivity between drug-derived  
neo-antigen and viral-specific memory T cells should include the atypical epitope 
identified in this body of work and the HSV/VZV cross-reactive epitope found by  
Jing et al. 2016 (231). Continued work should include improving computational and 
experimental methods to better identify HLA-restricted epitopes from candidate 
pathogens like HHV potentially responsible for the initial priming and maintaining the 
cross-reactive pathogenic T cell involved in heterologous driven immunopathogenesis 
models. 
Combining the experiments of Chapter 4, Chapter 5, and Chapter 6 to identify HLA-
B*15:02-restricted epitopes that elicit granulysin responses in the memory T cells 
which express specific TCR sequences would provide strong evidence of the 
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heterologous model. The preliminary work on this has so far failed to show the 
epitopes, identified in Chapter 4, elicit the same granulysin response as seen in CBZ 
stimulation highlighted in Chapter 5, in memory T cells which express the TCR 
sequences shown in Chapter 6 (Appendix 9, Section 9.6 Future experimentation for 
HLA-15:02-restricted CBZ-SJS/TEN). The method and experimentation in these 
Chapters have provided a way forward to continue the search for potential HLA-
B*15:02-restricted epitope responses to prove or disprove the heterologous model. 
In contrast to ABC-HSS and CBZ-SJS/TEN, genetic screening for NVP-HSR 
associated HLA alleles has been difficult, due to the number of varied HLA allele and 
the associated incomplete predictive values. We proposed that the variation in NVP-
HSR associated HLA alleles was due to several HLA alleles similar HLA binding 
cleft/groove properties and/or predicted peptide/NVP-binding characteristics. The 
shared association between the F-pocket of the NVP-SCAR predictive allele HLA-
C*04:01 and other ethnic-specific predictive HLA alleles like HLA-C*05:01 and HLA-
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9.1 Nevirapine isolation from Viramune tablets 
One tablet of Viramune contains 200mg of NVP; one tablet of Viramune extended-
release (XR) contains 400mg of NVP. NVP extraction from its tablet form requires the 
separation of NVP from the drug excipients. In a sterile environment, like that of a 
class-II biological hood: 
 A 200mg NVP tablet was crushed into a fine powder, transferred into a sterile 50 
mL Schott bottle (autoclaved), and diluted in 40 mL of DMSO (5mg of NVP per mL 
of DMSO). 
 Tablet/DMSO solution was then transferred to the appropriate tubes, centrifuged at 
7224 RCF (10,000 RPM) for 5 minutes. 
 Supernatant, containing NVP dissolved in DMSO, was then transferred to a sterile 
50 mL Schott bottle (autoclaved). 
 NVP/DMSO solution was diluted with sterile 1x PBS, giving a final concentration of 
1 mg/mL (1:5 dilution). 
 NVP solution was then filtered using a 0.22 μm filter and transferred to a correctly 
labelled sterile 50 mL Schott bottle (autoclaved) wrapped in aluminium foil, and 
stored in a dark environment at room temperature. As a means of quality control 
any NVP made and stored in this manner would be disposed of after 2 weeks. 
 Check on Nano drop for absorbance at 260nm, should read at 6.0 (For NanoDrop, 
make up three Eppendorf tubes). 
o Tube 1 = 750uls of PBS alone 
o Tube 2 = 750uls of PBS plus 250 of DMSO 
o Tube 3 = 750uls of PBS plus 250 of NVP 1mg/mL 
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9.2 Chapter 5 Specific T-cell clonotype and 
detection by ddPCR 
9.2.1 Reference Sequence Amplicon Analysis QPCR Primer 
Validation 
The first step in setting up a TCR CDR3 sequence specific PCR assay involves 
designing the oligonucleotide primer sets and optimising various aspects of the assay, 
including the optimal thermocycling conditions. This was done using a real time, 
quantitative PCR assay and the EvaGreen master mix. Firstly multiple variations of the 
primer sets were designed, but failed and were excluded. The primer sets and master 
mix highlighted Chapter 2 Methods and Materials, Section 2.4.2 Digital Droplet PCR 
Table 2.15, Table 2.17, and Table 2.17 were used, and thermocycling conditions 
optimised. This included analysing various annealing temperatures. As shown in 
Figure 9.2 and Figure 9.2, it was determined that an annealing temperature of 58°C for 
30 sec was better for all this specific ddPCR assay, in preference to the manufactures 
recommended protocol of having a 60 sec annealing and denaturing combined step at 
60°C. 
 
Figure 9.1: Analysis of specific Vβ CDR3 primers using serial dilutions of the reference sequence 




Figure 9.2: Analysis of specific Vβ CDR3 primers using serial dilutions of the reference sequence 
amplicons, with the annealing temperature set at and 60◦C. 
9.2.2 The ddPCR Sensitivity Analysis 
The sensitivity of the ddPCR assay was assessed using the serially diluted synthetic 
construct amplicons. This analysis confirms the manufactures claims that the ddPCR 
method is sensitive enough to detect single copies of target DNA. The range of the 
ddPCR copy number detection, using the EvaGreen ddPCR assay is sensitive enough 
to detect DNA from 105 copies of DNA, down to the single copy level. This was shown 





Figure 9.3: the QuantaSoft raw digital droplet PCR plots. Reference sequence amplicons, serially 
diluted to test the sensitivity of the digital droplet PCR and qualifying the assay parameters. 
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Figure 9.4: the QuantaSoft digital droplet PCR output of positive and total events recorded for the raw 
plots outlined in Figure 9.10 Reference sequence amplicons, serially diluted to test the sensitivity of the 
digital droplet PCR and qualifying the assay parameters. 
 
 
Figure 9.5: Digital droplet PCR Reference sequence amplicons serial dilution result and QuantaSoft 
output (copies/μL). Reference sequence amplicons, serially diluted to test the sensitivity of the digital 
droplet PCR and qualifying the assay parameters. 
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9.3 Future experimentation for HLA-15:02-restricted 
CBZ-SJS/TEN 
9.3.1 Preliminary granulysin expression data 
Stimulation of Donor PBMC’s with CBZ and with the HLA-B*15:02-restricted peptides 
identified in Chapter 4 Predicted HLA-Restricted Peptide Screening, failed to show 
increased granulysin expression in peptide stimulation CD8+ T cells significantly above 
that of the unstimulated response, matching that of the CBZ-stimulated CD8+ T cells 
(Figure 9.16). 
 
Figure 9.6: Mean (+/- SD) Granulysin expression by CD8
+
 T cells, stimulated by the epitopes discovered 
in Chapter 4 Predicted HLA-Restricted Peptide Screening (10μg/mL) and CBZ (10μg/mL). 
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9.3.2 Preliminary TCR expression data 
Stimulation of Donor PBMC’s with CBZ and with the HLA-B*15:02-restricted peptides 
identified in Chapter 4 Predicted HLA-Restricted Peptide Screening, failed to show an 
expansion of TCR Vβ-12 CDR3 LAGELF and Vβ-11 CDR3 ISGSY in Donor 1 (CBZ-
TEN) matching that of the CBZ-stimulated response (Figure 9.17). 
 
 
Figure 9.7: TCR Vβ-12 CDR3 LAGELF and Vβ-11 CDR3 ISGSY sequence profile of Donor 1 (CBZ-
TEN) when stimulated with stimulated by the epitopes discovered in Chapter 4 Predicted HLA-
Restricted Peptide Screening (10μg/mL) and CBZ (10μg/mL). Raw data analysed using Bio-Rad 
QuantaSoft software, results normalised against RPHH1 expression, and calculated as a percentage 
(%) of normalised Cβ expression. 
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9.4 Publication and Conference Abstracts 
9.4.1 Journal Publications 
Title: HLA Class-I restricted CD8 (+) and Class-II restricted CD4 (+) T cells are 
implicated in the Pathogenesis of Nevirapine Hypersensitivity. 
DOI:10.1097/QAD.0000000000000345 AIDS, London, 24 August 2014 - Volume 28 - 
Issue 13 - p 1891–1901. 
Niamh M Keanea*, Rebecca K Pavlosa*, Elizabeth McKinnona*, Andrew Lucasa, Craig 
Rivea, Christopher C Blythb,c, David Dunna, Michaela Lucasd, Simon Mallala,e, 
Elizabeth Phillipsa,e: aInstitute for Immunology and Infectious Diseases, Murdoch 
University, bDepartment of Paediatrics and Adolescent Medicine, Princess Margaret 
Hospital for Children, cSchool of Paediatrics & Child Health, dSchool of Medicine & 
Pharmacology and School of Pathology & Laboratory Medicine, The University of 
Western Australia, Perth, Western Australia, Australia, and eVanderbilt University 
School of Medicine, Nashville, Tennessee, USA 
 
Figure 9.8: Abstract of HLA Class-I restricted CD8 (+) and Class-II restricted CD4 (+) T cells are 
implicated in the Pathogenesis of Nevirapine Hypersensitivity paper.  
Published in AIDS, London, 24 August 2014 - Volume 28 - Issue 13 - p 1891–1901. 
DOI:10.1097/QAD.0000000000000345 (138). 
Title: Testing for Drug Hypersensitivity Syndromes. 
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3626363/ The Clinical biochemist. 
Reviews / Australian Association of Clinical Biochemists 02/2013; 34(1):15-38. 
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Craig M Rive1, Jack Bourke2, Elizabeth J Phillips1-4: 1Institute for Immunology and 
Infectious Diseases, Murdoch University, 2Department of Clinical Immunology & 
Immunogenetics, Royal Perth Hospital, Western Australia; 3Department of Clinical 
Immunology & Infectious Diseases, Sir Charles Gairdner Hospital, Western Australia; 
4Pathology & Laboratory Medicine, University of Western Australia, Australia 
 
Figure 9.9: Abstract of Testing for Drug Hypersensitivity Syndromes.  
Published in The Clinical biochemist. Reviews / Australian Association of Clinical Biochemists 02/2013; 
34(1):15-38. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3626363/ (2). 
9.4.2 Publications in development 
1. Title: Peptide-Binding Characteristics of HLA Alleles Associate with Cutaneous 
Nevirapine Hypersensitivity – Co-author based on Chapter 3: Nevirapine. 
2. Title: The use of droplet digital PCR to explore shared and restricted T-cell 
receptor use in HLA-B*15:02 driven, carbamazepine-induced Steven-Johnson 
syndrome / Toxic epidermal necrolysis – Primary author based on Chapter 5 - 
Carbamazepine induced Stevens-Johnson syndrome and toxic epidermal 
necrolysis Immunopathogenesis: Specific T-cell clonotypes. 
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9.4.3 Conference Proceedings 
9.4.3.1 Posters 
Title: HLA Class-I-drug-T-cell receptor interaction and cytokine expression 
in SJS/TEN. 
DOI: 10.13140/RG.2.1.4937.5207 Science on the Swan, Western Australia, Perth. 
April, 2015 
Authors: Craig Rive1, David Ostrov2, Abha Chopra1, Rebecca Pavlos1 Simon Mallal1,3, 
Elizabeth J. Phillips1,3:1Institute for Immunology and Infectious Diseases, Murdoch, 
Australia,2University of Florida College of Medicine, Gainesville, FL,3Vanderbilt 
University Medical Centre, Nashville, TN. 
 





Title: Specific Binding Characteristics of HLA Alleles Associate with 
Nevirapine Hypersensitivity. 
DOI: 10.13140/RG.2.1.1206.1287 Conference on Retroviruses and Opportunistic 
Infections (CROI), Boston, Massachusetts; 2014 
Authors: Rebecca Pavlos1, Craig Rive1, Elizabeth McKinnon1, David Ostrov2, Bjoern 
Peters3, Jing Yuan4, Silvana Gaudieri1,5, David Haas6, Simon Mallal1,6, and Elizabeth 
J. Phillips1,6: Institute for Immunology and Infectious Diseases, Murdoch, AUSTRALIA, 
2University of Florida College of Medicine, Gainesville, FL, 3La Jolla Institute for Allergy 
and Immunology, La Jolla, CA, 4Boehringer Ingelheim Pharmaceuticals Inc., 
Ridgefield, CT, 5University of Western Australia, Crawley, AUSTRALIA, 6Vanderbilt 
University Medical Centre, Nashville, TN 
 
Figure 9.11: Poster presented at Conference on Retroviruses and Opportunistic Infections (CROI), 
Boston, Massachusetts; 2014. https://www.researchgate.net/publication/275332026_Specific_Binding_ 
Characterstics_of_HLA_Alleles_Associate_with_Nevirapine_Hypersensitivity 
DOI: 10.13140/RG.2.1.1206.1287. (241) 
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9.4.3.2 Presentations 
Title: HLA class-I-drug-T-cell receptor interactions in SJS/TEN. 
DOI:10.1186/2045-7022-4-S3-P2 at Drug hypersensitivity meeting 6 (DHM6), Bern 
Switzerland April, 2014 
Authors: Craig Rive1, Rebecca Pavlos1, David Ostrov2, Pablo Plasencia2, Shien-Iu 
Hung3 WenHung Chung4, Bjoern Peters5, Soren Buus6, Simon Mallal1,7, Elizabeth J. 
Phillips1,7, 1Institute for Immunology and Infectious Diseases, Murdoch, Australia, 
2University of Florida College of Medicine, Gainsville, FL, 3Institute of Pharmacology, 
School of Medicine, Genome Research Centre, National Yang-Ming University, Taipei, 
Taiwan., 4Department of Dermatology, Chang Gung Memorial Hospital, College of 
Medicine, Chang Gung University, Keelung,5La Jolla Institute for Allergy and 
Immunology, La Jolla, CA, 6Laboratory of Experimental Immunology, University of 
Copenhagen, Copenhagen, Denmark. 7Vanderbilt University Medical Centre, 
Nashville, TN. 
 
Figure 9.12: Abstract for talk presented at Drug hypersensitivity meeting 6 (DHM6), Bern Switzerland 
April, 2014. 
http://www.ctajournal.com/content/4/S3/P2 DOI:10.1186/2045-7022-4-S3-P2 or 




Title: HLA Class-I-drug-T-cell receptor and Carbamazepine induced 
Stevens-Johnson syndrome / Toxic epidermal necrolysis 
DOI: 10.13140/RG.2.1.2709.2962. The Australian Society for Medical Research 
(ASMR), Perth Western Australia June, 2014. 
Authors: Craig Rive1, Rebecca Pavlos1, David Ostrov2, Pablo Plasencia2, Shien-Iu 
Hung3 WenHung Chung4, Bjoern Peters5, Soren Buus6, Simon Mallal1,7, Elizabeth J. 
Phillips1,7, 1Institute for Immunology and Infectious Diseases, Murdoch, Australia, 
2University of Florida College of Medicine, Gainsville, FL, 3Institute of Pharmacology, 
School of Medicine, Genome Research Centre, National Yang-Ming University, Taipei, 
Taiwan., 4Department of Dermatology, Chang Gung Memorial Hospital, College of 
Medicine, Chang Gung University, Keelung,5La Jolla Institute for Allergy and 
Immunology, La Jolla, CA, 6Laboratory of Experimental Immunology, University of 
Copenhagen, Copenhagen, Denmark. 7Vanderbilt University Medical Centre, 
Nashville, TN. 
Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN). CBZ-SJS/TEN has 
been associated with HLA-B*15:02 carriage and specific T-cell Background: 
Carbamazepine (CBZ) is associated with the severe cutaneous drug reaction 
clonotypes. We aimed to characterise the interactions between specific T-cell receptor 
(TCR) clonotypes, HLA-B*15:02 and CBZ. 
Methods: Peripheral blood mononuclear cells (PBMC’s) were isolated from patients 
with CBZ-SJS/TEN and healthy controls, stimulated with 10ug/mL CBZ (Sigma, cat. 
no. C4024-5G) and cultured over a 9-14 day period. RNA was isolated at various time 
points and TCR Vβ subtypes were assessed using digital droplet PCR (Bio-Rad 
QX100 droplet digital PCR system). Drug-specific T-cell IFN-γ and granulysin 
responses were assessed by ELISpot and ICS. In-silico modelling was used to 
examine the interaction between the known specific TCR Vβ and Vα chains, CBZ and 
HLA-B*15:02. 
Results: CBZ-specific T-cell IFN-γ and granulysin responses were detected many 
years following the original SJS/TEN reaction. Expansion of specific TCR CDR3 
sequences was confirmed in CBZ-SJS/TEN patient cultures. In-silico modelling of the 
CBZ-HLA-B*15:02-TcR interaction suggests that CBZ binds non-covalently in the P4 
binding pocket of the HLA-B*15:02 antigen binding cleft in a site that is typically 
occupied with bound peptide. 
Conclusions: These findings raise two non-mutually exclusive possibilities: 1) CBZ 
may block peptide-binding and be presented by HLA-B*15:02 in a solvent exposed 
manner available for direct recognition by the TCR, 2) CBZ binding the central portion 
of the HLA-B*15:02 antigen binding cleft may permit long peptides to bind 
conventionally at the peptide termini (in the A- and F-pockets) and bulge over the drug 
in the central residues to permit indirect recognition of CBZ (peptide mediated TCR 
contact). 
 
 
